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Executive Summary
This is the final report of a study undertaken by the Centre for Health Service Development
(CHSD), University of Wollongong. The study was commissioned by the NSW Department of
Health to provide a costing of blood and marrow transplantation services in NSW. Blood and
Marrow Transplantation (BMT) is a high cost and relatively low volume specialty service. The
scope of this study encompassed both inpatient and related outpatient BMT services. The aim
was to develop an understanding of cost structures associated with BMT services.
Blood and marrow transplantation is used to treat a range of diseases including haematological
(blood) diseases such as leukaemia, lymphoma and multiple myeloma, as well as some immune
disorders and, occasionally solid tumours. There are two main types of stem cell transplants
autologous (where the patient is their own cell donor) and allogeneic (where stem cells are
donated by another person). Allogeneic transplants are considered to be more complex, higher
risk and consume most resources.
Currently, fifteen hospitals deliver BMT services across NSW and there are eight specialty BMT
laboratories. Data collection was restricted to hospitals that operate ‘clinical costing’ systems and
could therefore produce ‘episode level’ cost data for BMT patients. This resulted in the inclusion of
data from eight hospitals: Sydney Children’s Hospital, Children’s Hospital Westmead, St Vincent’s
Hospital, Royal North Shore Hospital, Westmead Hospital, Nepean Hospital, Prince of Wales
Hospital and St George Hospital. Data from these eight hospitals formed what is referred to during
the remainder of this report as the ‘study dataset’.
We have compared the volume of activity in the study dataset with activity data reported by the
NSW Department of Health in its annual hospital cost data collection. This shows that for adults,
the study dataset represents approximately 90.1% of allogeneic and 58.1% of autologous BMT
transplant episodes undertaken annually in NSW. For paediatric services, it represents 96% of
allogeneic transplants and 97% of autologous transplants undertaken annually in NSW. On this
basis, we are confident that the study is representative of BMT services across the State.
The primary questions addressed in this study, as identified in the project brief are as follows:
• What is the average per patient cost of autologous and allogeneic BMT?
• What is the breakdown of costs for each of these, in terms of the inpatient and ambulatory
phase of treatment?
• Are there available costings from other States in Australia with which to compare, and if
significantly different, why?
• What proportion of BMT costs do pharmaceuticals represent?
• What, if any, difference is there between costs for adult patients and paediatric BMT?
• What are the financial implications of the projected increase in BMT activity in NSW by
2011?
This study has developed a set of cost results in relation to each of the above questions. A range
of associated cost results are included to provide a more detailed breakdown of various BMT cost
structures. The results are presented in the context of the NSW health system and the current
funding arrangements that operate within that context.
This report is structured to reflect the activities undertaken during the study.
Section 1 provides an overview of the project deliverables and context for the development of this
costing study.
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Section 2 provides a summary of the consultation process that has informed the study. Over fifty
consultation sessions occurred with predominantly clinical and costing personnel. There were
several purposes to this consultation process, including to: understand the clinical process of BMT;
inform the decisions about start and end points of the patient journey and identify costing issues of
concern to clinicians.
Section 3 provides the results of a targeted literature review undertaken to identify any relevant
previous costing studies of BMT services. As was expected, one of the major difficulties in
identifying relevant work is the widely varying objectives and methodologies used in previous
studies. In particular, many studies examined the cost of particular components of BMT, such as
certain types of pharmaceuticals or a particular method of stem cell harvesting. Whilst these
results provided useful background information, they often were of limited value in seeking to
develop an understanding of the overall cost of BMT services.
Section 4 flowcharts and discusses the ‘patient journey’ for all types of BMT services; adult and
paediatric and autologous and allogeneic. The patient journey follows similar key steps with all
autologous transplant patients requiring workup; mobilisation, stem cell harvest and cell
processing, transplant (including conditioning) and post transplant management. In addition,
allogeneic transplant patients require tissue typing and they are not subject to stem cell harvest – a
donor supplies the cells which must be collected and processed. The majority of the BMT patient
journey is consumed by the inpatient admission for transplant. Several aspects of clinical practice
were identified during the clinical consultation that could not be costed and this is discussed further
in the body of the report.
Sections 5 and 6 describe the process for developing the study data collection protocol,
corresponding dataset and costing methodology. Data from the eight hospitals previously
identified formed the ‘study dataset’. Cost estimates were developed for the various care
processes involved in the delivery of BMT services including BMT episodes, related inpatient
episodes and a range of outpatient BMT services. Several issues emerged during data collections
which are discussed in detail in Section 5. A range of preparatory data analysis tasks were
undertaken and business rules were developed to govern the inclusion of data in the final study
dataset. After the adjustments described in Section 6 were completed the final study dataset
consisted of:
• 508 BMT episodes
• 2,258 Related inpatient episodes
• 7,485 Outpatient medical, nursing and allied health clinic occasions of service
• 6,272 Outpatient dispensed drugs
• 435 Other outpatient treatments.
Section 7 presents the study results comprising a set of cost estimates for a range of BMT related
services undertaken in NSW. The total cost of BMT services by transplant type and adult and
paediatric hospital is shown in the table below. The total annual cost of BMT services (allogeneic
and autologous; adult and paediatric; inpatient and outpatient) for the study dataset is
$30,882,930. The average cost per BMT in paediatric hospitals is approximately double the
average cost per BMT in adult hospitals. The cost per allogeneic BMT is approximately twice as
much as the cost per autologous BMT in both adult and paediatric facilities.
Ward costs account for approximately 40% of the inpatient component of transplant episodes for
both adult and paediatric transplants. Pharmacy costs are the second highest cost bucket
representing approximately 30% in adult hospitals and 25% in paediatric hospitals. Across the
adult hospitals in the study dataset, ICU costs contributed 7% of total costs for allogeneic
transplant episodes and 11% in paediatric hospitals.
Table 1 below shows the total annual cost of both allogeneic and autologous transplant services
for each hospital that participated in the study. Total cost is $30.88 m annually for 134 allogeneic
and 153 autologous transplants undertaken across the eight hospitals. Total costs range from
$610,020 at St George Hospital which undertakes 11 autologous transplants, to $7.95m at
Page 2
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Westmead Hospital which undertakes an average of 57 allogeneic and 26 autologous transplants
annually.

Table 1 Total annual costs of allogeneic and autologous BMT – study dataset
Hospital

Cost Per
Allogeneic
Transplant

Number of
Allogeneic
Transplants

Cost Per
Autologous
Transplant

Number of
Autologous
Transplants

Total
Number of
Transplants
Per Year

Total
Annual
Cost

$120,510

27

$71,905

23

50

$4,907,576

$117,569
$93,571

57
17

$48,263
$67,581

26
39

83
56

$7,956,278
$4,226,365

$0

0

$69,440

9

9

$624,956

$0
$0
$114,316

0
0
101

$55,456
$63,183
$62,812

11
12
120

11
12
221

$610,020
$758,191
$19,083,386

Sydney Children's
Hospital

$237,407

15

$104,346

16

31

$5,230,632

Children's Hospital
Westmead

$218,851

18

$154,681

17

35

$6,568,895

Paediatric
Hospitals

$227,286

33

$119,367

33

66

$11,799,536

$142,137

134

$75,010

153

287

$30,882,930

St Vincent's
Hospital
Westmead Hospital
Royal North Shore
Hospital
Prince of Wales
Hospital
St George Hospital
Nepean Hospital
Adult Hospitals

Total

The financial implications of the projected increase in BMT activity in NSW are an increased in
Statewide expenditure to $46.49m by 2011 and $53.58m by 2016.
A set of key messages arising from the study follows.
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Key Messages
•

There are few published costing studies on BMT and those that are available usually include
insufficient detail to facilitate comparison between studies.

•

It is inherently difficult to cost BMT services because of the issue of determining the point at
which BMT treatment commences and treatment of the underlying disease ends. For this
study, it was decided to cost a window of services commencing 60 days prior to transplant and
ending 365 days post transplant.

•

The average (mean) cost of a BMT episode including inpatient and outpatient services in NSW
was found to be:
o adult allogeneic transplant: $114,316
o adult autologous transplant: $62,812
o paediatric allogeneic transplant: $227,286
o paediatric autologous transplant: $119,367

•

Costing studies inevitably require a trade-off between what is desirable and what is feasible.
This study sought to capture cost data on the major elements of BMT recognising that it was
not possible to identify all costs.

•

The projected cost of BMT services (all inpatient and outpatient) in NSW will increase from its
current level to $46.49m in 2011 and $53.58m in 2016.

•

In this study, there were 508 transplant episodes, which we consider to be an appropriate
sample size. Of these 60% were autologous and 40% allogeneic. The ratio is consistent with
levels of activity reported elsewhere.

•

The cost of paediatric BMT services is significantly higher than the cost of adult BMT services.
The difference in cost is less for the transplant episode component of the BMT, but is still large
enough to support an argument for the AR-DRG classification system to separate adult and
paediatric BMT transplant episodes.

•

Overall, the higher cost of paediatric services aligns with the views expressed by clinicians
during the clinical consultations. In part, this may be a reflection of the higher proportion of
unrelated donor transplants and the growing number of cord blood transplants undertaken at
these facilities.

•

There is considerable variation in the cost of individual episodes within both allogeneic and
autologous patients. This is a function of the variation in clinical condition between patients
and is reflected in the large difference between the mean and median costs across hospitals.

•

For adult hospitals providing unrelated allogeneic transplants (St Vincent’s and Westmead), the
costs are consistent with a slightly lower cost for Royal North Shore Hospital which undertakes
only sibling related allogeneic transplants.

•

There is no evidence to suggest that autologous transplants are more or less expensive at
hospitals that undertake only autologous transplants regardless of the number of transplants
undertaken. This may have implications in a planning context.

•

There may be growing demand for transplants due to the widening indications such as non
malignant conditions in children; transplant genetics; availability of cord blood and capacity for
reduced intensity conditioning to be used with older patients. Greater use of reduced-intensity
conditioning regimens, increasing worldwide donor availability and the availability of alternative
drug treatments were noted as significant trends likely to lead to increasing use of transplant
for a range of indications.
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1 Introduction
This is the final report of a study undertaken by the Centre for Health Service Development
(CHSD), University of Wollongong. The study was commissioned by the NSW Department of
Health to provide a costing of blood and marrow transplantation services in NSW. An interim
report was issued in September 2008 and circulated to stakeholders for comment. The major
principles set out in the interim report were acceptable to all parties. This report incorporates
modifications based on stakeholder feedback and data received from hospitals and provides cost
results for BMT services in NSW.
This study was commissioned in recognition of the importance of developing an understanding of
current cost structures associated with blood and marrow transplantation (BMT) services. The
outputs of this study will be used to inform the “NSW Blood & Marrow Transplantation Service
Plan” currently under development by the NSW BMT Service Plan Development Working Group. It
is hoped that this will in turn provide valuable information to feed into future policy and planning
processes.
The scope of this study encompassed both inpatient and related outpatient BMT services.
Currently, fifteen hospitals deliver BMT services across NSW as shown in Table 2 below. The
work of these transplant centres is supported by specialty blood and marrow laboratories. There
are eight BMT laboratories servicing NSW located at: Royal North Shore Hospital, Royal Prince
Alfred Hospital, St Vincent’s Hospital, Westmead Hospital, Liverpool Hospital, Newcastle Mater,
Prince of Wales Hospital and St George Hospital.

Table 2: Number of BMT transplants in NSW 2007
Adult Allogeneic and Autologous Transplants
St. Vincent’s Hospital (incl. Private)
Westmead Hospital
Royal North Shore Hospital
Royal Prince Alfred Hospital
Paediatric Allogeneic and Autologous Transplants
Sydney Children’s Hospital
Children’s Hospital Westmead
Adult Autologous Transplant Services
Concord Hospital
Gosford Hospital
Liverpool Hospital
Nepean Hospital
Newcastle Mater Hospital
Prince of Wales Hospital
St George Hospital
Wollongong Hospital
Paediatric Autologous Transplants
John Hunter Children’s*

Number of Transplants
60
79
42
37

Total

29
27
13
7
18
12
12
8
11
18
3
376

Source: Australasian BMT Recipient Registry, March 2008.
*John Hunter Children’s Hospital manages autologous transplants in collaboration with Newcastle Mater and Sydney
Children’s Hospital.
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1.1

Study objectives

The primary questions addressed in this study, as identified in the project brief are as follows:
• What is the average per patient cost of autologous and allogeneic BMT?
• What is the breakdown of costs for each of these, in terms of the inpatient and ambulatory
phase of treatment?
• Are there available costings from other States in Australia with which to compare, and if
significantly different, why?
• What proportion of BMT costs do pharmaceuticals represent?
• What, if any, difference is there between costs for adult patients and paediatric BMT?
• What are the financial implications of the projected increase in BMT activity in NSW by 2011?
This study has developed a set of cost results in relation to each of the above questions. A range
of associated cost results are included to provide a more detailed breakdown of various BMT cost
structures. The results are presented in the context of the NSW health system and the current
funding arrangements that operate within that context. In doing so, the study aims to identify the
major costs associated with BMT services in NSW.

1.2

Structure of this report

This report is structured to reflect the activities undertaken during the study.
•

Section 2 provides a summary of the consultation process undertaken at the commencement
of the study;

•

Section 3 provides summary results of a targeted literature review undertaken to identify any
relevant previous costing studies of BMT services. The full results are provided in Appendix 2

•

Section 4 presents an overview of the clinical processes associated with the BMT process
developed from a series of consultations conducted with clinicians throughout the project;

•

Sections 5 and 6 describe the process for developing the study data collection protocol,
corresponding dataset and costing methodology;

•

Section 7 presents the study results comprising a set of cost estimates for a range of BMT
related services undertaken in NSW;

•

Section 8 provides a discussion of the results in the context of implications for the planning
and delivery of BMT services in NSW in the future.

Page 6
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1.3

The study dataset

We raise this issue at the outset as it was identified in the early stages of the study and impacted
on the subsequent data collection and costing methodology. This issue is outlined in detail in
Section 5 and relates to the availability of activity and cost data from the fifteen BMT hospitals.
The models of care and treatment protocols vary to some extent between hospitals. Some key
areas of difference include drug regimens, methods of harvesting stem cells and the mixture of
services provided on an inpatient versus outpatient basis. As these differences potentially result in
variations in cost, it would have been ideal to obtain data from all fifteen BMT hospitals.
However, the information systems required to extract relevant data do not routinely operate at
each site. For this reason, it was necessary to restrict the data collection to hospitals that operate
‘clinical costing’ systems and could therefore produce ‘episode level’ cost data for BMT patients.
This comprised eight of the fifteen BMT hospitals. These hospitals provided cost data for all
transplant and related inpatient episodes for a one, two or three year period between 2004/05 and
2006/07. In most cases, data were available for either two or three years during this time.
Similarly, all but one of these hospitals could provide outpatient data for some or all of this period.
The one hospital that did not provide outpatient data undertakes only a small number of
autologous transplants each year.
Data from these eight hospitals formed what is referred to during the remainder of this report as
the ‘study dataset’. Details of the number of episodes and outpatient occasions of service are
provided in Section 6.6. We have compared the volume of activity in the study dataset with activity
data reported by the NSW Department of Health in its annual hospital cost data collection. This
shows that the study dataset represents approximately 90.1% of allogeneic and 58.1% of all
autologous BMT transplant episodes undertaken annually in NSW. For paediatric services, it
represents of 96% of allogeneic transplants and 97% of autologous transplants undertaken
annually in NSW. On this basis, we are confident that the study is representative of BMT services
across the State.
1.3.1

The NSW and annual cost data collection

We note here that the NSW Department of Health undertakes an annual hospital costing process
involving all NSW public hospitals including the fifteen BMT hospitals. The NSW cost study
produces cost results at the AR-DRG level. The cost data provided for this BMT study is
essentially the same data that was used in the NSW cost study. As such, the results for transplant
episodes at the eight hospitals are likely to be similar across the two studies. The key element of
our study that is additional to the NSW study is the inclusion of cost estimates for non-transplant
related inpatient episodes and outpatient services. Non-transplant inpatient episodes related to
BMT cannot be identified in the NSW study as they are assigned to potentially any AR-DRG and
cannot be separated from other episodes in that AR-DRG. Outpatient episodes are not in scope
for the NSW study.
We utilised the results of the NSW study to obtain costs for the three BMT AR-DRGs from the
seven hospitals that do not operate clinical costing systems. We have also included the results of
the NSW study for all hospitals in Appendix 5.
1.3.2

The National hospital cost data collection

We also note that the Commonwealth Department of Health and Ageing conducts a national
hospital cost data collection (NHCDC). This study involves all States and Territories and produces
cost results at the AR-DRG level. Again, for NSW services the AR-DRG level data obtained for
this BMT study is essentially the same data submitted by NSW public hospitals to the NHCDC. As
such, the results for transplant AR-DRGs at the eight hospitals are likely to be similar between this
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study and the NHCDC. The NHCDC results do however allow a comparison of the cost of BMT
AR-DRGs in NSW with other States. For this reason, at Appendix 6 we have included a
breakdown of the BMT AR-DRGs reported in the NHCDC.

1.4

Costing versus funding – an important distinction

It is important to distinguish between studies that deal with costing issues on the one hand and
studies that deal primarily with funding models. Whilst the two are closely related, the terms of
reference for this project are explicit in that issues relating to funding are out of scope.
We would note our understanding that Statewide and Selected Specialty Services (such as BMT)
receive enhancement funding from the NSW Department of Health. This funding is allocated to
the host Area Health Service to be passed on to the Statewide service. There is also an allowance
in the Resource Distribution Formula to ensure the host Area's target share of funding reflects the
fact that it hosts a Statewide service.
The primary objective of this study was to identify and cost the core services associated with
providing BMT services. During the clinical consultation process, a range of issues were raised in
relation to costs that are incurred by hospitals providing BMT services. In some cases, it was
suggested that current funding arrangements do not adequately reimburse hospitals for providing
these services.
To ensure that we have accurately and thoroughly represented the views expressed during the
consultations, we have included these issues in our summary of the clinical consultation process in
4 and in the discussion of costing issues in 7.4. We would suggest, however, that many of these
issues are more appropriately dealt with in a consideration of the broader funding issues
associated with BMT services.
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2 Consultations with stakeholders
The starting point for this study is to understand the patient journey for autologous and allogeneic
BMT as it applies in practice for both adults and children. This process assists in defining the
‘episodes of care’ that most accurately represent current clinical practice in blood & marrow
transplantation. A series of consultations have occurred with clinicians to ensure CHSD has a
comprehensive understanding of this process. These consultations have centred on four key
stakeholder groups: clinicians, casemix and costing staff, executive leaders and other agencies
with a major interest in BMT. A list of consultations completed to date is provided at Appendix 1.

2.1

Clinical

An important objective of the clinical consultations is to ensure that the costing process accurately
reflects the range of clinical processes that are associated with BMT services. Consultations have
been undertaken with twenty-eight clinicians including senior medical officers, clinical nurse
consultants, hospital scientists and pharmacists. Consultations have also been undertaken with
representatives from the three Children’s Hospitals in NSW to identify any differences between
paediatric and adult BMT. The CHSD team has consulted with personnel from twelve hospitals,
(all four facilities delivering adult allogeneic transplants have been consulted).

2.2

Casemix and costing

Obtaining appropriate service utilisation and financial/costing data is a critical input for this project.
Consultations with costing staff from nine hospitals have been undertaken. In some cases, these
staff have been able to provide data for several hospitals within an Area Health Service. As
expected, the consultation process has revealed considerable variation between facilities in terms
of their capacity to contribute cost data to the study. This issue is discussed in more detail in
Section 5.1 of this report. However, there has been a high degree of consistency across facilities
in terms of the various costing processes that are routinely undertaken. This has improved the
capacity to combine cost data across facilities to produce overall BMT cost estimates.

2.3

Executive

The proposed approach to the costing study has been outlined to the Director, Clinical Operations
from South Eastern Sydney Illawarra, (this Area Health Service has five BMT sites, including adult,
paediatric, autologous and allogeneic services) and to the Director, Clinical Services at Sydney
Children’s Hospital. This has been helpful in providing a broader strategic perspective in relation
to BMT services and in advising Statewide Services Development Branch (SSDB) about a
potential “validation” process for data obtained from Area Health Services.

2.4

Other agencies

Interviews have occurred with the Executive Officer and the Principal Scientist from the Australian
Bone Marrow Donor Registry. This has provided useful insights into the costs associated with the
procurement of stem cells both within Australia and internationally. Statewide Services
Development Branch (SSDB) has informed the NSW Cancer Institute of the progress of this study.
In addition, a preliminary presentation outlining the approach to this costing study was delivered to
the NSW BMT Service Plan Development Working Group in late September 2008.
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3 Literature review summary
A key question for this study was to determine the availability of cost data for BMT services from
other studies which might be compared with the results of this study. To this end, a targeted
literature review was undertaken at the outset of the study. The results are provided in
Appendix 2. This section provides an overview of methodology and the key findings of the
literature review. It identifies various cost drivers and a range of cost estimates found in the
Australian and international literature.
As was expected, one of the major difficulties in identifying relevant work is the widely varying
objectives and methodologies used in previous studies. In particular, many studies examined the
cost of particular components of BMT, such as certain types of pharmaceuticals or a particular
method of stem cell harvesting. Whilst these results provide useful background information, they
often are of limited value in seeking to develop an understanding of the overall cost of BMT
services.

3.1

Defining blood and marrow transplantation

Whilst the acronym BMT is commonly thought to stand for “bone marrow transplant” it actually
refers to the term “blood and marrow transplant”. Bradstock et al. (2006:7) note that:
“BMT is a general term used to cover all types of transplants using haematopoietic stem cells:
cord blood transplant (CBT), peripheral blood stem cell transplant (PBSCT), haematopoietic
stem cell transplant (HSCT) and bone marrow transplant.”
Blood and marrow transplantation is used to treat a range of diseases including haematological
(blood) diseases such as leukaemia, lymphoma and multiple myeloma, as well as some immune
disorders and, occasionally solid tumours. There are two main types of stem cell transplants
autologous and allogeneic.
“In autologous stem cell transplants, the patient is their own stem cell donor. The patient’s
blood stem cells are collected in advance (while they are in remission) and then returned to
them after they receive high-doses of chemotherapy…In allogeneic stem cell transplants the
stem cells are donated by another person. Allogeneic transplants are more complex and carry
more risks than autologous transplants.” (Daly 2006:15)
In allogeneic transplant, stem cells may be donated by a family member or unrelated donor,
including cord blood.

3.2

Introduction

The NSW BMT Service Plan Development Working Group provided the starting point for the
literature review. State government officials from the relevant departments in Victoria,
Queensland, South Australia and Western Australia were contacted regarding the existence of any
documented costing studies in those states. Only two studies were discovered – a very small
scale study undertaken in Queensland in 2004, and a study undertaken by the Royal Melbourne
Hospital. Permission to include details of the latter study was not granted.

3.3

Search strategy

Relevant papers were identified by searching the electronic databases Medline, EconLit, Science
Direct, Cinahl and Cochrane databases using combinations of the search terms transplant$, blood,
bone marrow, stem cell, cord, umbilical, cost$ and method, costing, costing method$, costing
model$, cost accounting, and case-mix. Key journals such as Bone Marrow Transplantation,
Blood, Clinical and Laboratory Haematology as well as Cancer Treatment Reviews and the
European Journal of Cancer were also searched separately to ensure all references were found.
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The resulting citations were culled to exclude those that did not focus on either costing or
economic evaluation of blood and bone marrow transplantation. Only English language citations
were retained. Additional citations were identified by internet searching, reviewing reference lists
in recently published work and searching for recent publications by key researchers in the field. A
second round of culling was undertaken based on reading the abstract or executive summary of
each paper or report. Full text copies of the remaining 34 papers/reports were then reviewed.

3.4

Overview

The literature on costing blood and bone marrow transplants comprises only a small number of
studies, with the main work undertaken in the USA and Europe, in particular Scandinavia and the
Netherlands. The studies are limited in scope, most are targeted to particular indications and
underlying disease, and few provide detailed costing of the stages of transplant.
While about a third of the papers were published in the last 5 years, many refer to research
undertaken more than a decade ago. Each of two recent systematic reviews (of the health
economics of managing multiple myeloma, and of the comparative costs of high-dose
chemotherapy and autologous stem cell transplantation vs. conventional chemotherapy), reported
on only five studies examining the cost of BMT services (Moeremans and Annemans 2006,
Simnett et al. 2000).
Several economic evaluations of blood and marrow transplantation were found. Whilst economic
evaluation was outside the scope of this project the studies were reviewed for details of the costing
methodologies employed. In most such studies, the costing methodologies were not fully
explained, nor were costing details reported, but they were useful for the purposes of shedding
light on the overall magnitude of costs of different BMT service types.
Very little economic analyses of BMT services that take account of recent changes in clinical
practice and/or advances in new technology and diagnostics in the past few years, in particular in
relation to gene therapy and sources of donor stem cells are available. Thus, in terms of informing
the development of costings for BMT service components, most of the literature was of marginal
value.
The terminology used to refer to the economic aspects of BMT services differs throughout the
literature, at times affecting interpretation. It was important to distinguish, for example, between
charges and costs, in particular in regard to studies undertaken in the United States, since studies
reporting the hospital charge for BMT services and products, may not necessarily report the actual
costs of services.
A major difficulty in costing BMT services is that widely differing assumptions and a variety of
different inputs may be used to derive costings. This is particularly the case because there are
many different treatment methodologies covering both autologous and allogeneic transplants, a
variety of donor stem cells, and an increasing range of indications and clinical practice modalities.
Moreover, costs do not remain static and, because of the complexity of treatments and indications,
even small changes in protocol can lead to a large difference in cost (Freeman et al 1996). Most
studies refer to this matter, in keeping with the general principle that robust cost comparisons can
only be made when cost measurement is in reasonable compliance with a standardised costing
methodology (Smith and Mogyorosy 2005).
The pace of change in BMT is rapid so that conclusions regarding changes in clinical practice and
emerging technologies that may impact on service provision, if based on retrospective studies,
may already be out of date with practices and technologies well-established.
In a recent paper that aimed to identify trends in Europe in BMT patient numbers and to anticipate
transplant rates for the next 5 years, estimates of activity and expected changes in practice were
used to estimate likely costs (Tan et al. 2007). Greater use of reduced-intensity conditioning
regimens followed by transplantation (RIC-HSCT) and increasing worldwide donor availability were
noted as significant trends likely to lead to increasing use of transplant for a range of indications.
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The availability of alternative drug treatments was another key factor expected to influence trends
in transplantation. The study predicted an increase in autologous transplantation in Europe of 6%
between 2005-2010, with particular reference to the treatment of acute leukaemia and autoimmune diseases. An even greater increase of about 20% in allogeneic transplantation was
predicted, with rises in use for all indications except chronic myeloid leukaemia, due mainly to the
expected increased use of RIC-HSCT in older patients and in patients with co-morbidities.
Changes in the characteristics of BMT service delivery and consequent changes in costs and shifts
in cost distribution are the subject of discussion in a number of papers.
In terms of disaggregated costing data, the most comprehensive analyses found were:
• a 2002 Dutch study of a cost analysis for HLA-identical sibling and voluntary unrelated
allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute
myeloid leukaemia (AML) or acute lymphoblastic leukaemia (ALL) (van Agthoven et al.
2002); and
• a 2005 report prepared for the Technology Assessment Unit of the McGill University Health
Centre (Canada) on allogeneic transplantation in adults of stem cells from unrelated
donors.
A study by Prajogo (2004) reporting the results of a cost comparison of high-dose chemotherapy
and autologous bone marrow transplantation vs. standard dose chemotherapy for patients with
non-Hodgkin’s lymphoma at the Calvary Mater Misericordiae Hospital in Newcastle (NMMH)
provided the most relevant Australian analysis.

3.5

Cost drivers

Many of the studies identified factors that have an important impact on costs. The cost drivers
depended partly on the type(s) of BMT services being studied, the aim of the study, the country in
which the study was undertaken, data availability and the study methodology.
A number of studies noted the fundamental structural differences between the United States and
Europe in terms of health service delivery, resulting in different cost drivers for BMT services
depending on where studies are conducted.
For studies of autologous BMT, examples of cost drivers include:
• number of hospital days and blood products (for the period from hospital admission to
discharge only)
• stem cell mobilisation costs (harvest phase), nursing costs and pharmacy
• room costs, laboratory, pharmacy, medical consultant fees; radiology and supportive care
• conditioning regimens, number of hospital days, blood products, antibiotic and supportive
care
• induction chemotherapy (and within this, the number of cycles to achieve remission); postinduction: blood products, inpatient costs (medical staff and accommodation),
laboratory/radiology and pharmacy
• number of hospital days, number of stem cells collected, phase and type of disease,
whether patient is a child or adult.
For allogeneic transplants, examples of cost drivers include:
• tissue typing and donor stem cell collection costs, medical and nursing staff costs,
pharmacy, blood products and laboratory costs
• pharmacy, number of hospital days
• total body irradiation (TBI)
• number of hospital days, medical and nursing staff costs
• GVHD prophylaxis
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•

3.6

number of hospital days, post-transplant complications including infections, veno-occlusive
disease, GVHD, death..

Detailed cost analyses by stage of transplant

A Dutch cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and
peripheral blood stem cell transplantation in adults with AML or ALL between 1994 and 1999
included costs for patients prepared for, but who did not undergo, transplantation, and covered all
stages from pre-transplant tissue typing up to 24 months after transplantation. Costs were
separately identified for three transplant types (bone marrow transplant (BMT), matched unrelated
donor (MUD) and peripheral blood stem cell transplant (PBSCT)) and allocated either to the
pre-transplant phase, transplantation phase, or to one of the three follow-up phases (that is, 1-6
months, 6-12 months and 12-24 months after transplantation). Total costs per living patient were
estimated to be approximately $195,6001 for BMT, $301,9002 (MUD) and $196,9003 (PBSCT).
A Canadian comparison of the costs of allogeneic transplantation in 17 adults in 2004, using either
cord blood or PBSCT from unrelated donors, included costs for the transplantation procedure and
estimates of costs for up to 10 years after transplantation. Based on possible relapses, infections
and chronic GVHD, the total cost of an allogeneic stem cell transplantation including a 10-year
follow-up (excluding the cost of procurement of stem cells) in an adult patient was estimated at
approximately $A65,5004 and $A69,5005 for bone marrow and cord blood transplantation
respectively.

3.7

Previous cost estimates

In 2004, a study at the Royal Brisbane and Women’s Hospital estimated the approximate total cost
of bone marrow transplants, by transplant type, at that hospital. It should be noted that only two
patients were enrolled in each costing type. The study suggested benchmark mean costs of
approximately $54,500 for autologous transplants and $130,500 for allogeneic transplants6.
Prajogo (2004) investigated the costs of high-dose chemotherapy and autologous bone marrow
transplantation vs. standard chemotherapy in patients with relapsed non-Hodgkin’s lymphoma
treated at Newcastle Mater Misericordiae Hospital from January 1995 to June 2002. The study
covered the period from induction chemotherapy to conditioning and transplant only. Nonpharmaceuticals comprised the largest overall cost (61%), with the cost of inpatient stay the major
factor within the non-pharmaceuticals component (40% of total). The estimated total mean cost
per patient of $37,490 (in 2001) was compared with the cost of autologous transplantation in
patients with either lymphoma or acute leukaemia ($A70,769), or non-Hodgkin’s lymphoma
($A59,500) in the Netherlands. It was suggested that the differences related to factors including
use of total body irradiation before transplantation, service utilisation rates and the costs of
hospitalisation and blood products in the two countries, the proportion of total costs of
pharmaceuticals, and whether the transplant was PBSCT or autologous bone marrow
transplantation (ABMT).

1 $A2007 – costs converted from Euro 2002 to A$ and escalated using Reserve Bank of Australia Inflation Calculator (RBA)
www.rba.gov.au

2 $A2007 – costs converted from Euro 2002 to A$ and escalated using Reserve Bank of Australia Inflation Calculator (RBA)
www.rba.gov.au

3 $A2007 – costs converted from Euro 2002 to A$ and escalated using Reserve Bank of Australia Inflation Calculator (RBA)
www.rba.gov.au

4 $A2007 – costs converted from CDN to A$ and escalated using Reserve Bank of Australia Inflation Calculator (RBA) www.rba.gov.au
5 $A2007 – costs converted from CDN to A$ and escalated using Reserve Bank of Australia Inflation Calculator (RBA) www.rba.gov.au
6 $A2007 – costs escalated using Reserve Bank of Australia Inflation Calculator (RBA) www.rba.gov.au
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4 An overview of the BMT clinical process
An understanding of the clinical process of BMT was fundamental in undertaking this costing
study. Clinicians assisted in flowcharting the patient journey to identify the key stages of the BMT
process from the clinical care or service delivery perspective. This section provides an overview of
the BMT process identified by clinicians.
An important element of the consultation process was to form a view regarding start and end
points of the BMT process for the costing process. A consistent view was expressed that BMT
physicians and other staff are involved in treating patient’s at several stages before and after
transplantation. At the same time, however, views on the detail of this involvement differed
between clinicians as well as between adult and paediatric services.
During the consultation, various hypotheses were generated that were tested with clinical activity
data provided by hospitals to determine appropriate ‘start’ and ‘end’ points in this context. Based
on this, business rules were developed and applied in the costing process. These are presented in
Section 6.2 for inpatient episodes and Section 6.5 for outpatient activity.
The remainder of this section set outs ‘patient journey’ flowcharts, and a discussion of clinical and
related issues that were raised during the consultation process. In the discussion, an emphasis
has been placed on the issue of determining start and end points in the BMT process. Separate
flowcharts are provided for allogeneic and autologous transplants as well as for adult and
paediatric transplants.

4.1

Adult autologous blood and marrow transplant

The stages of the adult autologous BMT patient journey are depicted below in Figure 1.

Figure 1: The adult patient journey - autologous blood and marrow transplant

¾Outpatient
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4.1.1

BMT Physician accepts patient for transplant

Autologous transplantation can be done if a patient is in remission or with responsive disease. The
patient is ideally clinically stable and the timing of the transplant is disease specific. Peripheral
blood stem cells are the most common source of stem cells for autologous BMT in adults (Eden et
al. 2007).
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Three views emerged on the “start” point or beginning of the patient journey:
• The BMT journey starts when a decision is made to transplant the patient; this is reflected
in practice by the BMT Physician or BMT team accepting the patient.
• The BMT journey starts when there is an intention to transplant the patient.
• The BMT journey starts from when a patient is diagnosed with a condition in which BMT
may be indicated.
The distinction between the “decision to transplant” and the “intention to transplant” has been
made particularly by clinicians working with children. Using “intention to transplant” as the starting
point will ensure that the activity related to patients who are intended for transplant and therefore
placed on certain treatment regimes, counselled and potentially “worked up” but never actually
proceed to transplant, are captured.
The course of the underlying disease may result in the period from intention to transplant to
decision to transplant ranging from as short as two weeks through to several years. Using this
definition as the “start” of BMT would make costing virtually impossible as the ability to distinguish
between costs relating to the underlying disease and costs relating to a future transplant would
become blurred. The same can be said for a start point coinciding with diagnosis of a condition
that may be an indication for BMT.
An option presented in our interim report suggested that for costing purposes, the BMT process
could be deemed to start at the point when the BMT Physician accepts a patient for transplant.
This is usually reflected in practice by a series of outpatient visits as the patient is assessed and
subsequently worked up for transplant. It is recognised that in practice, this process is not clear
cut. Patients who have an underlying cancer that indicates BMT may have been managed by the
hospital or treating haematologist/oncologist for some time prior to the transplant episode.
However, in generating an accurate cost of BMT it is necessary to exclude episodes of care that
can be attributed to the underlying disease as opposed to the transplant.
4.1.2

Work up

The consultation process confirmed the view expressed by key stakeholders, that there is a high
level of consistency in the range of tests performed in the work up phase. Most routine medical
tests occur on an outpatient basis before the patient is admitted to hospital for BMT. The range of
tests performed depends on the type of underlying disease but the aim is to determine if the
patient is fit enough to endure the physical stresses of BMT. Heart function may be tested by a
gated heart pool scan and/or cardiac echo; kidney function is measured as well as lung function.
A chest or sinus x-ray may be indicated and some patients may require computerised tomography
(CT or CAT) or Positron Emission Tomography (PET) scan. A number of blood tests are taken
and these may screen for viral and bacterial infections, iron levels, blood glucose, clotting, thyroid
and liver function. The patient will have a full blood count and blood group identified. Some
patients may require a lumbar puncture and a bone marrow biopsy. Patients are also encouraged
to have a dental check up and to maintain good nutrition prior to transplant (Eden et al. 2007 and
Daly 2006).
4.1.3

Mobilisation

Eden et al. (2007:25) note that:
“Mobilisation occurs when the bone marrow increases production of stem cells, which then spill
out into the circulating blood so they can be collected. Your BMT doctor will decide on the best
regimen to mobilise your peripheral blood stem cells. The regimen will depend on your
diagnosis, previous chemotherapy and radiotherapy, and your general health.”
Mobilisation usually includes chemotherapy (one dose) and G-CSF (Granulocyte colony
stimulating factor) a synthetic version of a naturally occurring hormone, which is administered daily
by injection for 8-10 days. G-CSF stimulates the growth of bone marrow stem cells and also
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causes the mobilisation of peripheral stem cells. If the patient is well enough, many facilities
provide this care on an outpatient basis. If the hospital has an appropriate outreach team, it is
possible on occasion, for this process to occur in the patient’s home. Some facilities prefer to
admit the patient for anywhere from one to three days, depending on their level of wellness; status
of their underlying disease and prescribed mobilisation regimen.
4.1.4

Stem cell harvest (cell processing and storage)

Stem cell harvest occurs when the circulating peripheral blood stem cells are deemed to have
reached a certain level. Daily blood tests occur from mobilisation to the date of harvest to allow
the BMT team to identify the optimal time for harvest. Stem cells are collected using an apheresis
machine and this procedure usually occurs on an outpatient basis or in some cases as a day only
admission.
The amount of blood processed during the harvest depends on the practice of the hospital. Two
hospitals use large volume collection and process a minimum of 20 litres of blood during the stem
cell harvest. This requires the patient to stay in hospital for an extended period of 6 – 8 hours.
Most hospitals process a smaller volume of blood and if an inadequate number of stem cells are
collected, ask the patient to return a couple of days later for a second collection. Should the
source of stem cells be from bone marrow then a day only admission to hospital is required as
bone marrow harvests are performed in the operating theatre under general anaesthesia.
After collection, the stem cells must be transported to an appropriate laboratory for processing.
Major BMT sites have a laboratory on site. In NSW eight of the fifteen sites providing BMT have
laboratory capacity. However smaller facilities transport the collected stem cells to an off-site for
processing and storage until they are required. Transport costs are usually met by the hospital
sending the stem cells, for example, if Wollongong Hospital sends stem cells to Westmead
Hospital for processing and storage, Wollongong Hospital meets these costs. However when
Westmead Hospital transports the cells back to Wollongong Hospital for the transplant procedure,
Westmead Hospital pays the transport costs.
We note here that the scope of this study prevented a separate costing of the BMT laboratories
from being undertaken. The issue is discussed further in Section 7.4.
4.1.5

Transplant (including conditioning)

The patient is admitted prior to transplant for the conditioning process. Usually a central venous
catheter will be inserted and the patient will receive several days of chemotherapy and/or
radiotherapy to destroy bone marrow and cancerous cells and make space in the bone marrow for
the new stem cells. Whilst some facilities may provide this stage of the patient journey on an
outpatient basis, our consultation process found that almost without exception this stage is
provided on an inpatient basis as part of the “transplantation” admission.
“There are many different types of conditioning therapies used in autologous stem cell
transplantation but as a general rule they involve between five and eight days of high-dose
chemotherapy…Occasionally, chemotherapy is given with radiation therapy in the form of total
body irradiation (TBI). The kind of conditioning therapy…will depend on several factors
including the type of disease…age and general health and the type of transplant…” (Daly
2006:32).
Eden et al. (2007:11) reports that the doses of chemotherapy and/or radiotherapy given to patients
during conditioning are much stronger than doses given to patients with the same disease who are
not having a BMT.
The transplant proceeds a couple of days after this conditioning treatment and consists of an
infusion of the previously collected stem cells. This occurs in a hospital room rather than an
operating theatre. The patient remains in hospital while engraftment occurs – in the period prior to
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this the patient is at high risk of infection. A range of drug therapy will be required at this time and
the patient typically spends 2 - 4 weeks in hospital (Eden et al. 2007).
The mean average length of stay (ALOS) for an adult autologous transplant is 26 days based on
the data analysis undertaken in this study. A relatively small proportion of autologous transplant
patients require admission to ICU during the transplant episode.
Some hospitals are implementing early discharge practices for adult autologous patients,
particularly those with multiple myeloma. However, this requires an effective outreach or early
discharge program to be in place and in practice, occurs only rarely. These patients are visited
daily for 10 days. A major barrier to early discharge is the lack of available week-end outreach
services.
4.1.6

Post transplant management

This stage commences from the end of the transplantation episode. Clinicians indicated that
patients are normally seen once or twice per week immediately following transplantation and then
with decreasing frequency. If the patient is progressing well he or she will return for review
monthly for approximately six months, then revert to two-monthly visits for the remainder of the
twelve month period post transplant. Practice of course varies in individual cases based on clinical
judgement. If the patient has travelled from a rural area to a metropolitan centre for BMT he or she
will return home, usually at the six week mark, with their referring haematologist or oncologist
resuming care. There is a high requirement for prophylactic medication post transplant such as
anti-viral and anti-biotic medications.
During the post transplant period, patients may be readmitted to hospital. The most common
reasons for readmission cited during the consultations included: infection, fever and dehydration.
In the case of autologous transplants readmissions are often due to the underlying disease. The
inpatient data sourced from facilities has provided greater detail about the frequency and cause of
readmissions and this is discussed in Section 7.2.
The views expressed regarding identifying an end point has been relatively consistent. Most
clinicians agreed that the BMT process has usually ended by twelve months post transplant.
Clinical management by the BMT team may finish earlier than this, with the patient referred back to
their treating haematologist or oncologist. This discussion has been important in establishing the
‘end’ point of the transplant process for costing purposes.
Data provided by hospitals has been analysed in conjunction with the advice received during the
consultation process to determine when the BMT process will be considered to have commenced
and ended for costing purposes. The results of this process is outlined in Section 6.
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4.2

Paediatric autologous blood and marrow transplant

The stages of the paediatric autologous BMT patient journey are depicted below in Figure 2.

Figure 2: The paediatric patient journey - autologous blood and marrow transplant
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The paediatric patient journey in autologous BMT mirrors the stages of the adult patient journey.
Whilst there are no major differences in the transplant process, several issues identified during the
consultation process are discussed for each stage.
4.2.1

BMT Physician accepts patient for transplant

During the consultation process, paediatric clinicians pointed out that the patient may not be in
remission prior to transplant. This may be related to the growing use of BMT in the management
of non-malignant disease. It has also been emphasised that there is a significant amount of
counselling and discussion that occurs with the patient’s family - and often extended family - prior
to the decision to transplant being made. In the case of children the transplant team have
additional issues to manage. For example, if the family lives some distance from the treating
hospital, they may all move to the metropolitan centre for the period of the patient’s hospitalisation.
This generates various support needs such as accommodation, financial assistance, counselling
and schooling for siblings. This support is co-ordinated by the transplant team. The family often
requires significant amounts of face to face time with the BMT Physician to understand the
transplantation process. A proportion of families choose not to proceed with the transplant after
this period of discussion and education.
Clinicians working in paediatric transplant centres recognise that time is invested in counselling the
adult patient and family prior to the patient deciding to proceed to transplant. However, the
dependent nature of the child does generate a greater degree of clinical and allied health input at
this stage of the patient journey. This view is supported by the volume of outpatient activity
reported by the paediatric facilities.
4.2.2

Work up

Where possible the patient work up occurs on an outpatient basis, however certain underlying
diseases (e.g. acute leukaemia) may mean that the child is already hospitalised and the transplant
work up occurs on an inpatient basis. Some patients require additional investigations
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e.g. neuroblastoma patients, but as this need is driven by the diagnosis it does not materially
impact the BMT costing process.
Clinicians identified that there is a cost associated with preparing paediatric patients for transplant
who do not then proceed to transplant. We recognise that this a legitimate cost and that it has not
been included in this study. The reason for its exclusion relates to data availability and the fact
that the study dataset is based on patients who had received a transplant during the study period.
As such, it was not possible to identify the range of costs incurred by patients that did not progress
to transplantation.
4.2.3

Mobilisation

The major difference identified in this stage of paediatric autologous BMT is that stem cells are
often mobilised ‘off the back’ of a course of chemotherapy that is being given to manage the
underlying disease. The paediatric patient is more often an inpatient than an outpatient. The costs
relating to mobilisation are captured through the inpatient episodes.
4.2.4

Stem cell harvest (cell processing and storage)

In the paediatric patient journey the primary source of stem cells is peripheral blood rather than
bone marrow. This means that the child may require a visit to operating theatre and a general
anaesthetic. The patient is always admitted in this situation. In children, stem cells may be stored
for long periods as the course of the underlying disease can be unpredictable. In addition, it may
be thought that a second transplant may be indicated at a future time.
4.2.5

Transplant (including conditioning)

The conditioning and transplant process is similar for adults - noting that conditioning regimens are
clearly tailored for each paediatric patient. Chemotherapy is usually given for several days and the
patient given two days break prior to the stem cell infusion. Patients who have myeloblative
conditioning therapy will be very ill and highly immunosuppressed. Anecdotal advice suggests the
average length of stay is longer for children than adults. An analysis of the data supplied resulted
in an average length of stay (mean=25 days) that is similar to that for adult autologous transplant
patients. (Refer to Section 7.1).
4.2.6

Post transplant management

Based on feedback provided during consultations, it appears that monitoring in the immediate post
transplant phase is more frequent in paediatric patients. Initial discussions suggested that the
period of post transplant management extends for 24 months. However, subsequent advice from
paediatric BMT clinicians has confirmed that 12 months post transplant reflects actual practice. As
children often do not have the comorbidities that may generate further readmissions post
transplant, it is likely that most readmissions are due to the underlying disease as opposed to
BMT.
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4.3

Adult allogeneic blood and marrow transplant

The stages of the adult allogeneic BMT patient journey are depicted below in Figure 3.

Figure 3: The adult patient journey - allogeneic blood and marrow transplant
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As many stages of care are similar to the autologous BMT patient journey, these are not restated
in detail. Comment is provided on aspects unique to allogeneic BMT.
Clinicians emphasised the differences in the patient journey for autologous and allogeneic patients.
The varying levels of complexity within the allogeneic transplant group have been consistently
raised during interview and concerns expressed that the one AR DRG may not accurately capture
the variations amongst allogeneic transplant patients.
The major determinants of complexity are three-fold:
• Donor status (related or unrelated; matched or unmatched);
• Source of stem cells (bone, peripheral blood or cord blood);
• Acuity of patient’s underlying disease.
4.3.1

BMT Physician accepts patient for transplant

Allogeneic transplant uses stem cells donated by another person (a donor). Bradstock et al.
(2006:8) describe two types of allogeneic transplants:
“Myeloblative or full allo: the aim is to destroy the patient’s marrow and kill the cancer
cells. Non-myeloblative (“mini” allo): the aim is to suppress the patient’s marrow and
allow the donor cells to grow and attack the cancer cells. This is the graft-versus-tumour
effect.”
With use of reduced intensity conditioning regimens in allogeneic transplantation, the age limit has
increased, permitting the inclusion of older patients. This patient group may have a range of
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comorbidities associated with advancing age and/or underlying disease. The patient is usually in
remission and must be clinically stable for transplant. The timing of the transplant is always
determined by each patient’s underlying condition.
4.3.2

Tissue typing and virology markers

The BMT Physician accepts the patient for transplant recognising that tissue typing and virology
markers are required. Unless a suitable donor can be found then it is not possible to proceed to
transplant. The donor may be related or unrelated; matched or unmatched and the source of stem
cells may be from peripheral blood, bone marrow or cord blood. In Australia in 2004, allogeneic
related donor transplants comprised 56% of all allogeneic transplants and allogeneic unrelated
donor transplants approximately 44%. (Nivison-Smith, Bradstock and Dodds et al. 2007)
Tissue typing is carried out by the Australian Red Cross. It is done to check how closely the
patient’s cells match the potential donor’s cells. HLA (human leukocyte antigen) markers are
found on almost all the cells in the body and they are one of the main ways the immune system
can tell the difference between the patient’s own cells and foreign cells. The closer the match in
HLA types, the better the chance of a successful transplant. (Bradstock et al. 2006:25).
Both the donor and patient are tissue typed - this occurs on an outpatient basis. How the process
proceeds depends on the nature (related or unrelated) of the donor and the location of the
donor/and or stem cells. Whilst the most suitable donor for a stem cell transplant is a fully
matched (tissue typed) family member, only about one person in three has such a donor. This
means that several family members will need to be tissue typed and, if a donor is not found in the
immediate family, a wider family search and/or unrelated donor search may be needed.
(Bradstock et al. 2006). The search for a donor starts with the hospital who works in conjunction
with the NSW Search Co-ordinator from the Australian Red Cross to try to find a related donor.
The search may then be passed to the Australian Bone Marrow Donor Registry (ABMDR), should
an unrelated donor be required.
Costs related to tissue typing have not been separately identified in this study. It should be
recognised that costs relating to tissue typing have increased significantly in recent years due to
the rapid advancements in tissue typing technology. Hospitals are only funded for Low Resolution
Class 1 typing. High Resolution typing is now standard practice.
4.3.3

Work up

The work up process is similar to that described for autologous BMT and usually occurs on an
outpatient basis.
4.3.4

Donor collection (cell processing and storage)

The donor collection stage is unique to allogeneic BMT, however the actual process of stem cell
collection is similar to that described in Section 4.1.4. If the donor is unrelated, the collection
process will occur in a separate facility to ensure patient confidentiality. Most transplants from
unrelated donors use bone marrow cells. The donor may be managed as an outpatient or
admitted. If for any reason the donor is admitted this is for a maximum of one to two days. The
patient receiving the transplant is always admitted prior to donor collection to ensure their
readiness for conditioning.
If the donor is related and resides within NSW they will normally travel to the hospital where the
patient will have the transplant. This means that the donor or family of the transplant recipient will
normally meet the costs related to the donor’s travel, whilst the hospital stay would normally
covered by Medicare. In these cases, it is possible that the NSW Isolated Patients Travel and
Accommodation Assistance Scheme (IPTAAS) may offer some financial assistance. IPTAAS is a
transport and accommodation subsidy scheme that assists people in isolated and rural
communities to gain access to specialist medical treatment not available in their own area.
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While donors outside NSW may choose to have their donor collection process in a transplant
facility in their own state, any donor to a NSW resident who is an Australian resident is eligible to
access the NSW IPTAAS. Usually collection of stem cells occurs from peripheral blood and this
can be done via apheresis as an outpatient. The hospital treating the transplant recipient then
arranges for collection and transport of the stem cells. The costs of this collection are met by the
NSW based hospital that will provide the transplant.
If the donor is overseas then the Commonwealth funds the costs of stem cell collection and
transport. International unrelated donor searches and cell procurement are managed by the
ABMDR. If a NSW donor is a match for another international patient requiring a BMT than the
assessment, work up and stem cell collection is done by a NSW hospital. The Commonwealth
reimburses the NSW hospital for these costs up to a maximum of $2000 per patient, (this fee has
apparently remained the same since 1992). If however a NSW donor is a match for another
Australian patient requiring a BMT then the NSW hospital has to assess, work up the donor and
collect the required stem cells at the cost of the hospital. According to the ABMDR, in NSW an
estimated 25 patients per annum (international and national) are admitted for donor collection.
Cord blood donations require specific attention as obtaining these from overseas cord blood banks
is very expensive, although the cost is usually mostly met by the Commonwealth. The ABMDR
currently have a contract with the Commonwealth and a parallel contract with State Cord Blood
Banks.
It has been suggested during consultation that there are higher costs of storage with allogeneic
transplant patients – this is related to the use of donor cells that may require more complex
processing and longer periods of storage.
4.3.5

Transplant (including conditioning)

The conditioning process is a critical part of the transplant process. For allogeneic transplant
patients this will include chemotherapy and frequently Total Body Irradiation (TBI). In TBI,
radiotherapy is given to the entire body to kill cancer cells and suppress the immune system to
allow the transplanted cells to engraft. It is usually given in six treatment sessions over three days
within the Radiation Oncology Department.
Often additional consultations are needed with other sub-specialists to manage any pre-existing
co-morbidities or anticipated complications. The most complex type of allograft is that which uses
a matched unrelated donor. These patients have a much higher incidence of admission to an
Intensive Care Unit post transplant and a longer average length of stay. Figure 3 provides the
mean ALOS for allogeneic transplants (all types) which is 34 days. Clinician advice suggests that
the ALOS for matched unrelated donors is usually substantially longer than that for matched sibling
donors.
4.3.6

Post transplant management

In the case of allogeneic transplants, whilst these patients are customarily followed up for longer
than twelve months, most of the major costs “post transplant” are likely to occur in the first year
post BMT. The post transplant stage follows a similar trajectory to that described for the
autologous BMT patient recognising that periodic monitoring may extend for at least 24 months.
In the post transplant period, patients may be readmitted to hospital. The major difference with
allografts is that the patient may develop Graft versus Host Disease (GVHD). This is a very
serious complication of allogeneic BMT. It occurs when the donor marrow cells begin to engraft
and multiply and the donor T lymphocytes see the patient’s own body as foreign and try to destroy
tissues and organs. The conditioning therapy has suppressed or eliminated the patient’s immune
system to stop their body rejecting the donor marrow. Acute GVHD occurs within 100 days after a
BMT and may be mild through to life threatening. Chronic GVHD develops more than 100 days
after BMT. Chronic GVHD is more common in people whose donor is unrelated or whose marrow
is not perfectly matched (Bradstock et al. 2006:87-92).
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The inpatient data sourced from facilities enumerates the major causes of readmission including
those linked to GVHD. GVHD arose as a major concern during the consultation process due to the
extraordinarily high costs of managing both acute and particularly chronic patients with this
condition. It was suggested that the multi-drug therapy required by these patients post transplant
for extended periods, has a significant cost impact, particularly anti-fungal therapy. Patients will
also need to be re-immunised twelve months post transplant.

4.4

Paediatric allogeneic blood and marrow transplant

The stages of the paediatric allogeneic BMT patient journey are depicted below in Figure 4.

Figure 4: The paediatric patient journey - allogeneic blood and marrow transplant
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Evidence gathered during consultations indicates that a higher proportion of unrelated donor
transplants are done in paediatric BMT patients. In addition, the majority of cord blood transplants
occur in paediatrics and these stem cells take longer to engraft therefore carrying higher risk and
resulting in a longer length of stay. The mismatched cord blood transplant is deemed the most
clinically difficult and costly.
4.4.1

BMT Physician accepts patient for transplant

This stage occurs in the same way that has been described for the paediatric autologous BMT
patient. However paediatric clinicians have highlighted the diversity of underlying conditions for
paediatric allograft patients and the fact that for complex non-malignant immunodeficiency or
metabolic indications, there may be a much higher level of sub-specialty consultant input require
both pre and post transplant.
4.4.2

Tissue typing and virology markers

The tissue typing stage is similar to that described for the adult allogeneic BMT patient journey. As
with adults, several family members may be tissue typed to find an appropriate related donor.
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4.4.3

Work up

Where possible the patient work up occurs on an outpatient basis. However as is the case in
paediatric autologous BMT, certain underlying diseases (e.g. acute leukaemia) may mean that the
child is already hospitalised and the transplant work up occurs on an inpatient basis. Anecdotal
advice suggests that approximately 10% of paediatric patients may not survive or not go into
remission and therefore do not proceed to transplant. Clinicians felt that if possible, these costs
should be captured. However, as identified in Section 7.4, the study was limited to those patients
who actually proceeded to transplant.
4.4.4

Donor collection (cell processing and storage)

There is no significant difference to the donor collection process except for the fact that the
majority of donor cells used in paediatric BMT are sourced from bone marrow. The donor will be
admitted for this bone marrow harvest. The transplant recipient is usually an inpatient at the time
of donor collection.
With children, some stem cells may be stored for future transplants, particularly if their underlying
disease makes them prone to relapse. As there are a higher proportion of unrelated transplants in
children, this can increase demand for additional cell processing measures. These measures are
high cost and are met by the treating hospital e.g. CD34 selection which filters out T cells from the
stem cell graft reducing the risk of GVHD.
A proportion of donor collections will incur additional costs for the transplanting hospital,
associated with stem cell procurement and transport.
4.4.5

Transplant (including conditioning)

The conditioning and transplant occur in the same episode. As conditioning is usually aggressive
it is provided on an inpatient basis. In paediatric allogeneic BMT, children with malignant disease
usually receive TBI unless they are younger than two years and/or have an existing developmental
problem.
As the indications for non-myeloblative conditioning are increasing, the potential for a second
transplant is becoming more common. Higher risk may be associated with paediatric patients
having a second transplant. Data analysis reveals that the mean average length of stay for
allogeneic paediatric patients is approximately 65 days. This longer length of stay is due in part to
the acuity of children who have had intensive chemotherapy prior to transplant (for example whilst
there has been some improvement in upfront treatment for leukaemia patients, these regimens are
more intensive so if the child does have to progress to transplant they are often sicker). The
higher proportion of unrelated donor transplants and the growing proportion of cord blood
transplants (the latter taking longer to engraft) also impact on average length of stay.
4.4.6

Post transplant management

The paediatric allograft patient is seen up to two to three times per week for the first three months
post transplant. Outpatient visits then reduce to weekly after three months post transplant and by
the six month mark, the child is usually seen once per month. A variety of allied health
professionals may be involved during the post transplant period, most often social work, dietetics,
physiotherapy and occupational therapy. Whilst the GP is kept informed throughout the course of
treatment, at the six month mark the BMT Physician actively tries to involve the child’s GP in
ongoing patient management.
Whilst the immediate transplant related complications occur in the first twelve months post BMT,
the use of myeloblative conditioning protocols and associated risk of GVHD can lead to
complications up to 24 months post transplant. The management of chronic GVHD can be
particularly resource intensive, even though it occurs less often than in adults. With children there
is the added complication of the potential impact of toxicity (from the high dose chemotherapy) on
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future growth and development e.g. children may require a cardiac echo every two years to
monitor risk of cardiac failure post high dose chemotherapy. This leads to a longer period of follow
up and periodic monitoring for children, with six monthly monitoring often occurring for up to five
years post transplant, with the patient then reverting to annual review.
Whilst it is recognised that paediatric patients do require follow up for longer periods than adults,
data analysis demonstrates that the vast majority of related inpatient episodes occur in the 12
months immediately post transplant (as discussed in Section 7.2).
Another major challenge for paediatric BMT services is transitioning adolescents to adult
haematology/oncology services. This is difficult as families often have a long association with their
respective Children’s Hospital and many are reluctant to transfer their child’s care to an adult
facility. Whilst adult patients can often be directed by the BMT Physician back to the referring
haematologist/oncologist, this is more difficult with children who may have been referred by a
generalist paediatrician. This means that paediatric haematologists/oncologists often manage the
general follow up of children on an ongoing basis until the patient transitions to an adult service.
There continues to be high drug use during the post transplant stage with immunosuppressants,
antifungals and antibiotics required. Patients will also need to re re-immunised twelve months post
transplant. Most readmissions (if not related to the child’s underlying disease) are due to BMT as
these patients rarely have comorbidities.

4.5

Differing clinical practices

In developing the costing methodology it is necessary to distil other clinical issues from the
consultations that may impact on BMT. These issues were “reality tested” with the Cost Study
Reference Group.
Generally there is a high level of consistency in the management of BMT patients. The Greater
Metropolitan Clinical Taskforce (GMCT) Bone Marrow Transplant Network has been highly
effective in ensuring there are agreed indications for BMT and a standardised approach to the
investigations required during the “work-up” stage pre transplant. If a patient has had extensive
treatment of their underlying disease prior to transplant, more tests may be indicated. There are
also common treatment protocols.
During the course of consultation very few differences in clinical practice have emerged. None of
these differences were seen to have a material impact on this study.
•

Extended Family Donor Search: When a related donor is being sought tissue typing
usually occurs of immediate family members. One facility pursues extended family
searches with as many as 20 – 30 persons tissue typed instead of the more common 3 – 4
persons. Tissue typing is recognised as an expensive process.

•

Mobilisation: Whilst varying stages of the patient journey occur in the outpatient setting
only one facility provides outreach services for BMT patients. This hospital has two Clinical
Nurse Consultants who manage a cohort of haematology patients, including those who are
to have, or have had BMT. These nurses assist suitable patients to manage the
mobilisation process at home and assist with injections if necessary and collection of blood
samples to monitor the CD34 cell count and predict the day of stem cell harvest. They will
also administer blood and platelet transfusions in the home, should they be indicated.

•

Stem Cell Harvest: A couple of hospitals use large volume collection and process a
minimum of 20 litres of blood during the stem cell harvest. This requires the patient to stay
in hospital (usually an outpatient setting) for an extended period of 6 – 8 hours. Best
practice of stem cell collections needs to be validated, that is, large volume versus small
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volume blood processing. For hospitals that perform small volume harvests, if inadequate
stem cells are collected, the patient returns the very next day for another collection.
•

Interval from Harvest to Transplant: This period can vary significantly from weeks to
months and is driven by the patient’s underlying disease. In children there may be a much
longer period as stem cells may be required years later, this impacts on cell storage
capacity and costs.

•

Rainy Day Harvest: Most BMT teams treating adult patients try not to do rainy day
harvests because of the additional costs and ongoing cell storage issues. However
paediatric patients that are expected to have an allogeneic transplant have their own
peripheral blood stem cells collected and these are routinely processed and stored as
backup if the allogeneic transplant fails.

•

Use of PET scan: Some clinicians advise that a PET (Positron Emission Tomography)
scan is completed pre and post transplant for most lymphoma patients. (Patients are sent
to either Royal Prince Alfred or Liverpool Hospital).

•

Post Transplant Care: A few hospitals are trying to implement early discharge practices
for adult autologous patients, particularly those with multiple myeloma, (there are strict
criteria for eligibility for early discharge). In practice this occurs rarely and is only possible
where there is an effective outreach or early discharge program. These patients are visited
daily for 10 days; a major barrier to early discharge is the lack of week-end outreach
services.

•

Extracorporeal Phosphoresis: ECP may be a treatment of choice in patients with GVHD.
Treatment occurs on consecutive days every two weeks for up to three months. Each
treatment is costly. ECP in Australia is currently only accessible in Victoria.

4.6

Clinical issues that impact on BMT costs

Most clinical issues relevant in autologous and allogeneic BMT have been covered during the
description of the respective adult and paediatric patient journeys. Some clinical issues were
identified that may have an impact on the cost of providing BMT services and are therefore
outlined here.
Firstly, it was noted that the growth in technology for tissue typing has increased the accessibility
and utility of extended tissue typing (high resolution or molecular tissue typing). The indication for
high resolution typing (HR Class 1) is becoming more standard and has cost implications.
The cost of donor stem cell procurement is borne by the transplanting hospital for related donors
that reside within Australia. This can result in travel costs to collect stem cells and lost productivity
or staff time as highly trained nursing personnel are those most often sent from hospitals to collect
stem cells.
Haematology/Oncology Units in large rural centres often meet the costs of work-up and the costs
of post transplant management (particularly drug costs) even though the transplant episode may
not have occurred in this facility. This issue was raised particularly by Newcastle Mater and John
Hunter Hospital who send all allogeneic transplant patients to Sydney. This occurs also in smaller
BMT centres that may only do autografts yet assist with pre and post management of patients
requiring allografts. NSW Health policy currently states that after one year post treatment the cost
of drugs will be met by the patient’s area of residence.
In paediatric care, the transplant team often needs to manage the entire family through the
transplant process. This requires significant time from senior clinicians and allied health
personnel. Paediatric cancer patients tend to have ongoing involvement of their paediatric
oncologist or haematologist and there are challenges in transitioning these patients to adult
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services. This is driving an emerging trend to ‘shared care models’ between paediatric oncologists
and adult oncologists.
In the case of Sydney Children’s Hospital (SCH), children sometimes travel from South Australia
for a BMT. In these cases, SCH may only meet a proportion of the costs because the pre and post
transplant management occurs in the child’s home state. The converse experience occurs with
children referred from the ACT, as all stages of the patient journey are managed at SCH.
The development of pre transplant genetics may extend the potential for unrelated donor
transplants in the future. This is already being seen overseas in families with a congenital history
of thalassemia.
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5 Data collection and the development of a BMT study dataset
The primary aim of this project was to develop cost estimates for the various care processes
involved in the delivery of BMT services. As such, it was important to obtain data relating to the
cost of BMT episodes, related inpatient episodes and a range of outpatient BMT services.
The scope and timeframe of the study precluded a prospective costing study being undertaken.
Instead, the data collection protocol developed for the study was based around retrospective data
available from hospitals that provide BMT services.
Each of the eight hospitals with clinical cost data was contacted to discuss their capacity to provide
data. Three types of data were potentially required:
• Costs of inpatient and outpatient services provided to BMT patients;
• Service utilisation data in relation to outpatient services provided to BMT patients;
• Clinical information comprising diagnosis and procedure data for BMT inpatient episodes.
The study team worked with each facility to obtain the range of required information related to BMT
services. This process took many weeks and often involved several iterations of data being
provided to the study team. During this process, several methodological issues arose in relation to
the structure of the study dataset and the proposed data analysis approach. The key issues and
the agreed outcome are discussed briefly below.

5.1

Inpatient cost data - clinical costing versus cost modelling data

This issue was identified in our project proposal and subsequently discussed in our Interim Report.
NSW public hospitals routinely participate in an annual hospital inpatient cost data collection that
involves an annual submission of cost data to NSW Health. The outcome of this process is the
development of AR-DRG costs for separations that occurred in the previous financial year.
Hospitals rely on two basic types of costing systems to produce data for this annual hospital cost
data collection. Firstly, an increasing number of hospitals have implemented what are referred to
as ‘clinical costing’ systems. Other hospitals rely on what is referred to as a ‘cost modelling’
approach to producing costing information.
In the current study, we are aiming to produce costs for two types of inpatient episode:
• BMT episodes;
• Other inpatient episodes related to the BMT treatment.
In the context of this study, there is an important difference in the capacity to use data extracted
from each type of costing system. Clinical costing systems produce a cost for individual episodes
of care by costing the various elements of care provided during an episode. These costs can be
analysed individually or rolled up to produce an average AR-DRG cost. Importantly, it is
straightforward to identify and obtain cost data for related inpatient episodes provided to BMT
patients.
Cost modelling systems produce cost estimates through a ‘top down’ process in which costs are
allocated to AR-DRGs using a set of existing relativities. The end result of the cost modelling
process is an average cost for each AR-DRG. The process does not produce costs at the
individual episode level.
The key issue in the context of this study is that cost modelling systems do not allow the costs of
BMT related episodes to be identified. Data from these hospitals can only be used to analyse the
cost of BMT episodes. This is because a BMT related episode could be assigned to virtually any
AR-DRG. BMT patients would comprise only a small proportion of the patients contributing data to
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that AR-DRG. As such, the average AR-DRG cost would be meaningless in terms of
understanding costs of episodes related to the BMT.
Given the limitation of data extracted from cost modelling systems, it was agreed to utilise data
from hospitals with clinical costing systems as the primary data source for inpatient cost data for
the study. Clinical costing data were available from eight of the fifteen hospitals that provide BMT
services. These facilities therefore formed the basis of the study dataset.
Importantly, of the six hospitals that undertake allogeneic BMT, Royal Prince Alfred Hospital is the
only facility that could not provide clinical costing data. As noted earlier, based on the average
number of BMT episodes currently undertaken in NSW annually for adults, the study captured data
on 90.1% of allogeneic transplants and 58.1% of autologous transplants. We are confident that
this is a representative sample of BMT episodes across NSW.
Table 3 below shows fifteen BMT hospitals and which of these have the type of costing system in
use during the study period at each of the BMT hospitals.

Table 3: Types of costing systems in NSW BMT hospitals
Hospital
St Vincent's Hospital*
Westmead Hospital*
Royal North Shore Hospital*
Royal Prince Alfred Hospital
Sydney Children's Hospital*
Children's Hospital Westmead*
Concord Hospital
Gosford Hospital
John Hunter Hospital
Liverpool Hospital
Nepean Hospital*
Newcastle Mater Hospital
Prince of Wales Hospital*
St George Hospital*
Wollongong Hospital

Type of Costing System
Clinical costing
Clinical costing
Clinical costing
Cost modelling
Clinical costing
Clinical costing
Cost modelling
Cost modelling
Cost modelling
Cost modelling
Clinical costing
Cost modelling
Clinical costing
Clinical costing
Cost modelling

Type of BMT Provided
Allogeneic and autologous
Allogeneic and autologous
Allogeneic and autologous
Allogeneic and autologous
Allogeneic and autologous
Allogeneic and autologous
Autologous
Autologous
Autologous
Autologous
Autologous
Autologous
Autologous
Autologous
Autologous

* Contributed data to the study dataset

5.2

Use of costing data from a different number of years

As noted, eight hospitals contributed data to the study dataset. These hospitals were able to
provide data for one, two or three financial years. The differing capacity to provide data between
hospitals was largely determined by the period of time that each hospital has been operating a
clinical costing system.
Four hospitals provided three years of data (2004/05,2005/06 and 2006/07), one hospital provided
two years of data (2005/06 and 2006/07) and three hospitals provided one year of cost data
(2006/07) as shown in Table 4 below. It was agreed not to consider using data from periods
earlier than 2004/05 because of the cost implications of changes that may have occurred in clinical
practice since that time.
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Table 4: Available inpatient cost data from hospitals in study dataset
Hospital
St Vincent’s Hospital*

Available Inpatient Cost Data
2005/06, 2006/07

Westmead Hospital

2006/07

Royal North Shore Hospital

2006/07

Prince of Wales Hospital

2004/05, 2005/06, 2006/07

St George Hospital

2004/05, 2005/06, 2006/07

Nepean Hospital

2006/07

Sydney Children’s Hospital

2004/05, 2005/06, 2006/07

Children’s Hospital Westmead

2004/05, 2005/06, 2006/07

* St Vincent’s also provided clinical data for 2007/08

A methodological issue that arose was whether to include data for a different time period from
different hospitals in the study dataset. At one level, it could be argued that a simple approach
would be to limit the study dataset to one year. However, BMT services are clearly a high cost/low
volume activity. As such, obtaining a sufficient sample size to derive reliable cost estimates was a
critical concern for the study.
Further, the hospitals that could provide three years of data tended also to be hospitals that
provided a small number of BMT episodes on an annual basis. In some cases, it would not have
been possible to produce meaningful cost estimates at the hospital level based on only one year’s
data.
For this reason, it was decided to include all available data from each facility between 2004/05 and
2006/07. Data from 2004/05 and 2005/06 were inflated to 2006/07 terms using rates provided by
the NSW Department of Health. In adopting this approach, it was important to ensure that
hospital’s with two or three year’s data were not over represented when calculating average BMT
costs across multiple hospitals.
The method adopted for the analysis was to calculate any multiple hospital average cost as the
average cost of those hospitals that contributed to that average weighted by each hospital’s
average number of BMT episodes per year. Clearly, it was not necessary to apply this weighting
when averages were being calculated for individual hospitals.
A final point is worth noting in relation to this issue. As both of the paediatric facilities were able to
provide three years of cost data, any averages calculated only for these facilities will not be
affected by the weighting approach. Similarly, for the three adult hospitals, as two provided one
year’s data and one provided two year’s data, the impact of the weighting approach will be
minimal. The only circumstance when the weighting will have an effect is if combined average
costs are produced across both paediatric and adult hospitals.
Overall, in our view, the approach adopted represents the most appropriate method to maximise
the available data whilst ensuring that each hospital is appropriately represented in the calculation
of average costs.

5.3

Collection of inpatient cost data

As noted, the primary source of inpatient cost data for the study was clinical cost data produced by
each of the eight hospitals as part of the NSW Health annual hospital cost data collection process.
Each hospital was asked to provide a dataset that contained episode level cost data for the
following two types of inpatient episodes:
• BMT episodes where the separation date was in the financial year/s being costed by that
hospital;
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•

Any other inpatient episode for these patients that occurred in any of the financial year/s for
which cost data were being provided by that hospital.

Relevant details such as episode dates and AR-DRG together with cost data for each episode
broken into the following cost buckets was provided by each hospital:
• Clinical (medical) costs
• Ward (nursing) costs
• Allied health costs
• Pharmacy costs
• Intensive care unit costs
• Imaging costs
• Pathology costs
• Operating room costs
• Emergency department costs
• On costs
• Depreciation costs
• Total costs
As outlined in Section 6.1, on receipt of each dataset, a range of edit checks were undertaken to
identify any potential anomalies in the data. Where necessary, hospitals were contacted to clarify
issues and any necessary re-submisson of data was arranged.
5.3.1

Pharmacy cost data

The importance of identifying the cost of pharmaceuticals was raised at each consultation as it
represents a significant proportion of both inpatient and outpatient BMT services.
For inpatients, sites provided patient level drug costs for patients in the study cohort. An issue was
identified by hospital pharmacists and other staff about the capacity to cost ‘imprest’ drugs (drugs
not dispensed to individual patients). In costing systems, a share of the cost of these drugs is
allocated to BMT patients on a per diem basis using AR-DRG based relative value scales. This
issue was discussed with each site’s costing staff (and pharmacy staff where necessary), during
the data preparation process. As a result of these discussions, we are confident that the cost of
imprest drugs has been accurately allocated to BMT patients.
In relation to outpatients, it was equally important to obtain patient level costs for drugs dispensed
to BMT patients. In this case, the issue of imprest drugs did not arise as all outpatient drugs are
dispensed on an individual patient basis. Here, an effort has been made to identify drugs that fall
under the Section 100 scheme as well as any drugs that are dispensed through the PBS.
At an initial meeting of the Study Reference Group, it was suggested that the process of costing
BMT drugs may be expedited by identifying the top 10 to 20 high cost BMT drugs. To this end,
several hospitals were able to provide separate cost data on the high volume drugs dispensed to
BMT patients. This information has been compiled and is presented in Section 7.3.2.

5.4

Collection of inpatient clinical data

Each of the eight hospitals provided ICD 10 diagnosis and procedure data for each of the years for
which financial data were provided. In one case, clinical data were provided for a year (2007/08)
for which cost data were not available. The clinical data included several (ranging from 3 to 10)
ICD 10 diagnoses codes and one procedure code.
These data were used for several purposes in the preparatory analysis process as discussed in
Section 6.2. Most notably, this information provided an important clinical profile of inpatient
services provided to BMT patients before and after their transplantation episode.
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5.5

Collection of outpatient data

During the consultation process, BMT clinicians and other staff were asked to provide a profile of
the range of pre and post transplantation services that are provided to BMT patients on an
outpatient basis. Some differences were identified in models of care between hospitals that impact
on the type and level of outpatient services that are typically provided.
The availability of outpatient activity and corresponding cost data was substantially less than for
inpatient services. This finding was expected given that the systems required to routinely generate
this information are not generally in place. This issue was flagged at the outset of the study. It
was agreed that where data were not available, cost estimates would be developed based on a
combination of service utilisation and the best available financial information.
A study protocol was developed and hospital’s asked to provide the details shown in Table 5 below
in relation to outpatient activity:

Table 5: Outpatient data collection
Outpatient Clinics

Drugs

Pathology

MRN

MRN

MRN

Date of service

Date dispensed

Date of test

Duration of service

Drug name

Test type

Clinic description

Drug cost

Cost of test

Imaging

Radiotherapy

Other Outpatient Services

MRN

MRN

MRN

Date of test

Date of service

Date of service

Test type

Cost of service

Description of service

Clinician seen
Cost of service

Cost of test

Cost of service

In practice, some hospitals were able to provide costed activity data for most of the outpatient
services identified above. However, most hospitals were able to provide activity data for only
some of the above services and very few hospitals were able to provide detailed cost data.
The exception to this was in the area of drugs where all but one hospital, (that provides a low
volume of adult autologous transplants), was able to provide the required drug data. This is
important as it represents the most expensive element of BMT outpatient services. For the
remaining services, cost estimates were developed base on the data that were available in each
area. The results are provided in Section 7.3. We stress that the areas in which data were not
available represent a relatively small component of the total cost of providing BMT services.
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5.6

Data quality

We have accepted data provided to us by each hospital as being both accurate and representing
the best data available for the purposes of the study. In our view, the quality of the data provided
by hospitals is of a high standard. We have not been given any reason to form the view that the
financial information is not an accurate reflection of each hospital’s current cost structures.
The validity of the inpatient data is supported by the fact that the inpatient cost data are costed as
part of the NSW Department of Health’s Program and Product Data Collection. Further, each
hospital is required to account for all expenses by an identified Program in the Unaudited Annual
Return and an appropriate reconciliation is undertaken as part of this process.
We recognise that some of the outpatient cost estimates are not as robust as the equivalent
inpatient costs. This is a function of the fact that outpatient costing systems and processes are not
as sophisticated as inpatient systems. However, we believe that these results are more than
adequate for the purposes of the current study and note that these estimates represent a relatively
small component of the total cost of BMT services.

Final Report: A Costing Study of Blood & Marrow Transplantation Services in NSW

Page 33

Centre for Health Service Development

6 Preparatory data analysis
Prior to the analysis, a series of preparatory data analysis tasks were undertaken. An outline of
these tasks is provided below. The end result was an edited study dataset that formed the basis of
the costing analysis.

6.1

Data edit checking

On receipt of data from each hospital, a set of edit checks were undertaken to identify systematic
data inconsistencies. In several cases, anomalies were detected and revised data were submitted
by the hospital concerned.
In addition, an edit check was undertaken to identify any individual episodes that appeared to be
outliers from a cost perspective. This process identified considerable variation in the average cost
of both transplant and related inpatient episodes. Where individual episodes were significantly
higher than the average, advice was sought from the hospital about whether to include these
episodes in the study dataset. As a result, no individual episode was excluded from the analysis
on the basis of cost.

6.2

Identifying inpatient episodes that are related to the BMT

An important methodological issue was to determine which non-BMT inpatient episodes to include
in the costing analysis. A total of 3,663 non-BMT inpatient episodes were submitted by the eight
hospitals. The number of episodes by hospital, BMT type and pre and post transplant episode is
shown in Table 6 below.

Table 6: Number of episodes by hospital, BMT type, pre and post transplant
Hospital

St Vincent’s Hospital
Westmead Hospital
Royal North Shore Hospital
Prince of Wales Hospital
St George Hospital
Nepean Hospital
Sydney Children’s Hospital
Children’s Hospital Westmead
Total

No. PreTransplant
Allogeneic
Episodes

No. PostTransplant
Allogeneic
Episodes

No. PreTransplant
Autologous
Episodes

No. PostTransplant
Autologous
Episodes

29
48
30
0
0
0
303
180
590

302
51
15
0
0
0
189
106
663

204
32
66
243
133
53
312
453
1496

164
16
23
155
32
9
204
282
885

This issue essentially revolves around forming a clinical view about whether an inpatient episode is
sufficiently related to the BMT to be included in the analysis of BMT costs. Ideally, each inpatient
episode could be considered individually and a decision made about whether it should be included.
In practice, however, this would require a detailed clinical review that was clearly beyond the scope
of this study. Instead, we were guided by the clinical consultation process and a data analysis of
inpatient episodes submitted by the eight hospitals.
During the clinical consultation (refer Section 2), advice was sought in relation to patterns of clinical
care and the number of inpatient episodes that would typically occur before and after a
transplantation episode.
In summary, the predominant view was that for adult allogeneic transplant patients, most pretransplant related episodes occur in a 30-60 day window prior to the transplant. Following the
transplant episode, most related acute admissions will occur within a twelve month period.
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For paediatric allogeneic transplants, it was suggested that children are managed by the transplant
team from the time a transplant is indicated. It was suggested that in some cases (such as
neuroblastoma), this would occur from the point of initial diagnosis, even though the treatment
pathway may extend for some time prior to transplant. This philosophy was quite different to that
found in adult hospitals. A key difference appears to be that with adults, virtually all patients are
referred to the transplant physician from a haematologist or oncologist who was already treating
the patient’s underlying disease.
As children do not usually have the comorbidities of adults, related inpatient episodes post
transplant are usually due to the underlying disease or the BMT and occur most frequently in the
12 months post transplant. Whilst children are followed up for much longer than 12 months,
particularly to identify the effects of chemotherapy toxicity on their development, this usually occurs
relatively infrequently on an outpatient basis.
In relation to autologous BMT’s, the adult services indicated that most services are typically
provided in the 30 days prior to transplant to ensure the patient’s readiness for transplant. Work
up, mobilisation and stem cell harvest and processing primarily occur on an outpatient basis.
However, inpatient admissions do occur for mobilisation in some cases in the two weeks prior to
transplant. In terms of post-transplant services, the clinicians suggested that most admissions
occur within a three month period. Following this, the patient is referred back to their original
treating haematologist/oncologist.
For paediatric autologous transplants, our advice was that related inpatient episodes do occur pre
transplant particularly for mobilisation and stem cell harvest (the latter requires general
anaesthetic). No distinct pattern of activity was identified during the consultation process. Post
transplant most related readmissions and/or outpatient services were reported as occurring in a
one to six months period.
Following receipt of data from each hospital, a detailed analysis of transplant episodes and other
inpatient episodes was undertaken. The analysis examined the frequency of days by time periods
before and after a BMT episode. In addition, the ICD 10 diagnoses associated with these
episodes were analysed to assess the likelihood that an episode was related to the BMT.
The following key findings emerged from this analysis:
• Across all hospitals, the vast majority of days occurred during the BMT episode;
• For adult hospitals, the vast majority of non-BMT inpatient days occurred within 60 days prior
to and 90 days following the BMT episode;
• For paediatric hospitals, although a larger proportion of non-BMT inpatient days occurred prior
to 60 days pre transplant than did for the adult hospitals a large majority of days still occurred
within 60 days prior to and 90 days following the BMT episode;
• There was lower incidence of inpatient episodes associated with GVHD that had been
expected;
• The majority of post transplant inpatient episodes related to infections than were demonstrably
related to the BMT.
Based on the clinical consultation and data analysis, we formed the view that at one level, this
issue can perhaps be considered as a philosophical issue about the point at which BMT services
commence. There were clearly differing views on this matter between clinicians and between adult
and paediatric services.
In the context of this study, we would stress that our objective was simply to develop a business
rule that would allow BMT costs to be reasonably estimated. On this basis, the business rule
below was developed in relation to the inclusion of non-BMT inpatient episodes for both adult and
paediatric hospitals.

Final Report: A Costing Study of Blood & Marrow Transplantation Services in NSW

Page 35

Centre for Health Service Development

Business rule for inclusion of inpatient episodes in the costing analysis
The following inpatient episodes were excluded from the costing analysis:
•

episodes where the separation date was more than 60 days earlier than the admission date
for the BMT episode; and

•

episodes where both the admission date was more than 90 days after the separation date from
the BMT episode and the diagnoses for the episode were not related to the BMT; and

•

any episodes where the admission date was more than 12 months after the separation date
from the BMT.

Overall, it is our view that the business rule we have applied is appropriate in the context of the
current study.

6.3

Grouping of related inpatient episodes for costing purposes

This is a technical issue that is outlined here as it was considered during the preparatory analysis
phase of the project.
Inpatient episodes related to a BMT may occur in the same year as the BMT or in a previous or
subsequent year. That is, for a given year, the estimated cost of related BMT episodes will
include:
•
•
•

Inpatient episodes related to a BMT that occurred in that year;
Inpatient episodes related to a BMT that occurred in the previous year;
Inpatient episodes related to a BMT that occurred in the following year.

For example, 2005/06 datasets will include related inpatient episodes where the transplant
occurred in 2004/05 but will also include related inpatient episodes where the transplant did not
occur until 2006/07. The same applies to both 2005/06 and 2006/07 datasets.
This data structure needs to be borne in mind when looking at results in this report that relate to
cost estimates for a particular year. That is, we have reported the cost of related inpatients
episodes that occurred in a particular year regardless of when that transplant occurred. In our
view, it is sensible to produce annual cost estimates in this way as it allows for planning and
funding processes to be based around the annual cost of BMT activity.
A related issue arises as we have used data from one, two and three years from different
hospitals. Specifically, hospitals that have provided three years data will have provided a complete
dataset for 2005/06 (i.e. the middle year). A proportion of prior episodes that occurred in 2003/04
and a proportion of subsequent episodes that occurred in 2007/08 will not be included. Hospitals
that have provided one year of data will not include a proportion of episodes from both the previous
(2004/05) and subsequent year (2007/08). The hospital that provided two years data (2005/06 and
2006/07) will not include a proportion of data from 2004/05 and 2007/08. The overall effect is that
the hospitals with more than one year’s data will be missing a smaller proportion of related
inpatient episode data. We have carefully considered this issue in the context of its likely impact
on the study results. Our proposed approach is not to make any adjustments in the primary cost
results that are reported.

6.4

Treatment of incomplete inpatient episodes for costing purposes

The study dataset comprised three subsets of episodes as shown in Figure 5 below. It is
theoretically possible that episodes that commenced prior to the study start may not have ended
by the study end. However, we are aware of no such episodes occurring at any of the study
hospitals.
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Figure 5: Incomplete episodes during the study period
Complete

Ending

Starting

Study Start

Study End

For costing purposes, it was necessary to apply a set of business rules regarding the treatment of
the small number of inpatient episodes that straddled the study period. This was necessary for
both BMT episodes and related inpatient episodes. Further, it was necessary regardless of
whether data were provided for a one, two or three year period.
In this study, three types of cost results are of primary interest:
•

Episode level costs such as the average cost per allogeneic BMT;

•

Per diem costs such as the average daily cost of an allogeneic transplant patient;

•

Annual costs such as total expenditure on BMT in a financial year by a given hospital.

No cost data were available for episodes in the starting cohort. For this reason it was necessary to
exclude them from all analyses. This will not impact on the calculation of episode level or per diem
costs other than by slightly reducing the overall sample size. However, it will have a small impact
on the calculation of annual costs for the study period.
The remaining two episode subsets were included in the analyses as follows:
The complete cohort
These are episodes that started and ended within the study period. Cost data were available for
the whole episode. These episodes were used in all analyses. Importantly, this subset represents
the vast majority of episodes in the study dataset.
The ending cohort
These are episodes that commenced prior to study start but ended during the study period. Cost
data were available for days after the study start but are not available for days prior to the study
start. With this subset, episodes where 90% or more of the episode fell in the study period were
used to calculate average per diem and average episode costs.
As shown in Table 7 below, the ending episodes represent only a small percentage of all episodes
and therefore only a minor proportion of costs have been estimated. This proportion is slightly
higher for hospitals which provided a single year of inpatient data (Nepean Hospital, Royal North
Shore Hospital and Westmead Hospital).
Annual costs were then calculated by multiplying the average episode costs by the number of
episodes per year. This is equivalent to estimating the costs of ending episodes using the
complete episodes.
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Table 7: Breakdown of transplant episode by hospital
Hospital

Complete
Episodes
98.0%
89.2%
92.9%
96.4%
91.7%
100.0%
96.8%
99.0%
95.8%

St Vincent's Hospital
Westmead Hospital
Royal North Shore Hospital
Prince of Wales Hospital
Nepean Hospital
St George Hospital
Sydney Children's
Children's Hospital Westmead
All

6.5

Ending
Episodes
2.0%
10.8%
7.1%
3.6%
8.3%
0.0%
3.2%
1.0%
4.2%

Inclusion of outpatient data in the study dataset

The advice received during the clinical consultation process enabled a profile to be developed of
typical patterns of outpatient care for BMT services (see Section 4). Whilst minor variations were
noted between hospitals, an overall high level of consistency was reported.
For the costing process, a business rule was required around the period before and after
transplantation that would determine which outpatient data would be included in the study dataset.
This issue was discussed with the Study Reference Group and the NSW BMT Service Plan
Development Working Party. It was agreed that subject to an analysis of the relevant data, a
period of twelve months would be applied. The data received by hospitals confirmed that the vast
majority of outpatient activity did occur within a twelve month period.
The study dataset for outpatient services was therefore developed on this basis. In applying this
business rule, we recognise that the data provided by hospitals will not include all outpatient
services for a twelve month period for all transplant patients. The same issues arise for outpatient
services that were discussed in relation to related inpatient episodes in Section 6.3.
Again, we have considered this issue in the context of its likely impact on the study results. Our
proposed approach is not to make any adjustments in the primary cost results that are reported.
We have estimated a cost for that proportion of activity that is not available from the sites that have
one and two year’s data and have included this in the results reported in Section 7.3.

6.6

The final study data set

After the adjustments described above, the final study dataset comprised 16,960 records made up
of:
•
•
•
•
•

508 BMT episodes
2,258 related inpatient episodes
7,485 outpatient medical, nursing and allied health clinic occasions of service
6,272 outpatient dispensed drugs
435 other outpatient treatments.

This dataset formed the basis of the cost estimates that are presented in the following section.

Page 38

Final Report: A Costing Study of Blood & Marrow Transplantation Services in NSW

Centre for Health Service Development

7 Analysis and results
As noted earlier, the project brief required the following questions to be addressed in relation to the
cost of providing BMT services in NSW:
• What is the average per patient cost of autologous and allogeneic BMT?
• What is the breakdown of costs for each of these, in terms of the inpatient and ambulatory
phase of treatment?
• Are there available costings from other States in Australia with which to compare, and if
significantly different, why?
• What proportion of BMT costs do pharmaceuticals represent?
• What, if any, difference is there between costs for adult patients and paediatric BMT?
• What are the financial implications of the projected increase in BMT activity in NSW by 2011?
The study dataset contained a large volume of data with which to consider these questions. The
results are set out below as follows:
Section 7.1 - Presents a profile and cost results for the 508 BMT transplant episodes in the study
dataset;
Section 7.2 - Presents a profile and cost results for the 2,258 related inpatient episodes in the
study dataset;
Section 7.3 - Presents a profile and related results for the 14,192 outpatient records included in the
study dataset;
Section 7.4 - Discusses a set of costing issues that were identified during the study.
Section 7.5 - Presents a set of cost projections for NSW BMT services based on activity projection
data provided by the NSW Department of Health
Section 7.6 - Combines all of the study results to present an overall profile of the cost of BMT
services in NSW.

7.1

BMT episodes

A total of 508 transplant episodes were included in the BMT inpatient study dataset. We are
confident this sample of transplant episodes is large enough to base the cost estimates that follow.
As discussed in Section 5.2, we have adjusted the data to reflect the fact that data from different
periods have been included in the dataset. These adjustments are noted in the remainder of this
section where relevant.
The breakdown of the 508 episodes is shown in Table 8 below. This table shows episodes for all
years for which data were provided by the eight hospitals. Of these 508 episodes, 60% were
autologous and 40% allogeneic. The ratio of autologous to allogeneic transplants is consistent
with levels of activity reported elsewhere.
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Table 8: Number of transplant episodes in the study dataset
Hospital

Autologous

Allogeneic

St Vincent's Hospital

45

Westmead Hospital
Royal North Shore Hospital

Number of Years
of Source Data

53

Total
Transplant
Episodes
98

26

57

83

1

39

17

56

1

2

Prince of Wales Hospital

28

0

28

3

St George Hospital

32

0

32

3

Nepean Hospital

12

0

12

1

Sydney Children's Hospital

48

45

93

3

Children's Hospital Westmead

52

54

106

3

282

226

508

17

Total

7.1.1

Allogeneic transplant episodes

Table 9 below presents length of stay data for the 226 allogeneic transplant episodes from the five
hospitals that contributed to the study dataset.

Table 9: Allogeneic transplants - average length of stay
Hospital

Mean
LOS

Median
LOS

Min

Max

35
37
23
34

26
31
21
28

19
4
16
4

177
90
35
177

Sydney Children's Hospital
45
54
42
4
Children's Hospital Westmead
54
82
62
16
Paediatric Hospitals
99
69.49
47
4
*Has been weighted to adjust for the number of year’s data submitted by each hospital.

202
254
254

St Vincent's Hospital
Westmead Hospital
Royal North Shore Hospital
Adult Hospitals*

No. of
Episodes in
study
dataset
53
57
17
127

There is considerable variation in length of stay both within and between facilities which reflects
variations in the clinical profile of patients. The considerably longer length of stay at the two
paediatric facilities is notable but is consistent with the issues raised during the clinical consultation
and discussed in Section 4.4. The longer length of stay at the paediatric hospitals confirms the
view that the conditioning regime for children can be aggressive and is predominantly undertaken
on an inpatient process and reflects the longer engraftment period associated with cord blood
transplants.
Table 10 below shows the costs of allogeneic BMTs from the five hospitals that contributed to the
study dataset. The most notable result is that for each hospital there is a large variation in cost
between the least and most expensive episode. This finding was supported by the views
expressed during the consultation about the clinical variation between individual BMT patients.
For this reason, it is sensible to examine the median, as well as the mean cost. For the adult
hospitals, this shows a consistent result between the two hospitals that undertake unrelated
transplants (St Vincent’s and Westmead) and a slightly lower cost for Royal North Shore Hospital
which undertakes only sibling related allogeneic transplants. The lower average cost per
allogeneic transplant at Royal North Shore Hospital was expected. For the paediatric hospitals,
the median cost is considerably higher that for the adult hospitals, but quite similar between the
two hospitals.
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Table 10: Allogeneic transplants - episode costs
Hospital

Mean
Cost

Median
Cost

Standard
Deviation
of Cost

Min

Max

$85,853
$92,440
$65,368
$86,124

$68,303
$70,120
$62,589
$68,367

$56,404
$73,816
$22,730
$61,942

$51,886
$11,461
$14,551
$11,461

$403,549
$402,035
$116,207
$403,549

Sydney Children's Hospital
$144,184
$106,050
$125,161
$9,181
Children's Hospital Westmead
$176,955
$115,956
$135,892
$41,571
Paediatric Hospitals
$161,986
$110,610
$131,320
$9,181
* Has been weighted to adjust for the number of year’s data submitted by each hospital.
# Royal North Shore does not undertake unrelated BMTs.

$679,370
$626,656
$679,370

St Vincent's Hospital
Westmead Hospital
Royal North Shore Hospital#
Adult Hospitals*

As total episode costs are largely a function of length of stay, it is useful to examine costs on a per
diem basis. Table 11 shows per diem costs for allogeneic transplants for the five hospitals that
contributed to the study dataset. Again, for all hospitals, the considerable variation between the
least and most expensive patient is consistent with comments provided during the clinical
consultation. However, the median per diem cost is quite consistent across the five hospitals. The
significant difference between adult and paediatric facilities is not evident here. Royal North Shore
Hospital has a slightly higher median per diem cost than the other hospitals.

Table 11: Allogeneic transplants - per diem costs
Hospital

Min

Max

$2,132
$782
$728
$728

$4,090
$5,507
$3,498
$5,507

Sydney Children's Hospital
$2,616
$2,587
$1,017
$1,358
Children's Hospital Westmead
$2,340
$2,325
$467
$904
Paediatric Hospitals
$2,466
$2,447
$776
$904
* Has been weighted to adjust for the number of year’s data submitted by each hospital.
** Royal North Shore does not undertake unrelated BMTs.

$7,098
$3,575
$7,098

St Vincent's Hospital
Westmead Hospital
Royal North Shore Hospital#
Adult Hospitals*

Mean Per
Diem Cost

Median
Cost

$2,582
$2,408
$2,842
$2,527

$2,566
$2,372
$2,956
$2,522

Standard
Deviation
of Cost
$284
$921
$638
$695

Table 12 below shows the average cost of each cost bucket across all five hospitals that
contributed episodes to the study dataset. The cost buckets are the standard ‘buckets’ used in
costing studies undertaken by the NSW Department of Health. This information is provided for
each hospital individually in Appendix 3. Ward costs account for 36% of costs in adult hospitals
and 37% of costs in paediatric hospitals. Pharmacy costs account for the second highest “bucket”
of costs with 33% in adult hospitals and 25% in paediatric hospitals.
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Table 12: Allogeneic transplants – average cost by cost bucket all hospitals
Cost bucket

Adult Hospitals*
Mean
% of
Total

Paediatric Hospitals
Mean
% of
Total

Ward costs
$31,232
36%
$60,623
37%
Pharmacy costs
$28,045
33%
$40,701
25%
ICU costs
$5,867
7%
$19,199
12%
Pathology costs
$5,748
7%
$9,629
6%
Medical costs
$5,435
6%
$12,840
8%
Oncosts
$3,849
4%
$6,010
4%
Allied health costs
$2,666
3%
$3,548
2%
Other costs
$2,626
3%
$7,570
5%
Imaging costs
$639
0.7%
$1,840
1%
Emergency dept costs
$17
0.02%
$26
0.02%
Total costs
$86,124
100.00%
$161,986
100.00%
*Has been weighted to adjust for the number of year’s data submitted by each hospital.

We note that transportation costs related to specimens sent from a hospital without an appropriate
laboratory and donor costs are not included in the cost buckets in Table 12 above. These costs
would be very small relative to the overall cost of the episode. It is recognised however, that there
remains a cost to the facilities affected. A donor may be managed as an outpatient or admitted,
the collection may occur in a NSW hospital or outside of this State. As there is no unique DRG for
admission of a stem cell donor it has not been possible to capture data relating specifically to
donor collection in NSW hospitals.
7.1.2

Cost of ‘matched sibling’ versus ‘other’ BMT episodes

In addition to the above results, we examined cost differences between ‘matched sibling’ and
‘other’ transplant episodes. We note that we have compared ‘matched sibling’ episodes with ‘all
other’ episodes rather than comparing ‘related’ and ‘unrelated’ episodes. The rationale for this was
based on clinical advice that mismatched related donor episodes (such as haploidentical
transplants) are more similar in terms of clinical complexity (and therefore cost) to unrelated
transplants that matched sibling transplants. However, we also note that the proportion of
mismatched related episodes in the ‘other’ group is very low.
Table 13 below shows the cost of matched sibling versus other transplants for each hospital. In
terms of the mean cost per episode, the most notable finding is the significant difference between
‘matched sibling’ and ‘other’ transplant episodes in the two paediatric hospitals. The cost
differential is similar for each hospital. There is a smaller, but noticeable mean cost difference
between two of the adult hospitals. This cost difference for the adult hospitals is much less when
the median cost per episode is compared.
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Table 13 ‘Matched sibling’ versus ‘other’ transplant episode costs
Hospital

Royal North
Shore
Westmead

Sample size
Matched
Other
sibling
n = 14
n=3

St Vincent's
Adult

Children's
Westmead
Sydney
Chilrdren's
Paediatric

Mean cost
Matched
Other
sibling
$65,199
$66,157

Median cost
Matched
Other
sibling
$61,930
$67,713

Min cost
Matched
Other
sibling
$47,186 $14,551

Max cost
Matched
Other
sibling
$95,268 $116,207

n = 28

n = 24

$85,913

$100,055

$69,538

$71,522

$21,112

$11,461

$402,035

$329,067

n = 17

n = 31

$69,472

$94,835

$65,196

$69,459

$52,130

$51,886

$100,621

$403,549

n=59

n=58

$76,261

$95,512

$65,758

$69,962

$21,112

$11,461

$402,035

$403,549

n = 16

n = 28

$86,561

$228,609

$79,959

$160,860

$41,571

$82,316

$232,844

$626,656

n = 16

n = 21

$79,622

$193,374

$65,732

$169,860

$9,181

$45,483

$167,949

$679,370

n=32

n=49

$83,092

$213,508

$79,541

$167,277

$9,181

$45,483

$232,844

$679,370

Table 14 below presents the same comparison based on per diem costs. The results here suggest
that there is very little difference in cost between matched sibling and other episodes on a per diem
basis for any of the five hospitals. Similarly, there is also little difference in the mean or median per
diem cost across the five hospitals. This is consistent with the results above and suggests that
differences in cost primarily reflect variation in length of stay both between matched sibling and
other transplant episodes and also between hospitals.

Table 14 ‘Matched sibling’ versus ‘other’ transplant per diem costs
Hospital

Sample size
Matched
Other
sibling

Mean per diem
Matched
Other
sibling

Median per diem
Matched
Other
sibling

Min per diem
Matched
Other
sibling

Max per diem
Matched
Other
sibling

Royal North
Shore
Westmead
St Vincent's
Adult

n = 14

n=3

$3,000

$2,102

$2,960

$2,257

$2,273

$728

$3,498

$3,320

n = 28
n = 17
n=59

n = 24
n = 31
n=58

$2,299
$2,603
$2,553

$2,533
$2,563
$2,527

$2,275
$2,570
$2,570

$2,642
$2,550
$2,557

$782
$2,360
$782

$1,169
$2,132
$728

$5,507
$2,874
$5,507

$3,664
$4,090
$4,090

Children's
Westmead
Sydney
Chilrdren's
Paediatric

n = 16

n = 28

$2,206

$2,439

$2,321

$2,392

$924

$1,486

$2,677

$3,575

N = 16

n = 21

$2,162

$2,962

$2,236

$2,745

$1,358

$1,487

$2,838

$7,098

n=32

n=49

$2,184

$2,663

$2,278

$2,587

$924

$1,486

$2,677

$7,098

7.1.3

Autologous transplants

Table 15 below shows length of stay statistics for the 282 autologous transplant episodes from the
eight hospitals that contributed to the study dataset. Again, there is considerable variation
between minimum and maximum average lengths of stay within each hospital. Whilst there is less
variation in length of stay between hospitals than for allogeneic transplants, it is notable that
Sydney Children’s Hospital has a shorter median length of stay than any other hospital.
An analysis of the data from this hospital has identified a different length of stay distribution with a
larger proportion of patients having a length of stay of between 1 and 3 days than at other
hospitals. Our discussions suggest that this may result from differing coding practices whereby
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episodes being assigned to the autologous AR-DRG at Sydney Children’s Hospital are not being
assigned to a BMT AR-DRG at other hospitals. This requires review as if this is the case this
presents a confounding factor in this study. This will require clarification with possible follow-up
action by NSW Health.

Table 15: Autologous transplants - average length of stay
Hospital
St Vincent's Hospital
Westmead Hospital
Royal North Shore Hospital
Prince of Wales Hospital
St George Hospital
Nepean Hospital
Adult Hospitals*

No. of
Episodes

Mean
LOS

Median
LOS

Min

Max

45
26
39
28
32
12
182

25
27
29
21
23
22
26

24
22
21
19
24
20
22

4
3
3
2
1
12
1

85
98
185
56
43
35
185

Sydney Children's Hospital
48
16
5
1
Children's Hospital Westmead
52
20
11
1
Paediatric Hospitals*
100
18
6.5
1
* Has been weighted to adjust for the number of year’s data submitted by each hospital.

86
88
88

Table 16 below shows the cost of autologous BMTs from the eight hospitals that contributed to the
study dataset.

Table 16: Autologous transplants - episode costs
Hospital

Mean
Cost

Median
Cost

Standard
Deviation
of Mean

Min

Max

$47,818
$36,688
$48,892
$53,011
$33,133
$34,415
$43,496

$39,739
$32,344
$45,574
$41,674
$35,081
$28,252
$38,616

$37,336
$22,810
$24,464
$38,268
$16,820
$16,326
$29,657

$10,279
$9,622
$11,909
$4,066
$3,330
$14,804
$3,330

$258,147
$89,650
$128,039
$216,821
$75,902
$61,459
$258,147

Sydney Children's Hospital
$36,841
$12,026
$56,975
$1,076
Children's Hospital Westmead
$38,117
$18,617
$34,733
$2,528
Paediatric Hospitals*
$37,505
$13,691
$46,479
$1,076
* Has been weighted to adjust for the number of year’s data submitted by each hospital.

$244,576
$151,782
$244,576

St Vincent's Hospital
Westmead Hospital
Royal North Shore Hospital
Prince of Wales Hospital
St George Hospital
Nepean Hospital
Adult Hospitals*

As expected, autologous transplants are considerably less expensive than allogeneic transplants.
As some autologous patients have very short lengths of stay (1-2 days), there is again a large
variation between the least and most expensive patient.
The median cost for autologous transplants actually shows more variation between hospitals than
the allogeneic transplants. This will be caused partly by the fact that there are more hospitals in
this group. The shorter mean length of stay at Sydney Children’s Hospital is reflected in a
correspondingly lower median cost here than at other hospitals, although this difference is not
evident in the mean cost per transplant at this hospital.
There is no clear pattern to suggest that autologous transplants are more (or less) expensive in
facilities that also undertake allogeneic transplants. This may have implications in a planning
context.

Table 17 below shows the per diem costs of autologous transplant episodes from the eight
hospitals that contributed to the study dataset.
Page 44

Final Report: A Costing Study of Blood & Marrow Transplantation Services in NSW

Centre for Health Service Development

Table 17: Autologous transplants - per diem costs
Hospital

Mean
Per Diem
Cost

Median
Per Diem
Cost

Standard
Deviation
of Mean

Min

Max

$1,815
$1,558
$2,117
$2,519
$1,519
$1,541
$1,859

$1,862
$1,638
$2,051
$2,303
$1,452
$1,729
$1,859

$356
$710
$518
$833
$408
$326
$645

$1,381
$655
$1,169
$1,731
$1,028
$1,188
$655

$3,037
$3,207
$3,970
$5,599
$3,330
$2,028
$5,599

Sydney Children's Hospital
$2,222
$2,189
$639
$1,076
Children's Hospital Westmead
$2,143
$2,023
$572
$1,191
Paediatric Hospitals*
$2,181
$2,062
$603
$1,076
* Has been weighted to adjust for the number of year’s data submitted by each hospital.

$4,322
$4,769
$4,769

St Vincent's Hospital
Westmead Hospital
Royal North Shore Hospital
Prince of Wales Hospital
St George Hospital
Nepean Hospital
Adult Hospitals*

It can be seen that there is still considerable (but less than for allogeneic transplants) variation
between the least and most expensive patient within hospitals. Between hospitals, there is greater
variation in per diem cost than for allogeneic transplants. It is difficult to identify any particular
pattern that could reasonably be explained by the range of BMT services provided at each
hospital.
The two children’s hospitals are very similar in terms of per diem cost. This confirms the lower
median episode cost at Sydney Children’s Hospital is a function of its shorter length of stay for
autologous transplant patients. Prince of Wales has the highest per diem cost for autologous
transplant patients. This may be the result of the coding issue raised above. At Prince of Wales
Hospital only 4% of patients had a length of stay of less than 14 days, compared with Sydney
Children’s Hospital, for example, where 36% had a length of stay of less than 14 days.
Table 18 and Table 19 below show the cost of autologous transplants broken down by the two
BMT AR-DRGs. As would be expected AR-DRG A08A (Autologous BMT with catastrophic
complications or comorbidities) has a higher mean and median cost for all hospitals than AR-DRG
A08B. Again, the cost of paediatric hospitals is higher than for the adult hospitals. There is no
particular difference in the cost of autologous transplants at the three hospitals that also undertake
allogeneic transplants. In fact, the cost at Prince of Wales is higher than at any other adult
hospital.

Table 18: Autologous transplant costs - AR-DRG AO8A**
Hospital

St Vincent's Hospital
Westmead Hospital
Royal North Shore Hospital
Prince of Wales Hospital
St George Hospital
Nepean Hospital
Adult Hospitals*

Mean Cost

Median
Cost

Standard
Deviation
of Mean

Min

Max

$59,123
$38,563
$57,605
$68,086
$40,510
$46,375
$51,913

$48,503
$20,540
$51,541
$51,866
$38,621
$47,081
$42,649

$45,509
$27,715
$24,330
$47,530
$13,954
$12,185
$33,882

$37,152
$9,622
$21,791
$33,700
$22,130
$28,252
$9,622

$258,147
$89,650
$128,039
$216,821
$75,902
$61,459
$258,147

Sydney Children's Hospital
$102,023
$76,723
$74,885
$13,562
$244,576
Children's Hospital Westmead
$60,012
$66,980
$28,968
$8,034
$100,600
Paediatric Hospitals*
$80,240
$69,939
$58,867
$8,034
$244,576
*Has been weighted to adjust for the number of year’s data submitted by each hospital.
**AR-DRG AO8A = Autologous Bone Marrow Transplant with catastrophic complications or comorbidities.
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For AR-DRG AO8B (no complications of comorbidities), Table 19 shows a high level of
consistency in terms of mean cost and median cost across the adult hospitals. Here, both the
paediatric hospitals have a lower median cost than the adult hospitals. We would suggest that the
noticeable difference in mean cost between the paediatric hospitals is a reflection of the higher
proportion of patients with a very low length of stay at Sydney Children’s Hospital that would
mostly be assigned to this AR-DRG.

Table 19: Autologous transplant costs - AR-DRG AO8B**
Hospital

Mean Cost

Median
Cost

Standard
Deviation
of Mean

Min

Max

St Vincent's Hospital
Westmead Hospital
Royal North Shore Hospital
Prince of Wales Hospital
St George Hospital
Nepean Hospital
Adult Hospitals

$34,817
$34,251
$29,883
$36,777
$22,352
$20,063
$30,643

$30,350
$32,572
$30,177
$38,000
$27,416
$21,384
$30,212

$18,730
$15,363
$9,687
$13,226
$15,056
$2,952
$15,472

$10,279
$11,135
$11,909
$4,066
$3,330
$14,804
$3,330

$109,043
$57,331
$49,471
$59,468
$42,726
$21,719
$109,043

Sydney Children's Hospital
Children's Hospital Westmead
Paediatric Hospitals

$11,164
$29,602
$39,640

$9,380
$13,131
$11,820

$7,479
$33,331
$26,157

$1,076
$2,528
$1,076

$34,189
$151,782
$151,782

*Has been weighted to adjust for the number of year’s data submitted by each hospital.
**AR-DRG AO8B = Autologous Bone Marrow Transplant without catastrophic complications or comorbidities

Table 20 below shows the average cost of each cost bucket across all five hospitals that
contributed episodes to the study dataset. This information is provided for each hospital
individually in Appendix 4.
The results show that ward and pharmacy costs comprise the vast majority of total costs. As was
expected, pharmacy costs represent a higher proportion of total costs than most other AR-DRGs.
The relatively small proportion of costs (4%) related to intensive care services in adult hospitals
confirms the expectations expressed in the clinical consultations. This proportion was 11% in
paediatric hospitals, which was also in line with expectations expressed in the clinical
consultations.

Table 20: Autologous transplants - cost by cost bucket
Hospital

Ward costs
Pharmacy cost
Pathology costs
Medical cost
Oncosts
ICU costs
Other costs
Allied Health costs
Imaging costs
Total cost

Adult hospitals*
Mean
% of
Total
$18,360
$13,240
$2,640
$2,087
$1,840
$1,648
$1,573
$1,331
$725
$43,496

42%
30%
6%
5%
4%
4%
4%
3%
2%
100%

Paediatric hospitals
Mean
% of
Total
$14,636
$8,071
$2,103
$3,522
$1,327
$4,058
$2,252
$953
$584
$37,505

39%
22%
6%
9%
4%
11%
6%
3%
2%
100%

*Has been weighted to adjust for the number of year’s data submitted by each hospital.
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7.1.4

Estimated annual cost of transplant episodes

The annual cost of transplantation episodes (allogeneic and autologous) is presented in Table 21
and Table 22. The average number of transplants per year is multiplied by the average cost per
transplant (values in Table 21) to produce an estimate of the total cost of transplants as shown in
Table 22. It shows that total annual expenditure on BMT transplants at the study hospital’s is
$19.67m per annum comprising $12.62m spent on allogeneic transplants and $7.05m spent on
autologous transplants.

Table 21: Average annual cost of transplant episodes
Hospital

Average
Number of
Allogeneic
Transplants
per Year

Average
Number of
Autologous
Transplants
per Year

Average Cost
per Allogeneic
Transplant*

Average Cost
per
Autologous
Transplant*

27
57
17
0
0
0
15
18

23
26
39
9
11
12
16
17

$85,853
$92,440
$65,368
$0
$0
$0
$144,184
$176,955

$47,818
$36,688
$48,892
$53,011
$33,133
$34,415
$36,841
$38,117

St Vincent's Hospital
Westmead Hospital
Royal North Shore Hospital
Prince of Wales Hospital
St George Hospital
Nepean Hospital
Sydney Children's Hospital
Children's Hospital Westmead

*Average here refers to the mean cost per transplant and not than the median cost.

Table 22: Total annual cost of transplant episodes
Hospital

St Vincent's Hospital
Westmead Hospital
Royal North Shore Hospital
Prince of Wales Hospital
St George Hospital
Nepean Hospital
Sydney Children's Hospital
Children's Hospital Westmead
Total

Total Annual
Cost Allogeneic
Transplants

Total Annual Cost
Autologous
Transplants

Total Annual
Cost All
Transplants

$2,318,031
$5,269,080
$1,111,256
$0
$0
$0
$2,162,760
$3,185,190
$14,046,317

$1,099,814
$953,888
$1,906,788
$477,099
$364,463
$412,980
$589,456
$660,695
$6,465,183

$3,417,845
$6,222,968
$3,018,044
$477,099
$364,463
$412,980
$2,752,216
$3,845,885
$20,511,500

7.2 Related inpatient episodes
A total of 3,663 episodes were included in the initial related inpatient episode dataset. Of these,
1,405 episodes were excluded from further analysis in line with the adjustments discussed in
Sections 5 and 6. This left 2,258 related inpatient episodes in the study dataset.
Table 23 below shows the total number of related inpatient episodes relative to the number of
transplant episodes. The numbers in this table have not been adjusted for the fact that different
hospitals contributed data for different periods. The frequency of related inpatient episodes per
transplant is higher at both paediatric hospitals as well as being very similar between these
hospitals. This finding is consistent with advice received during the clinical consultation process
about the need for a greater proportion of services to be provided to children on an inpatient basis.
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Table 23: Number of related inpatient episodes
Hospital

Number of
Transplant Episodes

Number of
Related Inpatient
Episodes

98
83
56
28
32
12
93
106
508

527
119
85
216
74
30
638
569
2258

St Vincent's Hospital
Westmead Hospital
Royal North Shore Hospital
Prince of Wales Hospital
St George Hospital
Nepean Hospital
Sydney Children's Hospital
Children's Hospital Westmead
Total

Table 24 below shows the average number of related inpatient episodes per patient. The
proportion of patients that had at least one related inpatient episode varied from 58% at Westmead
Hospital to 92% at Nepean Hospital. The number of related inpatient episodes per patient is also
greater at the two paediatric hospitals.

Table 24: Average number of related inpatient episodes
Hospital

St Vincent's Hospital
Westmead Hospital
Royal North Shore Hospital
Prince of Wales Hospital
St George Hospital
Nepean Hospital
Sydney Children's Hospital
Children's Hospital Westmead
All

Total
Transplant
Episodes

98
83
56
28
32
12
93
106
508

Number of
Patients with
Related
Inpatient
Episode
76
48
35
24
28
11
68
82
365

Average Number of
Related Inpatient
Episodes per
Patient
6.9
2.5
2.4
9.0
2.6
2.7
9.4
6.9
6.5

As discussed in Section 6.3, the annual cost and number of episodes are slightly underestimated for hospitals
that submitted data for one year as they are missing a higher proportion of episodes outside the reporting period.

Table 25 below shows the average length of stay, including and excluding sameday episodes by
hospital. This shows a surprising variation in the proportion of sameday related inpatient episodes
across adult hospitals. This may be a reflection of administrative practices and/or clinical
management preferences. The particularly high proportion of sameday episodes at St Vincent’s
Hospital is partly due to one patient with renal failure that had a large number of same day
episodes during the study period. The paediatric hospitals have less variation in their respective
proportions of same day episodes.
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Table 25: Average length of stay - related inpatient episodes
Facility

Average Length of
Stay All Episodes

St Vincent's Hospital
Westmead Hospital
Royal North Shore Hospital
Prince of Wales Hospital
St George Hospital
Nepean Hospital
Sydney Children's Hospital
Children's Hospital Westmead
All

7.2.1

3.5
6.3
8.5
2.0
4.9
7.8
5.4
5.6
5.1

Average Length of
Stay Excluding Same
Day Episodes
14.0
10.2
9.6
5.3
5.4
9.9
9.1
8.4
10.1

Percentage of Same
Day Episodes
81
42
13
76
11
23
46
38
51.4

Annual cost of related inpatient episodes

The above results highlight the importance of examining the casemix of related episodes to
understand their associated costs. Table 26 below show the twenty most expensive AR-DRGs in
terms of total cost across all hospitals. Here, episode costs have been adjusted to reflect the
average annual cost of related inpatient episodes. It can be seen that the most expensive
AR-DRG was Q60A Reticuloendothelial and Immunity Disorders W Catastrophic or Severe CC.
Advice from clinical and casemix staff confirm that this DRG is where episodes related to GVHD
are most commonly recorded. provides the same information for all AR-DRGs.

Table 26: Related inpatient episodes - Top 20 AR-DRGs by cost
DRG

DRG Description

Q60A

Reticuloendothelial and Immunity Disorders
W Catastrophic or Severe CC
Acute Leukaemia W Catastrophic CC
Acute Leukaemia W/O Catastrophic or
Severe CC
Lymphoma and Non-Acute Leukaemia W/O
Catastrophic CC
Tracheostomy or Ventilation >95 hours
Septicaemia W Catastrophic or Severe CC
Lymphoma and Non-Acute Leukaemia W
Catastrophic CC
Acute Leukaemia W Severe CC
Fever of Unknown Origin W CC
Lymphoma and Leukaemia with other OR
procedures W catastrophic or severe CC
Nervous System Neoplasm W/O
Catastrophic or Severe CC
Established Paraplegia/Quadriplegia W or
W/O O.R. Procs W/O Catastrophic CC
Craniotomy W Catastrophic CC
Nervous System Neoplasm W Catastrophic
or Severe CC
Other Circulatory System Diagnoses W
Severe CC
Respiratory Infections/Inflammations W
Severe or Moderate CC
Reticuloendothelial and Immunity Disorders

R60A
R60C
R61B
A06Z
T60A
R61A
R60B
T62A
R03A
B66B
B60B
B02A
B66A
F75B
E62B
Q60B

Number of
Episodes

Total Cost

45.3

$912,264

Per
Diem
Cost
$1,415

Average
Length of
Stay
14.22

14.8
181.8

$741,796
$665,420

$2,111
$1,644

23.7
2.2

86.3

$594,017

$1,513

4.5

4.2
23.5
11.3

$362,841
$326,041
$310,478

$2,452
$1,672
$1,568

35.5
8.3
17.5

19.8
29.0
4.2

$266,755
$244,690
$181,917

$1,524
$1,537
$1,487

8.8
5.5
29.4

31.0

$140,497

$1,489

3.0

1.0

$136,776

$1,169

117.0

1.0
11.0

$124,249
$119,202

$2,845
$1,568

43.7
6.9

9.3

$97,569

$1,517

6.9

6.5

$79,850

$1,369

9.0

9.0

$76,778

$1,525

5.6
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DRG

R61C
G02A
Other
DRGs
All

DRG Description

W/O Cat or Severe CC W Malignancy
Lymphoma and Non-Acute Leukaemia,
Same Day
Major Small and Large Bowel Procedures W
Catastrophic CC

Number of
Episodes

Total Cost

Per
Diem
Cost

Average
Length of
Stay

128.7

$71,729

$557

1.0

1.0

$70,473

$1,499

47.0

377.8

$2,305,165

$796

7.8

996.5

$7,828,507

$1,538

4.9

The number of related inpatient episodes per transplant was slightly less than anecdotal estimates.
Our analysis of the ICD 10 diagnosis data suggests that many of the complications arising from
transplantation are actually dealt with during the BMT episode. This appears to be the case with
acute GVHD. Nevertheless, after the data were adjusted, there were still a total 996 related
inpatient episodes during the study period representing a cost of $7.82m. The top twenty
AR-DRGs accounted for $5.52m or 71% of this amount.
The information on related inpatient episodes is consolidated in Table 27 below to provide an
estimate of the annual cost of related inpatient episodes at each hospital. This has been
calculated as the average number of episodes per year at each hospital multiplied by the average
cost per patient of a related inpatient episode at that hospital.

Table 27: Annual cost of related inpatient episodes
Hospital

Average Number of
Related Inpatient
Episodes per Year

Average Cost per
Related Inpatient
Episode

Average Annual Cost
of Related Inpatient
Episodes

St Vincent's Hospital
264
$4,435
$1,168,626
Westmead Hospital
119
$9,247
$1,100,357
Royal North Shore Hospital
85
$10,176
$864,954
Prince of Wales Hospital
72
$2,063
$148,544
St George Hospital
25
$7,031
$173,437
Nepean Hospital
30
$9,373
$281,182
Sydney Children's Hospital
213
$9,770
$2,077,682
Children's Hospital Westmead
190
$10,375
$1,967,792
* As discussed in Section 6.3, the annual cost and number of episodes are slightly underestimated for hospitals
that submitted data for one year as they are missing a higher proportion of episodes outside the reporting period.

The number of related inpatient episodes per year and the average cost of these episodes varies
between hospitals. This is not surprising given the differences in length of stay (including the
proportion of same day episodes) noted above. Overall, however, the results show a very
consistent result by type of hospital and BMT service provided. The average annual cost of related
inpatient episodes is very similar at St Vincent’s and Westmead Hospitals, the two hospitals that
provide adult unrelated allogeneic transplants. This similarity was also evident in the cost of
allogeneic transplants at these hospitals.
Further, the cost of related inpatient episodes is similarly less at Royal North Shore Hospital, which
does not undertake unrelated BMTs. As would be expected, the annual cost of related inpatient
episodes at the three adult hospitals that provide only autologous transplant is significantly less
than for the other hospitals.
The annual cost of related inpatient episodes at the two paediatric hospitals is significantly higher
that for the adult hospitals. Again, this mirrors the experience of the transplant episodes. Costs
are also very similar at each hospital in terms of total annual cost, number of annual episodes and
average cost per episode.
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7.3

Outpatient analysis and results

Outpatient services play a critical part in the process of providing BMT services. Whilst they
represent a smaller proportion of total costs than inpatient services, they are often provided over a
longer period of time. In some cases, such as drugs, they can also represent an ongoing cost to
hospitals.
A range of services are provided in outpatient clinics. Whilst these clinics predominantly involve
patients being seen by BMT Physicians, services are also provided by allied health and nursing
staff. In some cases, clinics operate specifically for BMT patients. In other cases, BMT patients
are seen in general outpatient clinics.
Hospitals were asked to provide activity and cost data on the range of outpatient services provided
to BMT patients (as outlined in Section 5.5). Seven of the eight hospitals provided data to form a
study dataset that comprised 7,485 outpatient clinic attendances, 6,272 dispensed drugs, 1,087
diagnostic tests and 435 other outpatient treatments. As was the case with inpatient data, different
hospitals also provided outpatient data across different time periods. In most cases, this covered
the same period as the inpatient data.
All but one hospital (that provides a low volume of adult autologous transplants) provided costed
patient level data for drugs dispensed in the outpatient setting. This is important as it represents a
large outpatient cost and potentially varies significantly between hospitals. For the other services,
the availability of outpatient data was substantially less than for inpatient services. A small number
of hospitals were able to provide costed activity data for most outpatient services identified above.
However, most hospitals were able to provide activity data for only some of the above services and
very few hospitals were able to provide detailed cost data.
The following is a summary of the data that were obtained for each outpatient service area and the
approach that was applied in developing corresponding cost estimates.
Drug costs
The cost of each outpatient drug dispensed to each BMT patient during the study period was
available for inclusion in the study dataset. Data from each hospital were collated into a single
data set and records which occurred outside of the reporting period were removed. Records were
kept if the date that a drug was dispensed occurred either within 60 days prior to transplant or
within 365 days post transplant. Any records that fell during a transplant episode or a related
inpatient episode as well as records which could not be linked by MRN with a transplant episode
were excluded.
Outpatient clinic costs
Six of the eight hospitals were able to provide details of the number of occasions of service,
duration of service and relevant clinic details. However, only two hospitals were able to provide
cost estimates at the occasion of service level.
For one hospital, the cost data were based only on the hourly salary rate of the clinician attending
the clinic. For the other hospital, the cost data were based on the hourly salary rate of the clinician
plus the overhead costs of the relevant clinical department. The data from the second hospital
clearly represented a more comprehensive estimate of the total cost of operating an outpatient
clinic.
This information was used to develop hourly rates for medical, nursing and allied health outpatient
clinic attendances. These rates were discussed with staff from the other hospitals to determine if
they could reasonably be applied across all hospitals. The emerging view was that this would be a
reasonable approach given the lack of routinely available cost data.
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On this basis, an hourly rate of $78 for nursing and allied health and $301 for medical occasions of
service was applied to the 7,485 occasions of service in the study dataset.
Outpatient treatments
The outpatient data received from hospitals included a relatively small number of treatment
services such as intravenous drug infusions that were provided in an outpatient setting. The
duration of these treatments was not provided. For costing purposes, we have applied a duration
of 60 minutes and used the nursing hourly rate, as clinical advice indicated that these treatments
would normally be undertaken by nursing staff. These treatments represent less that $50,000 in
cost across all hospitals and have been included in outpatient clinic cost results.
Diagnostic tests
Three of the eight hospitals were able to provide details of pathology and/or diagnostic imaging
services provided to BMT patients on an outpatient basis. The data from these facilities confirms
that this does not represent a large cost component for BMT patients.
The method developed to cost diagnostic tests (as a component of outpatient services) was
derived from a review of these data and advice provided during clinical consultations regarding the
likely range of diagnostic tests that a BMT patient would receive. We note that clinicians
consistently advised that whilst there was an accepted range of tests required during the “work up”
phase pre BMT, the additional diagnostic tests required by patients’ pre transplant would be
dependent on the clinical status and underlying condition of each patient.
In addition, whilst most routine post transplant outpatient visits would generate a similar range of
diagnostic tests, each patient may require more complex diagnostic procedures based on clinical
progress and their underlying condition. It was suggested however, that all BMT patients would
have a more comprehensive review of their progress (which means potentially more diagnostic
investigations) at least once within the twelve month period post BMT.
Based on the data received from hospitals and the clinical advice received during the consultation,
diagnostic profiles were developed for each of the following:
•
•
•
•

Routine pre transplant outpatient occasion of service
Pre transplant work up outpatient occasion of service
Routine post transplant outpatient occasion of service
Extended post transplant outpatient occasion of service

In the absence of reliable cost data from a sufficient sample of hospitals, the Commonwealth
Medical Benefits Schedule was used as a proxy for cost. Where service utilisation data was
available from hospitals, it was used to form a template for the number of diagnostic tests in each
of the above categories of activity. This resulted in an estimated total cost of outpatient diagnostic
tests for each hospital. As this methodology is less robust than other elements of the study, they
are deliberately conservative in terms of over estimating the range and number of diagnostic tests
likely to be undertaken.
Further, as this approach involves some assumptions, we have not attempted to separately cost
adults and children or allogeneic and autologous transplants. It is recognised that paediatric
patients (particularly those who have myeloblative conditioning protocols), may require more
frequent and complex diagnostic tests post transplant to assess the impact of chemotherapy
toxicity on their growth and development.
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7.3.1

Outpatient cost results

The results of the outpatient costing process are presented in Table 28 and Table 29 below for
allogeneic and autologous patients respectively. Overall, the results are consistent with anecdotal
expectations - with total cost at each facility largely reflecting the volume of activity that is
undertaken.
There is some variation in the annual cost of outpatient clinics between the two paediatric
hospitals. This may reflect a higher volume of clinic activity at Children’s Hospital Westmead or
may suggest that the outpatient clinic data from Sydney Children’s Hospital is incomplete.

Table 28: Average annual cost of outpatient services - allogeneic transplant patients
Hospital

Annual Cost
Drugs

Annual Cost
Diagnostics

Annual
Total

$103,246

$89,032

$192,278

Westmead Hospital
Royal North Shore Hospital

Annual Cost
Outpatient
Clinics
Data
unavailable
$63,634
$97,096

$243,063
Data
unavailable

$191,503
$57,115

$498,200
$154,211

Adult hospitals
Sydney Children's Hospital

$160,730
$36,726

$346,309
$175,937

$337,650
$50,396

$844,689
$263,059

$49,643
$86,369

$68,478
$244,415

$33,597
$83,993

$151,718
$414,777

St Vincent's Hospital

Children's Hospital Westmead
Paediatric hospitals

Table 29: Average annual cost of outpatient services - autologous transplant patients
Hospital

St Vincent's Hospital

Annual Cost
Outpatient
Clinics

Annual
Cost Drugs

Annual Cost
Diagnostics

Annual
Total

Data
unavailable

$57,669

$75,593

$133,262

$9,643
$68,303

$47,005
Data
unavailable

$87,352
$131,028

$144,000
$199,331

$9,829
$15,134
$102,909

$28,798
$8,579
$142,051

$35,837
$40,316
$370,126

$74,464
$64,029
$615,086

$22,283

$81,177

$53,755

$157,215

$94,506
$116,789

$71,726
$152,903

$77,273
$131,028

$243,505
$400,720

Westmead Hospital
Royal North Shore Hospital

St George Hospital
Nepean Hospital
Adult Hospitals
Sydney Children's Hospital
Children's Hospital Westmead
Paediatric Hospitals

7.3.2

Pharmaceutical costs

Pharmaceuticals represent a significant component of the cost of BMT services. For this reason,
in addition to the data used for the primary costing, hospitals were asked to provide a breakdown
of individuals prescriptions issued to patients that received a BMT during the study period and any
available documentation relating to BMT regimen’ that are routinely used.
As expected, only some hospitals were able to provide the very detailed information required to
undertake an analysis by individual drugs. However, we have undertaken an exploration of the
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available data. Drugs are grouped into pharmacological categories and Table 30 below shows the
proportion of annual inpatient and outpatient drug expenditure by hospital and category for the four
hospitals that provided data in this area. We would note the following points in relation to this
analysis:
•
•
•
•
•
•

The data includes both inpatient and outpatient drugs;
The results reported here do not include any drugs dispensed through a hospital imprest
system;
The analysis here includes all drug records provided by hospitals. That is, no records have
been excluded on the basis of the business rules used in the primary costing;
Only the top 20 most expensive drugs were categorised - other drugs are included in the other
category;
Where hospitals provided data for more than one year, the proportions have been averaged to
reflect an annual amount.
The number of years data provided by hospitals may have a slight impact on the distribution
between categories.

Table 30: Drug cost by type by hospital
Pharmacological Category

Antifungals
Antivirals
Antibiotics
Immunosuppressants
Colony Stimulating Factors
Monoclonal Antibodies
Chemotherapy Drugs
Nutrition
Others
Total

St Vincent's
Hospital
22%
5%
1%
18%
15%
5%
28%
0%
6%
100%

Westmead
Hospital
39%
9%
4%
15%
13%
7%
6%
0%
7%
100%

Sydney
Children's
Hospital
26%
17%
12%
13%
7%
5%
5%
10%
6%
100%

Children's
Hospital
Westmead
27%
11%
2%
5%
22%
0%
17%
2%
13%
100%

The following points summarise the key findings that arose from this analysis:
Adult hospitals
• There are significant differences in the use of antifungals (Westmead) and chemotherapy
agents (St Vincent’s) otherwise there is reasonable similarity on a per patient basis;
• The high cost of antifungal agents is heavily influenced by the liposomal delivery of
amphotericin as well as the general expense of triazole drugs;
• The use of the chemotherapy drugs is relatively inexpensive in comparison with anti
infective agents;
• Parenteral Nutrition is rarely listed in the adult hospitals;
• A lower than expected proportion of drugs were listed under Section 100.
Paediatric
• The two paediatric hospitals are similar in antifungal drug use;
• According to the data provided monoclonal antibodies are rarely used at the Children’s
Hospital Westmead while colony stimulating factors are three times more significant than at
Sydney Children’s Hospital.
• A lower than expected proportion of drugs were listed under Section 100.

Page 54

Final Report: A Costing Study of Blood & Marrow Transplantation Services in NSW

Centre for Health Service Development

7.3.3

BMT Laboratory costs

As noted previously there are eight specialist BMT laboratories servicing the fifteen hospitals that
provide blood and marrow transplants. These laboratories process and store the stem cells used
in BMT. To formulate a costing methodology for this cost component, advice was sought from the
Blood and Marrow Transplantation Cost Study Reference Group. This group supplied a copy of
information collated by the BMT Network NSW Executive Group in 2003 which provided an
estimated costing for ‘processing and cryopreservation of autologous PBCS’. This information was
subsequently revised using 2007 dollar values.
Further information was obtained from the NSW Blood and Marrow Transplantation Service Plan
(Working Draft – Sep 2008) on the number of stem cell collections per transplant per hospital,
performed by each respective BMT laboratory during 2007. Information was also gathered on the
relevant Medicare item numbers for common procedures performed by all eight BMT laboratories
in NSW, and information on the associated fee obtained from a search of the Commonwealth
Medical Benefits Schedule, (this is summarised in Table 31 below).

Table 31 Medicare items for procedures commonly performed in NSW BMT laboratories
Item Number
13760
71146

*

Description
MBS Fee
In vitro processing (and cryopreservation) of bone marrow or peripheral blood for
$ 704.60
autologous stem cell transplantation
Enumeration of CD34+ cells, only for the purposes of autologous or allogeneic
$ 105.85
haemopoietic stem cell transplantation, including a total white cell count on the
aphaeresis collection*
This test is performed 3 times per patient (morning PB CD34 test, bag CD34 count and thawed pilot vial CD34
counts)=$317.55

This information shows that a laboratory performing one common autologous cryopreservation
procedure would be eligible for approximately $ 1022.15 from Medicare. This fee does not
represent the full cost of staff time needed to process a product, storage and maintenance of cells
in liquid nitrogen tanks, other compulsory tests required to be performed on each product like
microbial studies, confirmatory blood group testing, colony assays etc.
Additional expert advice was sourced from the Scientific Director, Sydney Cellular Therapies
Laboratory at Westmead Hospital as this laboratory receives the highest number of stem cell
products for processing, manipulation and storage per year in NSW.
The Sydney Cellular Therapies Laboratory at Westmead Hospital represents the spectrum of
laboratory work required in BMT. For example:
•
•
•
•
•

Products collected are use in autologous, allogeneic and unrelated transplants
Products used for transplantation include bone marrow, peripheral blood stem cells and cord
blood
Products used are specifically intended for adults and paediatric transplant patients in NSW
Procedures performed in this laboratory include routine and specialised procedures (such as
CD34+ selection procedures)
A full time BMT Laboratory service is provided for other BMT hospitals in NSW (other than an
on-site service)

Data were examined for this laboratory for the previous three years, demonstrating consistent cost
patterns. The cost information supplied incorporated the running costs of the laboratory such as:
staff, consumables and reagents, equipment and maintenance as well as the routine tests
performed on each product.
The laboratory cost per product was calculated to be $2085 for the Sydney Cellular Therapies
Laboratory at Westmead Hospital for 2007/08. This figure is considered a realistic estimate of the
current cost of cell processing across NSW BMT laboratories. On this basis, it has been used to
generate current cost estimates. Activity data from 2007 has been used in this calculation. The
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results are shown in Table 32 by hospital and by laboratory. It shows the annual BMT laboratory
costs for NSW as being $1.651M. We note that all eight BMT laboratories have been included in
this Table.

Table 32 BMT laboratory costs estimated by volume of products processed in 2007
Laboratory

Westmead

Hospital utilising
laboratory

Number of
products
Per Hospital

226

$471,233

118
14

132

$246,042
$29,191

$275,233

Royal Prince Alfred
Concord

63
24

87

$131,361
$50,042

$181,404

Sydney Children's
Prince of Wales

57
19

76

$118,851
$39,617

$158,468

Royal North Shore

Royal North Shore

155

155

$323,191

$323,191

Liverpool

Liverpool

51

51

$106,340

$106,340

St George

St George

20

20

$41,702

$41,702

Calvary Mater
Newcastle

Calvary Mater Newcastle

42

Royal Prince Alfred

Sydney Children's

65
105
15
41

St Vincent's
Gosford

Total per
laboratory

$135,532
$218,936
$31,277
$85,489

St Vincent's

Children's Hospital
Westmead
Nepean
Wollongong

Total per
laboratory

Total cost per
annum
Per Hospital

John Hunter Children's
Total

7.4

$87,574

3

45

792

792

$6,255

$93,830
$1,651,399

Costs not included in this study

This study has aimed to cost the primary activities associated with the provision of BMT services in
NSW. As the study had a limited scope and timeframe, it was not possible to capture data on the
full range of activities associated with BMT services. In particular some indirect services have not
been included. We have identified these services below. We would note, however, that there was
a wide range of views expressed during the study about whether it is appropriate to include these
activities in a costing study of BMT services.
Services on which cost data was not captured in this study:
•
•
•
•
•
•
•
•
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costs attributable to cell processing, transport and storage borne by the treating hospital;
costs associated with pre transplant genetics and/or research;
family members who travel and stay close to the patient for long periods of time in
accommodation that may be provided in association with hospitals;
blood and blood products;
tissue typing (particularly extended tissue typing);
costs associated with donor stem cell collection (for NSW, national and international
transplant recipients);
‘rainy day harvests’;
patients prepared for transplant who do not then proceed to transplant;
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•
•
•
•
•
•
•
•

Haematology/oncology units in large rural centres which have met the costs of work-up and
the costs of post transplant management (particularly drug costs) even though the
transplant episode may not have occurred in this facility;
parts of the patient journey for selected interstate patients;
outpatient consultations or community outreach services provided by non BMT
physicians/clinicians;
additional patient education and support programs;
specialty bone marrow services that may be unique to one facility e.g. the Australasian
Bone Marrow Transplant Recipient Registry at St. Vincent’s Hospital;
service development elements of bone marrow services that are provided by NSW Health
e.g. the Greater Metropolitan Clinical Taskforce Bone Marrow Transplant Network;
treatment that may be provided interstate e.g. provision of extracorporeal phosphoresis by
the Peter McCallum Cancer Centre;
costs involved in the ongoing treatment of chronic GVHD post 365 days transplant which
applies to a significant proportion of allogeneic transplant patients long term treatment.
7.4.1

Revenue

We have not undertaken a detailed review of sources of revenue associated with BMT services as
this was outside the terms of reference for this project. We would, however note the following two
points that were identified during the consultation stage of the project.
•

All BMT hospitals indicated that the vast majority of outpatient services provided to BMT
patients are billed to Medicare. Further, some hospitals indicated that at some point following
transplantation, patients may be seen in doctor’s private rooms. In this latter case, both the
cost and the activity would have been excluded from this study.

•

Very few patients that receive a BMT are treated as private inpatients. While this proportion is
much lower than the actual proportion in the population, it is not uncommon for persons
requiring expensive and long-standing health care to elect non-chargeable status.

7.5

Estimated cost of BMT projections in NSW

The NSW Department of Health is currently working with the NSW BMT Service Plan Development
Working Group to develop a Statewide plan for BMT services. We have applied the results of this
study to produce cost estimates base on the current projections developed by this group.
In producing these estimates, we would make the following points:
•

Our costing is based on the projections set out on page 49 of the NSW Blood and Marrow
Transplantation Service Plan dated September 2008.

•

We have not attempted to adjust the average cost per patient other than keeping constant
dollars. The Service Plan document indicates that costs can be expected to rise with new
technology but quantification of the effect of that technology is not provided. It was also
beyond the scope of our study to attempt to cost these potential changes.

•

The projections indicate an increase in unrelated BMT relative to related donors. This
implies a higher cost because of the higher price of the unrelated transplants. This change
has not been factored into our costing.

•

The projections imply but do not explicitly state that both autologous and allogeneic BMT
for paediatric cases are expected to be constant over time.
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Table 33 below provides an estimate of the cost of BMT services in NSW based on constant 2007
dollars and constant real cost per patient. Estimated costs for 2011 are $46.84m which will
increase in 2016 to $53.92m.

Table 33: Projections for BMT for NSW residents
Transplant Type
Adult Allogeneic

2006/07 Cost per
transplant
$114,316

Adult Autologous

$62,812

$18,843,600

$23,303,252

Paediatric Allogeneic

$227,286

$7,955,010

$7,955,010

Paediatric Autologous

$119,367

$3,581,010

$3,581,010

$46,498,176

$53,587,096

TOTAL

7.6

2011 NSW Total
cost
$16,118,556

2016 NSW Total
cost
$18,747,824

Summary of results

This section consolidates the earlier results to provide an overall estimate of the current cost of
BMT services in NSW. These results are presented separately for allogeneic and autologous
services and for adult and paediatric hospitals.
Firstly, Table 34 shows the total annual cost for allogeneic transplants including the transplant
episode, related inpatient episodes and outpatient services. The average number of BMTs at each
hospital and the cost per BMT is also shown. Total expenditure on the 134 allogeneic transplants
undertaken annually is $19.04m of which $14.04m is spent on transplant episodes, $3.74m on
related inpatient episodes and $1.26 m on outpatient services.
The average cost of an adult allogeneic transplant is $114,316 compared with a paediatric
transplant with an average cost of $227,286. In our view, the large difference in cost between
adult and paediatric transplants means that there is little value in considering the overall average
cost of an allogeneic transplant. However, it is shown here ($142,137) for the sake of
completeness.

Table 34: Total annual costs of allogeneic transplant – study dataset
Hospital

Annual BMT

Annual RIE

Annual
Outpatient

Total
Annual

Number
BMTs/Year

Cost Per
BMT

St Vincent's Hospital
Westmead Hospital
Royal North Shore
Hospital
Adult Hospitals

$2,318,031
$5,269,080
$1,111,256

$743,452
$934,157
$325,234

$192,278
$498,200
$154,211

$3,253,761
$6,701,437
$1,590,701

27
57
17

$120,510
$117,569
$93,571

$8,698,367

$2,002,843

$844,689

$11,545,899

101

$114,316

Sydney Children's
Hospital
Children's Hospital at
Westmead

$2,162,760

$1,135,285

$263,059

$3,561,104

15

$237,407

$3,185,190

$602,415

$151,719

$3,939,324

18

$218,851

Paediatric Hospitals

$5,347,950

$1,737,700

$414,777

$7,500,428

33

$227,286

$14,046,317

$3,740,543

$1,259,466

$19,046,327

134

$142,137

All

BMT = Transplant episode. RIE = Related inpatient episode
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Table 35 shows the equivalent information for autologous transplants. Total expenditure on the
159 transplants undertaken annually is $11.98m of which $7.05m is spent on transplant episodes,
$3.90m on related inpatient episodes and $1.0 m on outpatient services.
The average cost of an adult autologous transplant is $62,812 compared with a paediatric
transplant with an average cost of $113,812. Again, in our view, there is little value in considering
the overall average cost of an autologous transplant, but it is shown here ($75,322) for the sake of
completeness.

Table 35: Total annual costs of autologous transplant – study dataset
Hospital

Number
BMTs/Year

Cost Per
BMT

$1,653,815
$1,254,841
$2,635,664

23
26
39

$71,905
$48,263
$67,581

$74,464
$64,029
$615,087

$624,956
$610,020
$758,191
$7,537,487

9
11
12
120

$69,440
$55,456
$63,183
$62,812

$922,857

$157,215

$1,669,528

16

$104,346

$660,695

$1,365,385

$243,505

$2,629,585

17

$154,681

Paediatric Hospitals

$1,250,151

$2,288,242

$400,720

$3,939,113

33

$119,367

All

$6,465,183

995,611

$1,015,807

$11,476,601

153

$75,010

St Vincent's Hospital
Westmead Hospital
Royal North Shore
Hospital
Prince of Wales Hospital
St George Hospital
Nepean Hospital
Adult Hospitals
Sydney Children's
Hospital
Children's Hospital
Westmead

Annual BMT

Annual RIE

Annual
Outpatient

$1,099,814
$953,888
$1,906,788

$420,739
$156,953
$529,545

$133,262
$144,000
$199,332

$477,099
$364,463
$412,980
$5,215,032

$147,857
$171,093
$281,182
$1,707,369

$589,456

Total
Annual

BMT = Transplant episode. RIE = Related inpatient episode

Finally, Table 36 shows the total annual cost of both allogeneic and autologous transplant services
for each hospital that participated in the study. Total cost is $30.88m annually for 134 allogeneic
and 153 autologous transplants undertaken across the eight hospitals. Total costs range from
$610,020 at St George Hospital which undertakes 11 autologous transplants, to $7.95m at
Westmead Hospital which undertakes an average of 57 allogeneic and 26 autologous transplants
annually.
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Table 36: Total annual cost of allogeneic and autologous transplants – study dataset
Hospital

Cost Per
Allogeneic
Transplant

Number of
Allogeneic
Transplants

Cost Per
Autologous
Transplant

Number of
Autologous
Transplants

Total
Number of
Transplants
Per Year

Total
Annual
Cost

$120,510

27

$71,905

23

50

$4,907,576

$117,569
$93,571

57
17

$48,263
$67,581

26
39

83
56

$7,956,278
$4,226,365

$0

0

$69,440

9

9

$624,956

$0
$0
$114,316

0
0
101

$55,456
$63,183
$62,812

11
12
120

11
12
221

$610,020
$758,191
$19,083,386

Sydney Children's
Hospital

$237,407

15

$104,346

16

31

$5,230,632

Children's Hospital
Westmead

$218,851

18

$154,681

17

35

$6,568,895

Paediatric
Hospitals

$227,286

33

$119,367

33

66

$11,799,536

$142,137

134

$75,010

153

287

$30,882,930

St Vincent's
Hospital
Westmead Hospital
Royal North Shore
Hospital
Prince of Wales
Hospital
St George Hospital
Nepean Hospital
Adult Hospitals

Total
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Appendix 1 Consultation Summary
Name

Position / Department

Area Health Service Facility

Director Haematology/BMT, Co-Chair of
BMT Network Executive
BMT Transplant Coordinator

South Eastern Sydney/Illawarra

St Vincent’s Hospital

Clinical Consultations
Associate Professor Tony Dodds
Annabelle Horne

South Eastern Sydney/Illawarra

St Vincent’s Hospital

Associate Professor Ken Bradstock Director BMT

Sydney West

Westmead Hospital

Dr Warwick Benson

Director Clinical Haematology

Sydney West

Westmead Hospital

Leng Leng Yee

Acting BMT Transplant Coordinator

Sydney West

Westmead Hospital

Professor Peter Shaw

Director Haematology/Oncology

Sydney West

Children’s Hospital, Westmead

Dr Chris Arthur

Director Haematology and BMT

Northern Sydney/Central Coast

Royal North Shore Hospital

Cassandra Reid

BMT Transplant Coordinator

Northern Sydney/Central Coast

Royal North Shore Hospital

Dr Stephen Larson

Haematologist

Sydney South West

Royal Prince Alfred Hospital

Jon Sanders

BMT Transplant Coordinator

Sydney South West

Royal Prince Alfred Hospital

Dr Sundra Ramanathan

Head of Cancer Services

South Eastern Sydney/Illawarra

St George Hospital

Dr David Rosenfeld

Director Haematology/BMT

Sydney South West

Liverpool Hospital

Patricia Ryan

Acting Transplant Coordinator

Sydney South West

Liverpool Hospital

Dr Tracey O’Brien

South Eastern Sydney/Illawarra

Sydney Children’s Hospital

Dr Carol Cheung

Head, Cord and Marrow Transplant
Program
Staff Specialist, Haematology

South Eastern Sydney/Illawarra

Prince of Wales Hospital

Alison Read

Clinical Nurse Consultant

South Eastern Sydney/Illawarra

St George Hospital

Cassandra Hobbs

Clinical Nurse Consultant

South Eastern Sydney/Illawarra

St George Hospital

Vicki Antonenas

Westmead Hospital

Dr David Gottlieb

Head Scientist, BMT Laboratory, Co-chair of Sydney West
BMT Network Executive, Chair BMT
Network Laboratory Services Working
Group
Medical Director, BMT Laboratory
Sydney West

Dr Stephen Larsen

Haematologist

Sydney South West

Royal Prince Alfred Hospital

Jon Sanders

BMT Transplant Coordinator

Sydney South West

Royal Prince Alfred Hospital

Genevieve Daly

Senior Pharmacist

South Eastern Sydney/Illawarra

Tom Fong

Acting Deputy Director, Pharmacy

South Eastern Sydney/Illawarra

Rebecca Walsh

Senior Pharmacy Technician

South Eastern Sydney/Illawarra

Prince of Wales/
Sydney Children’s Hospital
Prince of Wales/
Sydney Children’s Hospital
Prince of Wales/Sydney
Children’s Hospital

Westmead Hospital

Conducted by Teleconference
Associate Professor Phillp Rowlings Senior Staff Specialist Haematologist

Hunter/New England

Calvary Mater Newcastle

Louisa Bray

Transplant Coordinator

Hunter/New England

Calvary Mater Newcastle

Dr Frank Alvaro

Paediatric Haematologist/Oncologist

Hunter/New England

John Hunter Children’s Hospital

Dianne Cotterell

Clinical Nurse Consultant

Hunter/New England

John Hunter Children’s Hospital

Costing/Casemix/Finance
Personnel
Melita Howes

Casemix Manager

South Eastern Sydney/Illawarra

St Vincent’s Hospital

Sue-Ellen Fletcher

Senior Costing Analyst

Sydney West

Westmead Hospital

Winston Piddington

Senior Clinical Costing Officer

Northern Sydney/Central Coast

Royal North Shore Hospital

Penny Ison

Clinical Costing Offier

Northern Sydney/Central Coast

Royal North Shore Hospital

Christine Fan

Clinical Costing Manager

Sydney West

Children’s Hospital, Westmead

Micheline Hanna

Clinical Costing Officer

Sydney West

Children’s Hospital, Westmead

Jenny McNamee

Casemix Manager

South Eastern Sydney/Illawarra

Sydney Children’s Hospital

Chris Ellery

Manager, Performance Information

South Eastern Sydney/Illawarra

Prince of Wales Hospital

Robert Siu

Cancer Service Network Manager

Sydney West

Westmead & Nepean Hospitals

Jenna Balding

Finance and Information Resource Manager Sydney West

Westmead Hospital

Cara Dickson

Senior Costing Officer

South Eastern Sydney/Illawarra

St George Hospital

Alison Cochrane

Performance Analyst

Prince of Wales Hospital

Vineet Makhija

Casemix Policy Unit, Intergovernment &
Funding Strategies Branch

SESIHS Northern Hospital
Network
NSW Health

Intergovernment & Funding
Strategies Branch

Executive
Elizabeth Koff

Director Clinical Operations

South Eastern Sydney/Illawarra

Area Administration

Dr Michael Brydon

Director, Clinical Services

South Eastern Sydney/Illawarra

Sydney Children’s Hospital

Kathy Meleady

Director, Statewide Services Development NSW Health
Branch

Statewide Services Development
Branch

Cristalyn DaCunha

Manager, Casemix Policy Unit,
Intergovernment & Funding Strategies

Intergovernment & Funding
Strategies Branch

NSW Health
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Name

Position / Department

Area Health Service Facility

Branch
Bart Cavalletto
Lou-anne Blunden
Lyn Olivetti

Manager, Clinical Services Planning Unit,
Statewide Services
Director, Health Services Planning

NSW Health

Clinical Services Planning Unit, Statewide
Services Branch

NSW Health

Sydney South West

Statewide Services Development
Branch
Liverpool Hospital
Statewide Services Development
Branch

Other Key Stakeholders
Ms Sally Gordon

Executive Officer

Australian Bone Marrow Donor
Registry (ABMDR)

Dr Heather Dunckley

Principal Scientist

Australian Bone Marrow Donor
Registry (ABMDR)

NSW BMT Service Plan
Development Working Group

Meeting of 24/9/08
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Appendix 2 Literature review
A1 Search strategy
The NSW BMT Service Plan Development Working Group (the Working Group) was the starting
point for the literature review. The Working Group provided background to the current delivery of
blood and marrow transplant (BMT) services in New South Wales including information on:
• trends in service use and expected future service requirements based on population
projections for Area Health Services throughout NSW
• research underway and the potential for future research and diagnostic opportunities
involving BMT
• the potential for increased demand for BMT services both for new indications, and arising
from improvements in practice, technologies and pharmacological products
• the increasing availability of donor stem cells and the resulting impetus for significant
increase in some forms of BMT, in particular, alternative donor allogeneic transplants
• changes in clinical practice affecting demand, including different types of service delivery
such as early discharge and greater use of outpatient facilities and
• the infrastructure and personnel requirements of BMT services - in particular, laboratory
requirements (including for stem cell storage and processing), facilities needed by each
BMT unit (including design, operational and data collection requirements) and workforce
needs appropriate to the delivery of BMT services.
With this background, the literature review focussed on costing studies that might shed light on
these and other issues affecting BMT services in NSW.
Relevant papers were identified by searching the electronic databases Medline, EconLit, Science
Direct, Cinahl and Cochrane databases using combinations of the search terms transplant$, blood,
bone marrow, stem cell, cord, umbilical, cost$ and method, costing, costing method$, costing
model$, cost accounting, and case-mix. Key journals such as Bone Marrow Transplantation,
Blood, Clinical and Laboratory Haematology as well as Cancer Treatment Reviews and the
European Journal of Cancer were also searched separately to ensure all references were found.
The resulting citations were culled to exclude those that did not focus on either costing or
economic evaluation of blood and bone marrow transplantation. Only English language citations
were retained. Additional citations were identified by internet searching, reviewing reference lists
in recently published work and searching for recent publications by key researchers in the field. A
second round of culling was undertaken based on reading the abstract or executive summary of
each paper or report. Full text copies of the remaining 34 papers/reports were then reviewed.

A2 Overview
The literature on costing blood and bone marrow transplants comprises only a small number of
studies, with the main work undertaken in the USA and Europe, in particular Scandinavia and the
Netherlands. The studies are limited in scope, most are targeted to particular indications and
underlying disease, and few provide detailed costing of the stages of transplant.
While about a third of the papers were published in the last 5 years, many refer to research
undertaken more than a decade ago. For example, a UK study published in 2004 reviewing the
costs and cost-effectiveness of new interventions for the treatment of aggressive non-Hodgkin’s
lymphoma summarised information gathered between 1987 and 1999 (Beard et al 2004). Each of
two recent systemic reviews (of the health economics of managing multiple myeloma, and of the
comparative costs of high-dose chemotherapy and autologous stem cell transplantation vs.
conventional chemotherapy), reported on only five studies examining the cost of BMT services
(Moeremans and Annemans 2006, Simnett et al 2000). Another review of economic analyses of
acute myeloid leukaemia found only five studies that estimated per patient BMT costs, with only
two of these costing different components of BMT (Redaelli et al 2004).
Very little economic analysis of BMT services in light of recent changes in clinical practice and/or
advances in new technology and diagnostics in the past few years, in particular in relation to gene
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therapy and sources of donor stem cells, is available. A recent systematic review of ‘trends and
prospects’ in stem cell transplantation in Europe between 2005 and 2010 contained no costing
detail. Instead, it relied on estimates of activity based on trends in use for different indications and
expected developments in practice, to suggest possible expansions in budget (Tan et al 2007). In
terms of informing the development of costings for BMT service components, most of the literature
was of marginal value.
The terminology used to refer to the economic aspects of BMT services differs throughout the
literature, at times affecting interpretation. The terms costs, charges, expenditures, payments and
reimbursement can all be found. It was important to distinguish, for example, between charges
and costs, in particular in regard to studies undertaken in the United States. Studies reporting the
hospital charge for BMT services and products, are not necessarily reporting the actual costs of
services. For example, charges in some hospitals may be inflated to cover costs from other
departments and third-party payer costs may need to be taken into account (Westerman and
Bennett 1996).
The literature review identified several economic evaluations of blood and marrow transplantation.
Whilst economic evaluation was outside the scope of this project the studies were reviewed for
details of the costing methodologies employed. In most such studies, the costing methodologies
were not fully explained, nor were costing details reported, but they were useful for the purposes of
shedding light on the overall magnitude of costs of different BMT service types. In general, they
took a pragmatic approach, in keeping with the literature. “Analysts and decision makers must
consider whether the benefits of more accurate and detailed cost information justify the additional
costs incurred in obtaining that information.” (Smith and Mogyorosy 2005)
A major difficulty in costing BMT services is that widely differing assumptions and a variety of
different inputs may be used to derive costings. This is particularly the case because there are
many different treatment methodologies covering both autologous and allogeneic transplants, a
variety of donor stem cells, and an increasing range of indications and clinical practice modalities.
Moreover, costs do not remain static and, because of the complexity of treatments and indications,
even small changes in protocol can lead to a large difference in cost (Freeman et al 1996). This
issue is compounded when methodologies reported lack detail, or are ambiguous. Therefore, any
comparison of reported costings is difficult. Most studies refer to this matter, in keeping with the
general principle that robust cost comparisons can only be made when cost measurement is in
reasonable compliance with a standardised costing methodology (Smith and Mogyorosy 2005).
Some of the many possible sources of differences between studies that might lead to bias and/or
discrepancies are:
• the type and complexity of the service, for example, service settings, admission practice
• the availability of data and its validity
• the sample size and design - for example, whether randomised, prospective or
retrospective (typically, sample size is very small with most studies based on < 50 patients)
• the costing methodology – for example, (i) use of direct and/or indirect costs, whether
standard unit costs or fees, charges and/or market prices are used; and (ii) the
assumptions underlying cost estimation and/or extrapolation
• the time horizon for a study and the consequent technologies, diagnostics and level of
knowledge and sophistication of BMT services available at that time
• the stages or components of BMT included and the practices considered (for example,
conditioning regimens)
• the range of items that may or may not be included in costs
• the large variation in unit costs that is possible, particularly between countries
• the variations in price levels between treatment alternatives and treatment items,
particularly between countries
• assumptions regarding the static nature of costs (for example, for cycles of chemotherapy)
• whether donor costs are taken into account
• the duration of follow-up period, if any, that is covered in a study
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•

•
•

the indications and type and severity of disease covered by a study (for example,
Westerman and Bennett (1996) found that the main cost driver for severe combined
immunodeficiency was nursing care, while laboratory and radiology costs were the main
drivers for acute myeloid leukaemia, severe aplastic leukaemia and chronic granulocytic
leukaemia)
the study perspective and country in which it was undertaken
(as already noted) whether reimbursement costs for procedures are reasonable estimates
of the real costs borne by the treating facility.

(Beard et al 199, van Agthoven et al 2002, Moeremans and Annemans 2006, Mishra et al 2003,
Westerman and Bennett 1996).
The pace of change in BMT is rapid so that conclusions regarding changes in clinical practice and
emerging technologies that may impact on service provision, if they are based on retrospective
studies, may already be out of date with practices and technologies well-established. For
example, several studies refer to the use of high-dose chemotherapy with stem-cell support vs.
standard conventional chemotherapy for managing different conditions. Beard et al (2004)
referred to ‘a definite trend towards reduced costs for high-dose therapy {for patients with
aggressive non-Hodgkin’s lymphoma}, possibly reflecting increasing technical excellence and
improved bone marrow recovery through the use of stem cell transplantation and growth factors’.
Moeremans and Annemans (2006) note that the former practice ‘has clearly improved disease-free
survival’ for patients with multiple myeloma. They also note that ‘new promising agents…with
improved response rates, progression-free and potentially overall survival in different stages of
multiple myeloma’ are available, but that their acquisition costs are very high compared with some
established treatments. Mishra et al (2005) noted that high dose chemotherapy with autologous
peripheral blood stem cell support (PBSCT) was ‘an established treatment strategy for
poor-prognosis malignancies’ and that use of PBSCT replaced bone marrow at the Norwegian
Radium Hospital (NRH) in 1993 for malignant lymphoma.
The recent paper by Tan et al (2007) aimed to identify trends in Europe in BMT patient numbers
and to anticipate transplant rates for the next 5 years. The paper referred to the greater use of
reduced-intensity conditioning regimens followed by transplantation (RIC-HSCT) and increasing
worldwide donor availability as significant trends likely to lead to increasing use of transplant for a
range of indications. The availability of alternative drug treatments was another key factor
expected to influence trends in transplantation. The study predicted an increase in autologous
transplantation in Europe of 6% between 2005-2010, with particular reference to the treatment of
acute leukaemia and auto-immune diseases. An even greater increase of about 20% in allogeneic
transplantation was predicted, with rises in use for all indications except chronic myeloid
leukaemia, due mainly to the expected increased use of RIC_HSCT in older patients and in
patients with co-morbidities.
For specific indications, the following trends were noted:
• For acute lymphoblastic leukaemia (ALL), use of more intense early phase therapy, greater
use of RIC with allogeneic transplantation in elderly AML patients (already popular for AML
patients aged over 40), use of HSCT as a consolidation treatment or as a treatment option
for patients aged between 60 and 75, and an overall expansion in allogeneic transplants for
ALL.
• For myeloproliferative disorders, greater use of allogeneic HSCT for myelodysplastic
syndrome (MDS), with a possible slight decrease in use of allogeneic HSCT for chronic
myeloid leukaemia (CML), depending on new drug treatments for Imatinib resistant CML.
• For lymphoproliferative disorders, a modest increase in allogeneic HSCT based on the
increased likelihood of finding a compatible donor and greater use of RIC-HSCT.
• For multiple myeloma, possible use of RIC-HSCT after a preceding autologous transplant,
with almost all MM patients aged up to 65 receiving an autologous transplant; allogeneic
transplants likely to increase with greater use of RIC, though overall MM patient numbers
may drop due to the availability of alternative drug treatments.
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•

•

For solid tumours, RIC-HSCT could provide a new approach for renal cell carcinoma,
following a marked increase in allogeneic transplantation in the five years from 1997 to
2002 for solid tumours (mainly due to its application in renal cell carcinoma); a ‘constant but
steady increase [in use of autologous transplantation] for neuroblastoma and Ewing
sarcoma, but, due to the introduction of alternative drug treatments and disappointing
results from autologous transplantation, especially in the treatment of breast cancer, the
role of autologous transplantation in the treatment of other solid tumours could be
challenged.
For non-malignant disease, autologous transplantation currently mainly used for
auto-immune diseases but, because ‘different opinions prevail’, future use is difficult to
predict; growth likely in allogeneic transplantation, due to increased use of RIC_HSCT in
older patients and those with co-morbidities.

Changes in the characteristics of BMT service delivery and consequent changes in costs and shifts
in cost distribution are the subject of discussion in a number of papers. For example, Freeman et
al (1999) noted that overall treatment-related costs for BMT for patients diagnosed with nonHodgkin’s lymphoma (NHL) decreased by 35% between 1998 and 1995, and that the distribution
of costs changed with reductions in inpatient hospitalisations (71% of total cost in 1992 to 45% in
1995) and concomitant increases in outpatient visits (26% of total costs in 1992 to 49% in 1995).
Citing previous evidence that organisational improvements and technological advances can have
large effects on cost improvements, Freeman et al postulated that decreases in average length of
stay (ALOS) and inpatient admission costs between 1989 and 1995 for NHL patients arose from
three main sources: (i) organisational changes in relation to hospitals (including increased use
outpatient facilities, better referral systems and more efficient use of staffing and resource), (ii)
improvements in technology (for example, though use of granulocyte colony-stimulating factors or
G-CSF mobilised SCT, more cost-effective laboratory procedures and advances in pharmacology),
and (iii) improvements in patient case-mix and provider changes. Regarding pharmacy costs,
while costs decreased overall, the relative proportion of outpatient pharmaceuticals increased 10fold.
In terms of disaggregated costing data, the most comprehensive analyses were:
• a 2002 Dutch study of a cost analysis for HLA-identical sibling and voluntary unrelated
allogeneic bone marrow and peripheral blood stem cell transplantation in adults with AML
or ALL (van Agthoven et al 2002); and
• a 2005 report prepared for the Technology Assessment Unit of the McGill University Health
Centre (Canada) on allogeneic transplantation in adults of stem cells from unrelated
donors.
A study by Prajogo (2004) reporting the results of a cost comparison of high-dose chemotherapy
and autologous bone marrow transplantation vs. standard dose chemotherapy for patients with
non-Hodgkin’s lymphoma at the Calvary Mater Misericordiae Hospital in Newcastle provided the
most relevant Australian analysis (see Section 0).

A3 Regulation, compliance and quality management systems
The Working Group noted the impact that the regulation of BMT services and requirements for
compliance with quality management systems will have on laboratories and units providing BMT
services. In particular:
• regulation of BMT services by the Therapeutic Goods Administration (TGA) was expected
by mid-2009;
• collection units would be required to comply with new National Pathology Accreditation
Advisory Council (NAPAAC) standards June 2010, with inspection by the National
Association of Testing Laboratories (NATA); and
• if not already achieved, paediatric units were likely to want to obtain international
accreditation with the Foundation for Accreditation Cellular Therapy (FACT).
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The Working Group indicated the potential staffing, infrastructure and system requirements to
implement FACT accreditation requirements, based on two Australian facilities that have already
received TGA licences. In doing so it referred to a 2004 estimate of costs (150,000 euros or
$A240,000) for implementing processes to meet FACT standards and for compliance with Joint
Accreditation Committee – ISCT (International Society for Cellular Therapy) and EBMT (European
Bone Marrow Transplant Society) (JACIE) standards (Zahnd 2004).
Estimates were developed by the National Institute for Clinical Excellence (NICE) in 2003 of the
additional funds required to implement the JACIE standards throughout England and Wales.
Funds of from £25.2 to £51.5 (or $A70.63 - $A144.34 (2007)) were expected to be required,
depending on decisions regarding minimum levels of BMT services that might be provided by
hospitals (NICE 2003). The additional costs included the costs of providing specialist diagnostic
services; of establishing and resourcing multi-disciplinary teams; of resourcing additional Clinical
Nurse Consultants to deliver patient centred care; and of providing infrastructure, facilities and
resources for high-dose therapy and transplant services.

A4 Stages of transplantation
In undertaking the project, it was necessary to allocate the care of transplant patients into stages
or component periods of time based on clinical practice and reasons. While some of the literature
reflected the need for categorisation of BMT services, this varied across the range of studies. In
general, however, there was little reference, especially in economic evaluations, to the need to
distinguish between costs with a direct link to transplantation versus costs that would have been
incurred irrespective of whether a transplant was performed or not. Eckstein et al (2007) found
that, for heart-lung transplants, there was an argument that the costs incurred by being a candidate
for transplant ‘should not be allocated to the cost of the transplant, since they would be incurred, at
any rate, to maintain the patient or keep the patient alive, regardless of whether the patient is
waiting for a transplant or not’ (from Hauboldt and Ortner 2002 in Eckstein et al 2007).
Examples of studies that articulated stages or categories for which costs were derived include:
• mobilisation and recovery of PBPC; post-mobilisation phase; conditioning and transplant;
critical haematological reconstitution; non-critical haematological reconstitution; death
(Barosi et al 99)
• pre-transplant, transplant, post-transplant follow-up (Mishra et al 2001)
• harvesting (including G-CSF assisted stem cell mobilisation, cryopreservation, pharmacy
costs and nursing care) and high-dose chemotherapy phases for autologous
transplantation (Mishra et al 2003 and 2005)
• induction chemotherapy, post-induction/post-remission chemotherapy, transplantation and
complications arising (Redaelli et al 2004).

A5 Cost drivers
Many of the studies identified factors that have an important impact on costs. The cost drivers
discovered depended partly on the type(s) of BMT services being studied, the aim of the study, the
country in which the study was undertaken, data availability and the study methodology. While,
some studies found that there was no association between patient baseline characteristics and
costs (for example, Lee et al 2000), several studies highlighted the importance of post-transplant
complications, including disease relapse as well as infections and, in the case of allogeneic
transplants, graft-vs.-host disease (GVHD) in terms of predicting high-cost (for example, Griffiths
1993 in Westerman and Bennett 1996, Esperou et al 2004).
A number of studies noted the fundamental structural differences between the United States and
Europe in terms of health service delivery, resulting in different cost drivers for BMT services
depending on where studies are conducted.
One cost component that receives funding from the US Department of Health and Human Services
is the National Bone Marrow Donor Registry ($US23m in 2005-06 budget, including $US10 for the
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Cord Blood Stem Cell Bank) to assist the approximately 16,000 people under 55 diagnosed with
leukaemia or another blood or genetic disorder who would need a blood stem cell transplant (FY
2005 Budget in Brief. USA). For patients with private health insurance, the costs of transplantation
for certain types of cancer are covered by that insurance, while government financial assistance
programs (through Medicaid and Medicare) are limited. In 2005, the cost of tissue typing (range
$US65 to $US96 or $A 90.38-$A 133.48 (2007)) was also funded by the donor, either fully or in
part with the remainder covered by the donor centre. Patient care costs for participants in clinical
trials that are funded by the National Cancer Institute are often covered - either by patients’ health
insurers or by Medicare (National Cancer Institute, U.S. National Institutes of Health).
Gajewski et al (2004) discussed attempts during the past 20 years for the leading payers of US
health care to control growth in health-care spending through managed care strategies. Providers
of expensive services such as BMT are particularly scrutinized, with their clinical programs subject
to new methods of pricing medical services and financial accountability. To protect themselves
from excessive financial risk, providers have developed different payment rates for different types
of transplant, eg, autologous versus HLA or genotypically matched related versus HLA
mismatched transplants. Because at certain times in the HCT process risk is more unpredictable,
HCT providers require different payment system strategies for the different time periods of care
such as evaluation, pre-transplant disease management, harvesting, and cell processing, as well
as short and long-term follow-up. These case rate agreements attempt to manage the
unpredictable consequences of BMT such as regimen-related toxicities, infections and GVHD.
Thus, hospital inpatient, medical staff costs and overheads along with pharmacy costs are much
higher in the United States than in Europe or countries with so-called ‘socialised medicine’. USbased studies, therefore, tend to report significantly higher costs per patient than non-US based
studies reflecting this difference in healthcare systems (Beard 2004). Redaelli’s review of studies
of AML (2004) found that, while hospital stays comprised 47-56% of total costs regardless of the
country of study, the high overall cost found in US studies was due to higher hospital stay and
pharmacy costs combined (34% and 31% respectively, from Du Foir 1992 and Bennett 1999 in
Redaelli 2004). That study also found that pharmacy costs were a considerably smaller proportion
of overall costs in Europe (11-16%), while laboratory costs (in particular, pathology tests) and
blood products were reported as major cost drivers in Europe (Westerman and Bennett 1996).
For studies of autologous BMT, examples of cost drivers include:
• Number of hospital days and blood products (for the period from hospital admission to
discharge only) – (Hartmann et al 1997)
• Stem cell mobilisation costs (harvest phase), nursing costs and pharmacy (Mishra et al
2003 and 2005)
• Room costs, laboratory, pharmacy, medical consultant fees; radiology and supportive care
(Freeman et al 1999)
• Total body irradiation (TBI) and conditioning regimens, number of hospital days, blood
products, antibiotic and supportive care (Vicent et al 2001)
• Induction chemotherapy (and within this, the number of cycles to achieve remission); postinduction: blood products, inpatient costs (medical staff and accommodation), lab/radiology
and pharmacy (Redaelli et al 2004)
• Number of hospital days, number of stem cells collected, phase and type of disease, posttransplant GVHD prophylaxis; whether patient is a child or adult (Barosi et al 99).
For allogeneic transplants, examples of cost drivers include:
• Tissue typing and donor stem cell collection costs, medical and nursing staff costs,
pharmacy, blood products and laboratory costs (Mishra et al 2001)
• Pharmacy, number of hospital days (Dooley et al 2007)
• Number of hospital days, medical and nursing staff costs (Van Agthoven et al 2002)
• Number of hospital days, post-transplant complications (Esperou et al 2004).
For studies involving both autologous and allogeneic BMT, cost drivers include:
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•

Whether donor stem cells are matched or mismatched, year of transplantation and
complications (infections, veno-occlusive disease, GVHD, death) (Lee et al 2000)
• Pharmacy, blood bank and nursing costs (Yoder 98).
In terms of overall costs, systematic reviews by Moeremans and Annemans (2006), Simnett et al
(2000) and Redaelli et al (2004) provided cost summaries, as follows.

Table 37: Overall costs from studies of autologous transplantation using peripheral blood
stem cells for patients with multiple myeloma
Mishra (2005)

Mishra (2003)

Country
Total cost

Norway
$US32160
(hospital
perspective)

Norway
$US38186
(hospital
perspective)

Kouroukis
(2003)
Canada
Can $ 32320
(payer
perspective)

$A (2007)

$42,204

$58,896

$35,565

Time horizon

Peripheral stem
Peripheral stem
cell
cell
transplantation
transplantation
Source: Moeremans and Annemans 2006

90 months

Van Agthoven
(2004)
Netherlands
€ 67563 - 80630
(hospital +
ambulatory
drugs)
$114,167$136,247
36 months

Gulbrandsen
(2001)
Norway
$US 34000
(societal costs)

$52,440
36 months

Simnett et al (2000) reported five studies (one randomised and four non-randomised comparisons)
that compared use of high-dose chemotherapy and autologous transplantation with conventional
chemotherapy for patients with either non-Hodgkin’s lymphoma, multiple myeloma, relapsed
Hodgkin’s lymphoma or breast cancer, as follows:

Table 38: Overall costs from studies of high-dose chemotherapy and autologous
transplantation with NHL, MM, relapsed HL or breast cancer
Indication

Total cost
(US$1993)
$A (2007)
Number of
patients

Uyl-de Groot et
al (1995)
Non-Hodgkin’s
lymphoma

$51,479 vs.
$15,742
$109,348 vs.
$33,438
42

Zaidi et al 1996
Non-Hodgkin’s
lymphoma

$25,473 vs.
$5660
$54,108 vs.
$12,022
11

Henon et al
(1995)
Myeloma – first
line therapy

$56,700 vs.
$46,555
$120,438 vs.
$98,889
22

Desch et al
(1992)
Hodgkin’s
disease –
treatment of
recurrent disease
$84,577 vs.
$18,021
$179,653 vs.
$38,279
-

Hillner et al
(1992)
Metastatic breast
cancer

$99,171 vs.
$39,911
$210,653 vs.
$84,776
-

For acute myeloid leukaemia, five studies published between 1989 and 1999 yielded proportions of
cost drivers and total costs for BMT (for both autologous and allogeneic transplantation) as follows:
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Table 39: Overall costs from studies of BMT for acute leukaemia
Bennett et al
(1999)
US
Transplant
34%

Dufoir et al
(1992)
France
5 years
24%

Viens-Bitker
et al (1989)
France
12 months
32%

Barr et al
(1996)
Canada
18 months
51%

Uyl-de Groot
(1995)
Netherlands
2 years
55%

Dufoir et al
(1992)
France
5 years
23%

31%
11%
13%

15%
25%
30%

17%
16%
29%

11%
38%

14%
18%
13%

8%
45%
19%

11%
$51,479 vs.
$15,742
$A (2007)
$89,208 vs.
$27,279
BMT type
Allogeneic
Source: Redaelli et al 2004

6%
$25,473 vs.
$5660
$44,142 vs.
$9,808
Allogeneic

5%
$56,700 vs.
$46,555
$98,256 vs.
$80,675
Allogeneic

$84,577 vs.
$18,021
$146,564 vs.
$31,228
Allogeneic

$99,171 vs.
$39,911
$171,854 vs.
$69,162
Autologous

6%
$99,171 vs.
$39,911
$171,854 vs.
$69,162
Autologous

Country
Time horizon
Medical staff and
accommodation
Drugs
Blood
Labs/radiation
oncology/diagnostic
radiology
Other
Total cost (€2001)

Beard et al (2004) reported total direct medical costs of high-dose chemotherapy with stem cell
support (either autologous bone marrow transplantation or peripheral blood stem cell
transplantation) for 15 studies of patients with either non-Hodgkin’s lymphoma or other
malignancies such as breast cancer and leukaemia. Some studies were retrospective (study
periods range from 1989 to 1999) and each covered one or more stages including: induction
(mobilisation and harvesting), treatment, post-transplant and post-discharge period. Comparisons
were therefore difficult, with costs ranging from $US9,100 (or $A19,312 (2007)) for PBSCT with
G-SCF for NHL (from Lee et al 1998) to $US74,000 (or $A157,049 (2007)) for PBSC for lymphoma
(Bennett et al 1995).

A6 Detailed cost analyses, by stage of transplant.
A6.1 Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone
marrow and peripheral blood stem cell transplantation in adults with AML or ALL
In a cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and
peripheral blood stem cell transplantation in adults with AML or ALL in four Dutch hospitals, van
Agthoven et al (2002) retrospectively allocated direct medical costs for patients treated between
1994 and 1999, in two ways:
• by multiplying the medical consumption units used by patients by the unit cost of each item;
and
• by identifying cost not tied to the patient’s medical registration from hospitals’ financial
departments and by expert opinion
The analysis included costs for patients prepared for, but who did not undergo, transplantation,
and covered all stages from pre-transplant tissue typing up to 24 months after transplantation.
Costs were separately identified for three transplant types (bone marrow transplant, matched
unrelated donor and peripheral blood stem cell transplant) according to the following categories:
• pre-transplant screening of patient using serological and molecular methods (average total
cost 2.342 euros (2002) (or $A4,620 (2007))
• stem cell harvesting in one session (for BMT patients), or two sessions (for PBSCT
patients);
• CD34 selection or T-cell depletion;
• donor lymphocyte infusion (if patients needed one or more additional infusions);
• total body irradiation and transplantation personnel.
Costs were further allocated either to the pre-transplant phase, transplantation phase, or to one of
the three follow-up phases (that is, 1-6 months, 6-12 months and 12-24 months after
transplantation).
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For unrelated donors, the costs included ‘donor costs’ involving family HLA-typing and typing of the
selected donor; the cost of requesting blood samples or donor grafts; sample typing (HLA-retyping
of blood samples collected in each of the Dutch hospitals); and Europdonor intermediation). The
calculation of average costs was based on unit costs of hospital days, day care treatments and
outpatient visits (van Agthoven 2002 Table 1, p. 245), as well as personnel costs based on FTE
requirements and employer costs per FTE (van Agthoven 2002 Table 3, p. 247). Table 40 shows
average costs per patient for the transplant phase.

Table 40: Average costs per patient for transplantation stage components
Cost component

BMT

MUD

PBSCT

Euro 2002

Euro 2002

Euro 2002

2342

2342

2342

Donor costs

10 843

47 063

11 137

Haematology ‘isolation’
hospital days

16 248

17 622

17 716

98

113

120

Pretransplantation
screening

Consultations
Cytostatics

94

102

124

2700

3394

2058

Hematopoietic growth
factors

337

34

103

Immunosuppressants

510

638

720

0

2723

0

451

473

497

1303

2405

2552

Antibiotics

ATG anti-thymocyte
globulin
Other medication
Blood components
Parenteral nutrition

602

645

341

TBI (P&M-9)

1441

1441

1441

Laboratory diagnostics

2038

2763

2610

Microbiology diagnostics

1047

1452

1271

Pathology diagnostics

993

752

1306

Radiology diagnostics

396

509

817

Other imaging diagnostics

290

182

300

Other procedures

396

295

279

Total costs, excluding
personnel costs

42 129

84 948

45 734

Total costs, excluding
personnel costs $A (2007)
Source: van Agthoven 2002, Table 4 p 248

83,820

16,9013

90,992

Table 41 shows average costs per living patient for the three follow-up phases, and Table 42
shows average costs per transplanted patient. The analysis directly links allogeneic infrastructure
requirements in the Netherlands to costs.
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Table 41: Average costs per (living) patient in follow-up phases
Cost component

Haematology
‘regular’ hospital
days
Intensive Care
hospital days
Haematology
outpatient visits
Other
consultations
Antibiotics
Hematopoietic
growth factors
Other medication
Day care
department
Radiotherapy
Blood components
Laboratory
diagnostics
Microbiology
diagnostics
Pathology
diagnostics
Radiology
diagnostics
Other imaging
diagnostics
Other procedures
Donor
lymphocytes
infusion
Total costs,
excluding
personnel costs
Total costs, excl
personnel costs
($A)*
Total costs, excl
personnel costs
($A) (2007)**

Follow-up phase 1
BMT
MUD
PBSCT
Euro
Euro
Euro
2002
2002
2002
6066
8801
4121

Follow-up phase 2
BMT
MUD
PBSCT
Euro
Euro
Euro
2002
2002
2002
3993
5866
3103

Follow-up phase 3
BMT
MUD
PBSCT
Euro
Euro
Euro
2002
2002
2002
3912
5620
2129

0

543

0

0

1143

0

0

0

0

1436

1216

1253

805

678

593

654

1696

365

402

707

657

286

523

482

326

572

402

11
0

1006
368

109
0

132
0

166
0

12
0

0
0

0
0

0
0

7
106

116
260

88
112

9
46

35
14

4
15

0
104

6
46

0
0

0
1317
2717

0
2740
4796

0
1127
2486

0
1006
1800

216
1735
3161

0
1027
2769

83
599
1358

0
1270
2256

0
210
1403

732

1180

706

359

757

766

255

202

493

1692

2413

2201

811

1765

1159

411

509

706

525

1119

441

394

879

1133

163

714

293

469

1060

567

340

904

1065

129

398

261

94
1012

568
3402

172
1012

177
0

632
0

135
0

99
0

42
0

52
0

16587

30292

15051

10157

18473

12265

8093

13331

6313

28843

52675

26172

17662

32123

21328

14073

23181

10977

33,001

60,269

29,945

20,208

36,754

24,402

16,101

26,523

12,560

Follow-up phase 1 = from first discharge after transplantation up to 6 months after transplantation date. Follow-up phase
2 = 6–12 months after transplantation date. Follow-up phase 3 = 12–24 months after transplantation date.
Source: van Agthoven 2002, Table 6 p 249
* Not escalated ** Escalated using Reserve Bank of Australia Inflation Calculator (RBA) www.rba.gov.au
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Table 42: Average costs per transplanted patient
Cost
component

Ave
costs per
living
patient
26543
42129
16587
10157
8093
103509
205,942

BMT
*%
=Ave costs
alive
per
transplant
patient
26543
100
42129
98
16255
81
8227
64
5180
98334
195,646

Personnel
Transplantation
FU1-phase
FU2-phase
FU3-phase
Total costs
Total costs
($A 2007)
Source: van Agthoven 2002, Table 7 p 249

A6.2

Ave
costs per
living
patient
26543
84948
30292
18473
13331
173587
345,369

MUD
*%
=Ave costs
alive
per
transplant
patient
26543
100
84948
90
27263
48
8867
31
4133
151754
301,930

Ave
costs per
living
patient
26543
45734
15051
12265
6313
105906
210,711

PBSCT
*%
=Ave costs
alive
per
transplant
patient
26543
100
45734
92
13847
77
9444
54
3409
98977
196,925

Study 2 – Evaluation of the use of cord blood as alternative stem cell source

The Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC) reported
on an evaluation of the use of umbilical cord blood as an alternative source of donor stem cells for
treatment of adults at that centre, for allogeneic transplantation from unrelated donors. Costs were
calculated separately for: (i) the transplantation procedure up to the time of hospital discharge, and
(ii) subsequent costs up to 10 years after transplantation. Costs were obtained from the Finance
Department at MUHC and based on resource use by 15 patients who underwent allogeneic stem
cell transplantation from related donors, and 2 patients who underwent cord blood transplantations
from unrelated donors in 2004.

Table 43: Hospitalisation cost of an allogeneic stem cell transplantation at MUHC
Cost estimate at the MUHC
(CDN 2005)
Allogeneic peripheral blood stem
cell transplantation (N=15)
38
$15,646

Mean length of stay (days)
Staff (Transplant coordinator,
nursing*)
Supplies
$1,191
Pharmacy
$18,324
Imaging and diagnostic tests
$989
Laboratory
$1,582
HLA matching
$753
Stem cells laboratory (virology and
$1,823
microbiology tests, staff and
supplies)
Haematologist fees
$1,835 (38 x $48.30§)
Infectologist consultation fees
$77 ($95.40 x 81%)¶
Total cost of an allogeneic stem cell
$42,220
transplantation at the MUHC
Total cost of an allogeneic stem
$48,516
cell transplantation at the MUHC
($A 2007)
Note: Excludes overhead, bone marrow harvesting and donor costs.

Cost estimate at the MUHC
(CDN 2005)
Allogeneic cord blood stem cell
transplantation (N=2)
45
$18,528
$1,410
$18,324
$989
$1,582
$753
$1,823

$2,070 (40 x $48.30 + 5 x $27.5)
$77 ($95.40 x 81%)¶
$45,556
$52,349

The MUHC results were compared with the estimated direct hospitalisation costs obtained from
five European economic analyses of stem cell transplantation (four of stem cell transplantation and
one of allogeneic stem cell transplantation) of from $34,475 to $66,500 (CDN 2005) (or $A39,616
to $A52,349 (2007)).
MUHC also estimated the costs of complications that might occur during a 10 year follow-up period
(see Table 44), while noting that only ‘extremely meagre’ data on which to base estimates existed.
Based on possible relapses, infections and chronic GVHD, MUHC estimated that the total cost of
an allogeneic stem cell transplantation including a 10-year follow-up (excluding the cost of
procurement of stem cells) in an adult patient at the MUHC would be approximately CDN$57,000
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and CDN$60,500 (or $A65,500 and $A69,522 (2007)) for bone marrow and cord blood
respectively.

Table 44: Costs during the follow-up period
Treatment

Unit cost (CDN 2005)

Relapses

$4,169 Chemotherapy
$2,165 – palliative care
$95,500 – cord blood transplantation
Infection
$4,097
Chronic GVHD
$3,228 (outpatient visit, nursing costs and physician fee – 3x per week,
pathology, medication costs (cyclosporine, prednisolone)
Follow-up visits
$60 (physician fee $20; nursing cost $11 for 15 mins; lab tests $29
Note:
Costs discounted 3%

Unit cost
$A (2007)
$4,790
$2,487
$10,9742
$4,988
$3,709
$68

A7 Casemix and transplantation
Two studies found that Diagnosis Related Group (DRG) based reimbursement underestimated the
average total costs of BMT services. A study in Norway (based on a small sample of only 17
patients) collected costs prospectively for blood and bone marrow transplantation for patients
diagnosed with leukaemia (both chronic myeloid and acute lymphatic leukaemia ) and
myelodysplastic syndrome. Costs for pre-transplant services, the transplant itself and 1 year
post-transplant follow-up services were collected and compared with hospital reimbursement. The
results indicated that DRG reimbursement costs for blood and bone marrow transplantation greatly
underestimated the actual costs, with treatment being heavily subsidised by basic hospital grants
(Mishra et al 2001).
A French 2004 study found a similar discrepancy between the DRG prospective payment system
in that country and actual costs (Esperou et al 2004).
An Australian analysis found that some Australian DRG cost weights were too low, with
consequent adverse impacts on the funding of State-wide referral services (Antioch and
Walsh 2004). The study was targeted towards high-complexity DRGs relating to State-wide
referral services, specifically, for respiratory, cardiology and stroke conditions. Given that the
analysis was completed almost 5 years ago, and that the three Australian BMT DRGs encompass
a wide range of increasingly complex and costly BMT service types, it is reasonable to apply the
conclusion from that study to the current situation regarding BMT services.

A8 Previous cost estimates
State government officials from the relevant departments in Victoria, Queensland, South Australia
and Western Australia were contacted regarding the existence of any documented costing studies
in those states. Only two studies were discovered – a very small scale study undertaken in
Queensland in 2004, and a study undertaken by the Royal Melbourne Hospital. Permission to
include details of the latter study has not yet been granted and remains the subject of negotiation
with Royal Melbourne Hospital.
A8.1

Queensland – 2004

A study of approximate costs of bone marrow transplants, by transplant type, undertaken at the
Royal Brisbane and Women’s Hospital dated 2004 yielded overall costs per patient type only. It
should be noted that the study used a very small sample of only two patients in each costing type.
Costs included:
• direct inpatient ward costs
• indirect patient costs
• pharma/drug costs
• pathology costs
• medical imaging costs
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•
•
•
•
•
•

bone marrow transplant lab costs
bone marrow transplant donor costs
bone marrow transplant courier costs
total body irradiation
allied health professional costs
day therapy unit/clinic costs.

Costs were estimated using either direct patient costs or estimated costs calculated on the basis of
the number of separations/bed days per patient.

Table 45: Total costs by transplant type (2004)
Transplant Type
Unit Range ($A)
Unit Range ($A2007)
Allogeneic BMT – MUD (voluntary unrelated donor)
115,411-276,575
125,545- 300,861
Allogeneic BMT – sibling
85,106-180,392
92,579- 196,232
Non myelo-ablative (mini) Allogeneic BMT – MUD
14,552***-135,748
15,830- 147,668
(voluntary unrelated donor)/sibling
Autologous BMT – Lymphoma
45,848**-47,207
49,874- 51,352
Autologous BMT – Myeloma
48,751-53,503
53,032- 58,201
Note:
All patients survived after transplant with one exception - **deceased at 12 days post-transplant
***Excludes transition inpatient costs.

Based on these costs, senior bone marrow staff were consulted to determine mean approximate
minimum costs for autologous and allogeneic transplants. Figures of $50,000 and $120,000 (or
approx $54,500 and $130,5007) respectively were agreed.
A8.2

Newcastle Mater Misericordiae Hospital (NMMH)- 2004

In analysis undertaken for a (2004) Master of Medical Science thesis, Prajogo investigated the
costs of high-dose chemotherapy and autologous bone marrow transplantation vs. standard
chemotherapy in patients with relapsed non-Hodgkin’s lymphoma.
Data was obtained for a small sample of eligible local patients with intermediate-high grade NHL
treated at NMMH from January 1995 to June 2002. Out of a total of 69 patients with NHL, 23
patients were included in the study which examined direct medical costs drawn from medical
records for the period from induction chemotherapy to conditioning and transplant only. The costs
of each chemotherapy cycle were assumed to be constant. High-dose chemotherapy
encompassed three doses of ESHAC (etoposide, solumedreol, Ara-C and carbolatin) followed by
LACE (lomustine, Ara-C, cyclophosphamide and etoposide) and transplantation. Costs comprised
pharmaceuticals (chemotherapy drugs, G-CSF, antibiotics, antivirals, antiemetics, other),
laboratory, radiology, blood component therapy, special medical consultations, allied health
services (dietician, physio, social worker, pastoral care), inpatient admissions and outpatient
attendances.
Unit prices were used to calculate costs for hospital bed-days (NSW Health 2000 charges),
medical procedures, pathology, radiology, blood bank services (Medicare Benefits Schedule
2001), transplant procedure charge (Medicare item 13700) and drugs (Pharmaceutical Benefits
Schedule August 2001 or MIMS 2001).
A8.3

Induction Phase Costs

Each patient received three cycles of ESHAC delivered in the outpatient setting, as reflected in the
higher outpatient attendance costs relative to inpatient admissions.

7 Escalated using Reserve Bank of Australia Inflation Calculator (RBA) www.rba.gov.au
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Table 46: Pharmaceuticals - induction phase
Item

Mean cost per cycle
($A 2001)
1233
1227
53
81
18
2,612

Mean cost per cycle ($A 2007)*

Chemotherapy
G-CSF
Antibiotics, Antivirals
Antiemetics
other drugs
Total
(from Prajogo 2004, Table 4.24 p. 63)
* Escalated using Reserve Bank of Australia Inflation Calculator (RBA) www.rba.gov.au

1453
1446
62
95
21
3,078

Table 47: Non-pharmaceuticals - induction phase
Item
Mean cost per cycle ($A 2001)
Mean cost per cycle ($A 2007)*
Laboratory
287
338
Radiology
188
221
Blood component therapy
39
45
Medical consultation
103
121
Inpatient admissions
686
808
Outpatient attendances
1645
1938
Total
2,948
3,516
(from Prajogo 2004, Table 4.25 p. 64)
* Escalated using Reserve Bank of Australia Inflation Calculator (RBA) www.rba.gov.au

Table 46 shows that G-CSF alone comprised almost 50% of total pharmaceutical cost per cycle.
When pharmaceutical and non-pharmaceutical costs were combined, the total mean cost per
patient per cycle for the induction phase was $5560.
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A8.4

Conditioning and BMT phase

Table 48: Pharmaceuticals - conditioning and BMT phase
Mean cost per patient
$ ($A 2001)
2402
1867
2049
658
312
7,288

% of total

Chemo (conditioning)
33
G-CSF
25
Antibiotics, Antivirals, antifungals
28
Antiemetics
9
other drugs
5
Total
100
(from Prajogo 2004, Table 4.27 p. 66)
* Escalated using Reserve Bank of Australia Inflation Calculator (RBA) www.rba.gov.au

Mean cost per patient*
($A 2007)
2830
2200
2414
775
367
8,518

Table 49: Non-pharmaceuticals per cycle - conditioning and BMT phase
Mean cost per patient
$ ($A 2001)
2391
1377
1045
1078
7000
1409
14,300

% of total

Laboratory
17
Radiology
10
Blood component therapy
6
Medical consultation
8
Inpatient admissions
49
Outpatient attendances
10
Total
100
(from Prajogo 2004, Table 4.28 p. 67)
Note: Assumes cost of allied health services is included in inpatient admissions costs
* Escalated using Reserve Bank of Australia Inflation Calculator (RBA) www.rba.gov.au

Mean cost per patient*
($A 2007)
2817
1622
1231
1270
8249
1660
16,852

Examination of Table 48 and Table 49 together show that the cost of inpatient admissions
comprised almost 50% of the total non-pharmaceuticals cost for the conditioning and BMT phase,
that is, about the same proportion of total cost as pharmaceuticals for this phase. Addition of costs
for pharmaceuticals and non-pharmaceuticals shows that the mean total cost per patient for the
conditioning and BMT phase was $21589 (or $25,370 (2007)).
Table 50 shows mean costs per patient for induction, conditioning and BMT combined. The total
pharmaceuticals and non-pharmaceuticals cost per patient are shown, as well as the component
costs within each of the two main groups.

Table 50: Total mean costs per patient - induction, conditioning and BMT
Pharmaceuticals
Non-pharmaceuticals
Total
Pharmaceuticals (total)
Chemotherapy (conditioning)
G-CSF
Antibiotics, Antivirals, antifungals
Antiemetics
Other drugs
Total

Mean cost ($A 2001)
14757
22733
37,490

%
39
61
100

Mean cost ($A 2007)*
17391
26791
44,182

5928
5376
2200
890
363
14,757

40
36
15
6
3
100

6986
6335
2592
1048
427
17,391

Non-pharmaceuticals
Laboratory
3212
14
Radiology
1915
8
Blood component therapy
1157
5
Medical consultation
1373
6
Inpatient admissions
8962
40
Outpatient attendances
6114
27
Total
22,733
100
(from Prajogo 2004, Tables 4.30, 4.31 and 4.32 pp. 69-71)
* Escalated using Reserve Bank of Australia Inflation Calculator (RBA) www.rba.gov.au
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A8.5 Cost drivers
This study found that non-pharmaceuticals comprised the largest overall cost (61%) of the
induction, conditioning and BMT stages of treatment for NMMH patients with relapsed NHL using
high-dose chemotherapy and autologous bone marrow transplantation between 1995 and 2002.
This was due mainly to the cost of inpatient stay (40% of total non-pharmaceuticals cost). In terms
of component costs of pharmaceuticals, the largest cost drivers were chemotherapy and G-CSF.
The estimated total mean cost per patient of $37,490 (2001) can be compared with costs reported
in two Dutch studies of autologous transplantation (i) in patients with lymphoma and acute
leukaemia, and (ii) in patients with NHL. Total costs were equivalent to $A70,7698 and $A59,5009
respectively (from Uyl-De Groot 1995a and 1995b, in Prajogo). The differences between these
costs and those reported by Prajogo can be attributed, in part, to use of total body irradiation
before transplantation in the Dutch studies, as well as lower utilisation rates (for example, medical
consultations) in Australia, and differences in the costs of hospitalisation and blood products
between the two countries. Also germane were: (i) the much lower proportion of total costs of
pharmaceuticals in the second Dutch study (13% compared with 39% in Prajogo), consistent with
the introduction of G-CSF and the greater role of the outpatient setting in the latter study; and (ii)
the use of PBSCT rather than ABMT, leading to shorter hospital stays and reduced blood product
support in the latter (Prajogo 2004).
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Appendix 3 Cost by cost bucket allogeneic transplants
St Vincent's
Cost Bucket
Allied Health costs
Emergency Dept cost
ICU costs
Imaging costs
Medical cost
Oncosts
Other costs
Pathology costs
Pharmacy cost
Ward costs
Total cost

Royal North Shore

Westmead

Sydney Children's Hospital

Children’s Hospital
Westmead

Mean

% of Total

Mean

% of Total

Mean

% of Total

Mean

% of Total

Mean

% of Total

$653
$23
$1,040
$759
$8,940
$4,700
$1,902
$4,704

0.76%
0.03%
1.21%
0.88%
10.41%
5.47%
2.21%
5.48%

$4,625
$65
$0
$969
$1,977
$1,703
$3,829

7.07%
0.10%
0.00%
1.48%
0.00%
3.02%
2.60%
5.86%

$3,018
$0
$9,860
$484
$5,427
$4,011
$3,238
$6,806

3.26%
0.00%
10.67%
0.52%
5.87%
4.34%
3.50%
7.36%

$2,768
$22
$12,328
$1,649
$18,790
$5,256
$7,180
$7,539

1.92%
0.02%
8.55%
1.14%
13.03%
3.65%
4.98%
5.23%

$4,220
$33
$30,253
$2,041
$7,836
$6,644
$7,898
$11,386

2%
0%
17%
1%
4%
4%
4%
6%

$30,561
$32,571
$85,853

35.60%
37.94%
100.00%

$27,013
$25,189
$65,368

41.32%
38.53%
100.00%

$27,183
$32,412
$92,440

29.41%
35.06%
100.00%

$33,388
$55,264
$144,184

23.16%
38.33%
100.00%

$46,850
$59,795
$176,955

26%
34%
100.00%
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Appendix 4 Cost by cost bucket autologous transplants
St Vincent's
Cost Bucket

Mean

Allied Health costs
Emergency Dept cost
ICU costs
Imaging costs
Medical cost
Oncosts
Other costs
Pathology costs
Pharmacy cost
Ward costs
Total cost

$411
$4,044
$504
$3,800
$2,721
$1,292
$2,776
$13,930
$18,340
$47,818

% of
Total
0.86%
0.00%
8.46%
1.05%
7.95%
5.69%
2.70%
5.80%
29.13%
38.35%
100.00%

Sydney Children's
Hospital
Cost Bucket
Allied Health costs
Emergency Dept cost
ICU costs
Imaging costs
Medical cost
Oncosts
Other costs
Pathology costs
Pharmacy cost
Ward costs
Total cost
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Mean
$714
$0
$4,197
$503
$5,331
$1,630
$2,802
$1,822
$7,925
$11,918
$36,841

% of
Total
2%
0%
11%
1%
14%
4%
8%
5%
22%
32%
100%

Royal North Shore
Mean
$2,797
$162
$1,158
$1,097
$1,930
$1,565
$2,904
$16,944
$20,335
$48,892

% of
Total
5.72%
0.33%
2.37%
2.24%
0.00%
3.95%
3.20%
5.94%
34.66%
41.59%
100.00%

Westmead
Mean
$715
$1,012
$237
$3,600
$1,963
$1,891
$3,392
$6,330
$17,548
$36,688

% of
Total
1.95%
0.00%
2.76%
0.65%
9.81%
5.35%
5.15%
9.24%
17.25%
47.83%
100.00%

Prince of Wales
Mean
$264
$1,497
$441
$1,397
$3,264
$2,029
$29,937
$14,182
$53,011

% of
Total
0.50%
0.00%
2.82%
0.83%
2.64%
0.00%
6.16%
3.83%
56.47%
26.75%
100.00%

St George
Mean
$825
$616
$561
$2,106
$1,300
$878
$2,239
$7,267
$17,341
$33,133

% of
Total
2.49%
0.00%
1.86%
1.69%
6.36%
3.92%
2.65%
6.76%
21.93%
52.34%
100.00%

Nepean
Mean
$904
$1,166
$1,354
$2,899
$1,538
$735
$729
$7,199
$17,892
$34,415

% of
Total
2.63%
0.00%
3.39%
3.93%
8.42%
4.47%
2.14%
2.12%
20.92%
51.99%
100.00%

Children’s Hospital
Westmead
Mean
$1,192
$576
$1,937
$738
$1,859
$1,047
$1,745
$2,367
$8,204
$18,451
$38,117

% of
Total
3%
2%
5%
2%
5%
3%
5%
6%
22%
48%
100%
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Appendix 5 The NSW cost data collection
Table 51 below shows the results of the 2006/07 NSW Department of Health annual hospital cost
data collection for the three BMT AR-DRGs.

Table 51: Average total BMT cost (NSW Health Cost Data Collection)
Hospital
A07Z
A08A
A08B
St Vincent's Hospital
$81,365
$63,883
$30,234
Westmead Hospital
$127,402
$38,508
$23,453
Royal North Shore Hospital
$67,180
$55,525
$28,518
Royal Prince Alfred Hospital
$100,196
$64,720
$36,798
Concord Hospital
$0
$43,891
$19,050
Gosford Hospital
$0
$54,786
$23,544
Liverpool Hospital
$0
$39,006
$19,810
John Hunter Hospital
$0
$104,129
$24,014
Nepean Hospital
$0
$130,240
$35,373
Newcastle Mater Hospital
$0
$37,697
$8,485
Prince of Wales Hospital
$0
$66,355
$33,546
St George Hospital
$0
$38,743
$23,063
Wollongong Hospital
$0
$44,102
$18,380
Sydney Children's Hospital
$163,867
$64,372
$8,789
Children's Hospital Westmead
$191,334
$56,522
$17,915
AR-DRG AO7Z = Allogeneic Bone Marrow Transplant
AR-DRG AO8A = Autologous Bone Marrow Transplant with catastrophic complications or comorbidities
AR-DRG AO8B = Autologous Bone Marrow Transplant without catastrophic complications or comorbidities
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Appendix 6 The National Hospital Cost Data Collection
Table 52 below presents summary results for Round 11 (2006/07) of the National Hospital Cost
Data Collection for the three BMT AR-DRGs.

Table 52 Average total BMT cost (National Hospital Cost Data Collection)
ARDRG

A07Z
A08A
A08B
A07Z
A08A
A08B
A07Z
A08A
A08B
A07Z
A08A
A08B
A07Z
A08A
A08B
A07Z
A08A
A08B
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AR-DRG Description

Average Cost
per DRG ($)

National
Allogeneic Bone Marrow Transplant
Autologous Bone Marrow Transplnt+Ccc
Autologous Bone Marrow Transplnt-Ccc
New South Wales - Estimated
Allogeneic Bone Marrow Transplant
Autologous Bone Marrow Transplnt+Ccc
Autologous Bone Marrow Transplnt-Ccc
Victoria - Estimated
Allogeneic Bone Marrow Transplant
Autologous Bone Marrow Transplnt+Ccc
Autologous Bone Marrow Transplnt-Ccc
Queensland - Estimated
Allogeneic Bone Marrow Transplant
Autologous Bone Marrow Transplnt+Ccc
Autologous Bone Marrow Transplnt-Ccc
South Australia - Estimated
Allogeneic Bone Marrow Transplant
Autologous Bone Marrow Transplnt+Ccc
Autologous Bone Marrow Transplnt-Ccc
Western Australia - Estimated
Allogeneic Bone Marrow Transplant
Autologous Bone Marrow Transplnt+Ccc
Autologous Bone Marrow Transplnt-Ccc

Number of
separations

Number of
hospitals

$95,303
$44,301
$15,127

343
478
394

19
36
35

$115,121
$56,555
$22,157

118
137
121

9
15
15

$86,313
$38,086
$11,477

91
164
96

5
8
8

$62,676
$42,757
$19,014

78
90
50

2
5
5

$83,092
$30,793
$13,391

18
35
43

2
3
2

$128,873
$41,916
$4,453

37
31
55

3
4
4
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Appendix 7 Related Inpatient Episodes – Cost by AR-DRG
DRG

DRG title

Q60A

Reticuloendothelial and Immunity Disorders W
Catastrophic or Severe CC
Acute Leukaemia W Catastrophic CC
Acute Leukaemia W/O Catastrophic or Severe
CC
Lymphoma and Non-Acute Leukaemia W/O
Catastrophic CC
Tracheostomy or Ventilation >95 hours
Septicaemia W Catastrophic or Severe CC
Lymphoma and Non-Acute Leukaemia W
Catastrophic CC
Acute Leukaemia W Severe CC
Fever of Unknown Origin W CC
Lymphoma and Leukaemia with other OR
procedures W catastrophic or severe CC
Nervous System Neoplasm W/O Catastrophic
or Severe CC
Established Paraplegia/Quadriplegia W or W/O
O.R. Procs W/O Catastrophic CC
Craniotomy W Catastrophic CC
Nervous System Neoplasm W Catastrophic or
Severe CC
Other Circulatory System Diagnoses W Severe
CC
Respiratory Infections/Inflammations W Severe
or Moderate CC
Reticuloendothelial and Immunity Disorders
W/O Cat or Severe CC W Malignancy
Lymphoma and Non-Acute Leukaemia, Same
Day
Major Small and Large Bowel Procedures W
Catastrophic CC
Operative insertion of peritoneal catheter for
dialysis W cat or Severe CC
Red Blood Cell Disorders W/O Catastrophic or
Severe CC
Digestive Malignancy W Catastrophic or Severe
CC
Sequelae of Treatment W Catastrophic or
Severe CC
Fever of Unknown Origin W/O CC
Connective Tissue Malignancy, including
Pathological Fx W/O Cat or Sev CC
Other Procedures for Kidney and Urinary Tract
Disorders W Cat CC
Radiotherapy
O.R. Procedures for Infectious and Parasitic
Diseases W Catastrophic CC
Reticuloendothelial and Immunity Disorders
W/O Cat or Sev CC W/O Malignancy
Hypertension W CC
Lymphoma and Leukaemia W Major O.R.
Procedures W Catastrophic or Severe CC
Septicaemia W/O Catastrophic or Severe CC
Other Circulatory System Diagnoses W
Catastrophic CC
Complex Gastroscopy W Catastrophic or

R60A
R60C
R61B
A06Z
T60A
R61A
R60B
T62A
R03A
B66B
B60B
B02A
B66A
F75B
E62B
Q60B
R61C
G02A
L02A
Q61C
G60A
X63A
T62B
I65B
L09A
R64Z
T01A
Q60C
F67A
R01A
T60B
F75A
G46A

Number of
Episodes

Total Cost

Per Diem
Cost

45.3

$912,264

$1,415

Average
Length of
Stay
14.22

14.8
181.8

$741,796
$665,420

$2,111
$1,644

23.7
2.2

86.3

$594,017

$1,513

4.5

4.2
23.5
11.3

$362,841
$326,041
$310,478

$2,452
$1,672
$1,568

35.5
8.3
17.5

19.8
29.0
4.2

$266,755
$244,690
$181,917

$1,524
$1,537
$1,487

8.8
5.5
29.4

31.0

$140,497

$1,489

3.0

1.0

$136,776

$1,169

117.0

1.0
11.0

$124,249
$119,202

$2,845
$1,568

43.7
6.9

9.3

$97,569

$1,517

6.9

6.5

$79,850

$1,369

9.0

9.0

$76,778

$1,525

5.6

128.7

$71,729

$557

1.0

1.0

$70,473

$1,499

47.0

1.0

$69,575

$1,449

48.0

17.3

$69,574

$1,273

3.2

8.7

$69,083

$1,524

5.2

2.5

$62,301

$1,016

24.5

8.3
13.3

$58,855
$58,710

$1,682
$2,072

4.2
2.1

0.3

$54,474

$1,993

82.0

19.3
1.7

$53,515
$53,493

$2,768
$1,888

1.0
17.0

10.8

$51,956

$1,332

3.6

1.7
1.7

$51,276
$51,000

$1,690
$477

18.2
64.2

4.8
2.0

$48,977
$48,124

$1,477
$1,641

6.9
14.7

2.7

$46,786

$1,477

11.9
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DRG

G12A
Q61B
T63A
Q61A
A41A
F04A
F75C
I04Z
D67A
S65B
L63A
K64B
E01A
E01B
R63Z
S65A
E62A
L60B
I65A
G60B
Z64B
T64A
G67A
R01B
K64A
B07A
D63A
S60Z
K62B
E71B
G67B
G12B
E75B
R03B
L63C
B02C
Q02A
Page 84

DRG title

Severe CC
Other Digestive System O.R. Procedures W
Catastrophic or Severe CC
Red Blood Cell Disorders W Severe CC
Viral Illness Age >59 or W CC
Red Blood Cell Disorders W Catastrophic CC
Intubation Age<16 W CC
Cardiac Valve Proc W CPB Pump W/O Invasive
Cardiac Inves W Cat CC
Other Circulatory System Diagnoses W/O
Catastrophic or Severe CC
Knee Replacement and Reattachment
Oral and Dental Disorders Except Extractions
and Restorations
HIV-Related Diseases W Severe CC
Kidney and Urinary Tract Infections W
Catastrophic CC
Endocrine Disorders W/O Catastrophic or
Severe CC
Major Chest Procedures W Catastrophic CC
Major Chest Procedures W/O Catastrophic CC
Chemotherapy
HIV-Related Diseases W Catastrophic CC
Respiratory Infectn/Inflamm+Cc
Renal Failure W Severe CC
Connective Tissue Malignancy, including
Pathological Fx W Cat or Sev CC
Digestive Malignancy W/O Catastrophic or
Severe CC
Other Factors Influencing Health Status, Same
Day Geriatric
Other Infectious and Parasitic Diseases W
Catastrophic or Severe CC
Oesophagitis, Gastroent & Misc Digestive
System Disorders Age >9 W Cat/Sev CC
Lymphoma and Leukaemia W Major O.R.
Procedures W/O Catastrophic or Severe CC
Endocrine Disorders W Catastrophic or Severe
CC
Peripheral and Cranial Nerve & Other Nervous
System Procedures W CC
Otitis Media and URI W CC
HIV, Same Day
Miscellaneous Metabolic Disorders Age >74 or
W Severe CC
Respiratory Neoplasms W Severe or Moderate
CC
Oesophagitis, Gastroent & Misc Digestive
System Disorders Age >9 W/O Cat/Sev CC
Other Digestive System O.R. Procedures W/O
Catastrophic or Severe CC
Other Respiratory System Diagnosis Age >64 or
W CC
Lymphoma and Leukaemia W Other O.R.
Procedures W/O Catastrophic or Severe CC
Kidney and Urinary Tract Infections Age <70
W/O Catastrophic or Severe CC
Craniotomy W/O CC
Other O.R. Procedure of Blood & Blood Forming

Number of
Episodes

Total Cost

Per Diem
Cost

Average
Length of
Stay

2.0

$46,601

$1,571

14.8

6.0
4.2
2.0
1.3
1.0

$45,538
$45,360
$44,851
$35,983
$35,500

$1,469
$1,495
$1,583
$2,570
$2,958

5.2
7.3
14.2
10.5
12.0

7.0

$35,421

$1,586

3.2

0.3
3.0

$35,141
$33,743

$1,506
$1,066

70.0
10.6

2.0
1.7

$32,920
$32,358

$1,606
$1,184

10.3
16.4

8.3

$31,926

$1,520

2.5

1.0
2.3
31.0
1.5
0.8
1.3
3.0

$31,843
$31,552
$29,750
$29,531
$29,253
$29,000
$27,439

$2,123
$2,868
$960
$3,109
$1,463
$1,338
$1,914

15.0
4.7
1.0
6.3
24.0
16.3
4.8

9.0

$26,842

$1,610

1.85

26.3

$25,926

$985

1.0

2.3

$24,141

$1,766

5.9

4.2

$21,080

$1,318

3.8

2.0

$20,585

$1,287

8.0

3.3

$20,428

$2,043

3.0

1.0

$19,647

$756

26.0

3.7
26.5
3.7

$18,555
$18,546
$16,394

$1,295
$700
$1,329

3.9
1.0
3.4

4.3

$16,391

$1,891

2.0

3.8

$15,572

$857

4.7

1.0

$15,335

$2,556

6.0

3.5

$15,198

$1,216

3.6

2.0

$15,116

$2,387

3.2

1.3

$14,615

$4,872

2.3

0.3
0.8

$14,331
$14,253

$1,869
$586

23.0
29.2
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DRG

A41B
F63A
J68A
X63B
I66A
I28A
Z62Z
F21A
D40Z
K62C
G68A
K61Z
L60C
E02A
L03B
B81A
G69Z
D64Z
K63Z
I12A
F71B
G66A
K03Z
I68A
M62A
Q62Z
Q01Z
T61A
D06Z
I71B
T01B
F71A
L63B
L67B
L62B
L65A
G44A

DRG title

Organs W Cat or Sev CC
Intubation Age<16 W/O CC
Venous Thrombosis W Catastrophic or Severe
CC
Major Skin Disorders
Sequelae of Treatment W/O Catastrophic or
Severe CC
Inflammatory Musculoskeletal Disorders W Cat
or Severe CC
Other connective tissue Procedures W CC
Follow Up W/O Endoscopy
Other Circulatory System O.R. procedure w
Catastrophic CC
Dental Extractions and Restorations
Miscellaneous Metabolic Disorders Age <75
W/O Catastrophic or Severe CC
Gastroenteritis Age <10 W CC
Severe Nutritional Disturbance
Renal Failure W/O Catastrophic or Severe CC
Other Respiratory System O.R. Procedures W
Catastrophic CC
Kidney, Ureter and Major Bladder Procedures
for Neoplasm W/O Cat or Sev CC
Other Disorders of the Nervous System W
Catastrophic or Severe CC
Oesophagitis and Misc Digestive System
Disorders Age<10
Laryngotracheitis and Epiglottitis
Inborn Errors of Metabolism
Infect/Inflam of Bone & Joint W Misc Musc Sys
& Conn Tiss Procs W Cat CC
Non-Major Arrhythmia and Conduction
Disorders W/O Catastrophic or Severe CC
Abdominal Pain or Mesenteric Adenitis W CC
Adrenal Procedures
Non-surgical Spinal Disorders W CC
Inflammation of Male Reproductive System W
CC
Coagulation Disorders
Splenectomy
Postoperative and Post-Traumatic Infections
Age > 54 or W (Cat or Sev CC)
Sinus, Mastoid and Complex Middle Ear
Procedures
Other Musculotendinous Disorders Age >69 or
W CC
O.R. Procedures for Infectious and Parasitic
Diseases W Severe or Moderate CC
Non-Major Arrhythmia and Conduction
Disorders W Catastrophic or Severe CC
Kidney and Urinary Tract Infections Age >69 or
W Severe CC
Other Kidney and Urinary Tract Diagnoses W
Severe CC
Kidney and Urinary Tract Neoplasms W/O
Catastrophic or Severe CC
Kidney and Urinary Tract Signs and Symptoms
W Catastrophic or Severe CC
Other ColonoscopyWCatastrophic or Severe cc

Number of
Episodes

Total Cost

Per Diem
Cost

Average
Length of
Stay

0.3
1.3

$13,224
$12,673

$2,204
$939

18.0
10.1

2.0
1.3

$12,516
$12,383

$1,211
$728

5.2
12.8

1.0

$12,231

$1,595

7.7

0.5
18.0
0.3

$11,771
$11,249
$11,117

$1,070
$625
$1,588

22.0
1.0
21.0

3.0
2.0

$11,113
$10,679

$3,704
$2,464

1.0
2.2

3.0
0.5
2.3
0.3

$9,909
$9,854
$9,839
$9,644

$1,651
$1,159
$1,181
$1,447

2.0
17.0
3.6
20.0

0.7

$9,093

$2,728

5.0

1.3

$8,894

$1,721

3.9

1.0

$8,891

$1,667

5.3

0.3
1.7
0.5

$8,840
$8,511
$8,497

$1,894
$1,824
$2,832

14.0
2.8
6.0

1.8

$8,031

$1,662

2.6

1.3
0.7
0.8
0.5

$7,957
$7,934
$7,902
$7,579

$1,591
$2,645
$1,693
$842

3.8
4.5
5.6
18.0

6.2
0.3
0.5

$7,498
$7,457
$7,102

$1,046
$1,721
$1,015

1.2
13.0
14.0

1.0

$7,017

$7,017

1.0

1.3

$6,775

$1,452

3.5

0.3

$6,742

$1,190

17.0

0.8

$6,697

$913

8.8

1.0

$6,531

$1,399

4.7

1.7

$6,280

$1,570

2.4

2.3

$6,053

$1,513

1.7

0.8

$5,992

$1,160

6.2

0.5

$5,969

$853

14.0
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DRG

DRG title

G45A

Other Gastroscopy for Non-Major Digestive
Disease
Disorders Of Biliary Tract +Cc
Diabetes W Catastrophic or Severe CC
Abdominal Pain or Mesenteric Adenitis W/O CC
Kidney, Ureter and Major Bladder Procedures
for Neoplasm W Catastrophic CC
Other Disorders of the eye W CC
Postoperative & Post-traumatic Infections Age
<55 W/O Cat or Sev CC
Inflammatory Musculoskeletal Disorders W/O
Cat or Sev CC
Other Hip & Femur Pr -Cscc
Other Factors Influencing Health Status
Respiratory Neoplasms W/O CC
Gastroenteritis Age <10 W/O CC
Kidney and Urinary Tract Neoplasms W
Catastrophic or Severe CC
Poisoning/Toxic Effects of Drugs & Other
Substances Age >59 or W CC
Complex Gastroscopy W/O Catastrophic or
Severe CC
Infect/Inflam of Bone & Joint W Misc Musc Sys
& Conn Tiss Procs W Sev CC
Syncope and Collapse W Catastrophic or
Severe CC
Seizure W Catastrophic or Severe CC
Major Skin Disorders, Same Day
Minor Skin Disorders
HIV-Related Diseases W/O Catastrophic or
Severe CC
Testes Procedures W CC
Other Musculoskeletal Disorders Age >69 or W
CC
Stroke, Died or Transferred < 5 days
Other Respiratory System OR Procedures W/O
CC
Bone and Joint Diagnostic Procedures including
Biopsy
Dysequilibrium
Respiratory Neoplasms W Catastrophic CC
Degenerative Nervous System Disorders W Cat
or Sev CC
Rehabilitation + Cscc
Admit for Apheresis
Myringotomy W Tube Insertion
Respiratory Signs and Symptoms W/O
Catastrophic or Severe CC
Conisation, Vagina, Cervix and Vulva
Procedures
Malignancy, Male Reproductive System W
Catastrophic or Severe CC
Anxiety Disorders
Circulatory Disorders W/O AMI W Invasive
Cardiac Inves Proc W Complex DX/Pr
Distal Femoral Fractures
Ungroupable
Respiratory Signs and Symptoms W

H64A
K60A
G66B
L03A
C63A
T61B
I66B
I08B
Z64A
E71C
G68B
L62A
X62A
G46B
I12B
F73A
B76A
J68B
J67A
S65C
M04A
I76B
B70D
E02C
I25Z
D61Z
E71A
B67A
Z60A
B62Z
D13Z
E67B
N09Z
M60A
U65Z
F42A
I61Z
960Z
E67A
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Number of
Episodes

Total Cost

Per Diem
Cost

0.5

$5,137

$856

Average
Length of
Stay
12.0

0.3
0.3
0.7
0.3

$5,124
$4,983
$4,943
$4,729

$1,025
$2,492
$2,471
$2,837

15.0
6.0
3.0
5.0

0.7
0.7

$4,609
$4,278

$1,728
$1,426

4.0
4.5

2.5

$4,130

$1,652

1.0

0.3
1.3
1.0
0.7
1.0

$3,892
$3,777
$3,654
$3,466
$3,455

$1,061
$2,266
$2,741
$1,486
$1,727

11.0
1.3
1.3
3.5
2.0

0.3

$3,121

$1,873

5.0

0.5

$3,063

$875

7.0

0.3

$3,015

$393

23.0

1.5

$2,935

$839

2.3

0.7
0.3
0.3
0.5

$2,918
$2,886
$2,814
$2,761

$2,189
$8,657
$1,055
$5,522

2.0
1.0
8.0
1.0

0.7
1.5

$2,757
$2,716

$4,136
$1,811

1.0
1.0

0.3
0.3

$2,620
$2,496

$1,965
$2,496

4.0
1.0

0.3

$2,449

$1,837

4.0

0.3
0.7
0.3

$2,374
$2,028
$1,940

$1,780
$1,521
$1,940

4.0
2.0
3.0

0.3
1.8
0.3
1.0

$1,757
$1,666
$1,616
$1,533

$479
$909
$2,425
$1,533

11.0
1.0
2.0
1.0

1.0

$1,409

$1,409

1.0

0.3

$1,250

$1,874

2.0

0.7
0.5

$1,241
$1,199

$1,861
$2,398

1.0
1.0

0.3
0.3
0.3

$1,173
$1,101
$930

$1,760
$3,304
$1,396

2.0
1.0
2.0

Final Report: A Costing Study of Blood & Marrow Transplantation Services in NSW

Centre for Health Service Development

DRG

G03B
L65B
E69B
G44C
G70A
L41Z
T64B
P67D
Z01A
E74C
E65B
I68C
I64A
R62B
G45B
F74Z
D66A
C60B
D63B
L61Z
D62Z
J67B
M60B
All

DRG title

Catastrophic or Severe CC
Stomach, Oesophageal and Duodenal
Procedures W/O Malignancy W Cat or Sev CC
Kidney and Urinary Tract Signs and Symptoms
W/O Catastrophic or Severe CC
Bronchitis and Asthma Age >49 or W CC
Other Colonoscopy, Same Day
Other Digestive System Diagnoses W CC
Cystourethroscopy, Same Day
Other Infectious and Parasitic Diseases W/O
Catastrophic or Severe CC
Neonate, AdmWt > 2499 g W/O Significant O.R.
Procedure W/O Problem
O.R. Procedures W Diagnoses of Other
Contacts W Health Services W Cat/Sev CC
Interstitial Lung Disease W/O Catastrophic or
Severe CC
Chronic Obstrct Airway Dis-Cscc
Non-surgical Spinal Disorders, Same Day
Osteomyelitis W CC
Other Neoplastic Disorders W/O CC
Other Gastroscopy for Non-Major Digestive
Disease, Same Day
Chest Pain
Other Ear, Nose, Mouth and Throat Diagnoses
W CC
Ac & Mjr Eye Infectn A<55-Cscc
Otitis Media & Uri - Cc
Admit for Renal Dialysis
Epistaxis
Minor Skin Disorders, Same Day
Malignancy, Male Reproductive System W/O
Catastrophic or Severe CC

Number of
Episodes

Total Cost

Per Diem
Cost

Average
Length of
Stay

0.3

$908

$2,725

1.0

1.3

$904

$452

1.5

0.3
1.0
0.3
0.3
0.3

$863
$807
$804
$769
$731

$1,295
$807
$2,412
$2,308
$2,194

2.0
1.0
1.0
1.0
1.0

0.3

$696

$1,044

2.0

0.3

$620

$1,860

1.0

0.3

$557

$1,670

1.0

0.7
0.8
0.3
0.7
1.0

$549
$509
$493
$411
$409

$823
$611
$1,480
$617
$409

1.0
1.0
1.0
1.0
1.0

0.5
0.3

$356
$343

$712
$1,028

1.0
1.0

0.3
1.3
0.3
0.3
0.3
0.3

$332
$295
$264
$202
$108
$52

$996
$221
$791
$607
$325
$157

1.0
1.0
1.0
1.0
1.0
1.0

996.5
$7,828,507
$1,538
4.9
** Includes only costs that occurred in year of separation for ending episodes
Note: Data adjusted for hospitals with data from different time periods & costs adjusted for inflation
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